

TTAB

100 Pine Street • PO Box 1166 • Harrisburg, PA 17108-1166 Tel: 717.232.8000 • Fax: 717.237.5300

Harvey Freedenberg Direct Dial: 717.237.5267 Direct Fax: 717.260.1693 hfreedenberg@mwn.com

September 21, 2012

United States Patent and Trademark Office Trademark Trial and Appeal Board Attention: Commissioner for Trademarks P.O. Box 1451 Alexandria, VA 22313-1451

> RE: Mylan, Inc., Opposer v. Beaufort County Allergy, Applicant Opposition No. 91195868

Dear Commissioner:

Enclosed for filing please find Opposer Mylan, Inc.'s Notice of Reliance regarding the above-referenced opposition proceeding.

We simultaneously are serving copies of all of the materials filed herewith upon counsel for Applicant.

Thank you for your attention to this filing request.

Sincerely,

MCNEES WALLACE & NURICK LLC

Bv reedenber

HF:jh Enclosures c: Anthony Verna III, Esquire (w/encl.)



U.S. Patent and Trademark Office #72

www.mwn.com

HARRISBURG, PA • LANCASTER, PA • STATE COLLEGE, PA • COLLIMBUS, OH • WASHINGTON DC.

United States Patent and Trademark Office Trademark Trial and Appeal Board Commissioner for Trademarks September 21, 2012 Page 2

bc: Lisa Pessa, Esquire (w/encl.)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

MYLAN, INC.,	:	
Opposer,	:	
	:	
V.	:	Opposition No. 91195868
	:	
BEAUFORT COUNTY ALLERGY,	:	
Applicant.	:	

OPPOSER MYLAN, INC.'S NOTICE OF RELIANCE

Opposer Mylan, Inc. ("Mylan") notifies the Trademark Trial and Appeal Board and Applicant Beaufort County Allergy ("Beaufort") of its intent to rely upon the following materials in the above-captioned proceeding. Copies of said materials are attached hereto and filed of record:

1. Printouts of information from the electronic database records of the USPTO showing the current status and title of the following registrations to establish the priority of Mylan's EPIPEN and EPI marks and to establish the existence of a family of said marks:

a. Mylan's federal trademark registration for the mark EPIPEN,

Registration No. 1,124,454. See Exhibit 1.

b. Mylan's federal trademark registration for the mark EPIPEN, Registration No. 1,479,294. See Exhibit 2.

c. Mylan's federal trademark registration for the mark EPIPEN JR. 2-PAK, Registration No. 2,576,013. See Exhibit 3. d. Mylan's federal trademark registration for the mark EPIPEN 2-PAK, Registration No. 2,576,014. See Exhibit 4.

e. Mylan's federal trademark application for the mark EPIPEN-READY, Serial No. 77/919,265. See Exhibit 5.

f. Mylan's federal trademark application for the mark EPIPEN PREPARED, Serial No. 77/919,257. See Exhibit 6.

g. Mylan's federal trademark application for the mark EPI-PREPARED, Serial No. 77/919,269. See Exhibit 7.

h. Mylan's federal trademark application for the mark EPI-SET, Serial No. 77/919,271. See Exhibit 8.

i. Mylan's federal trademark application for the mark EPICARD, Serial No. 77/927,738. See Exhibit 9.

2. Excerpts from the discovery deposition of Thomas C. Beller, M.D., taken on February 13, 2012. See Exhibit 10. The Board's attention is directed specifically to the listed pages of Dr. Beller's deposition that are relevant to the following issues:

a. Identical nature of Mylan's and Beaufort's goods (pp. 20-21).

b. Competitive nature of Mylan's and Beaufort's goods (pp. 30-31;

67).

c. Recognition of EPIPEN® as a brand name (pp. 29-31).

d. Recognition of the importance of training patients in the proper use of a prescribed autoinjector (pp. 63-64).

e. Market share of EPIPEN® autoinjector (p. 66).

f. Consumers and channels of trade for Beaufort's autoinjector device (p. 105).

3. Internet Materials consisting of dictionary and other references to the term EPIPEN® that reflect its recognition as a brand name and support Mylan's contention that the mark has become famous:

a. American Heritage Medical Dictionary (definition of "EPIPEN®".See Exhibit 11.

b. Oxfordreference.com (definition of "adrenaline"). See Exhibit 12. c. Oxfordreference.com (definition of "EPIPEN®"). See Exhibit 13. d. Wikipedia (entry for "Epinephrine autoinjector"). See Exhibit 14. Oxford English Dictionary (definition of "EPIPEN®"). See Exhibit e. 15. f. Consumer Health Complete (entry for "Epinephrine") See Exhibit 16. Consumer Health Complete (entry for "EPIPEN®"). See Exhibit g. 17. h. "Epinephrine Auto-injectors - Patients May Need Retraining," Website of The Food Allergy & Anaphylaxis Network, May 24, 2010. See Exhibit 18. i. "When is an Epi-Pen Not an Epi-Pen?" About.Com, June 24, 2010. See Exhibit 19.

j. "Teen Dies After Eating Cooking Containing Peanut," Atlanta Journal-Constitution, August 18, 2011. See Exhibit 20.

3

k. "Food Allergies Can be Deadly," Atlanta Journal-Constitution,August 19, 2011. See Exhibit 21.

4. Expert reports from the following physicians to refute Beaufort's claim that the term "Epipen" has become generic for epinephrine autoinjectors and to support Mylan's contention that the mark has become famous:

- a. Ray S. Davis, M.D. See Exhibit 22.
- b. Phil Lieberman, M.D. See Exhibit 23.
- c. Martha V. White, M.D. See Exhibit 24.
- d. Myron Zitt, M.D. See Exhibit 25.
- e. Kevin R. Murphy, M.D. See Exhibit 26.
- 5. Trademark Trial and Appeal Board docket entries in the following

opposition and cancellation proceedings to establish that Mylan has vigorously protected its rights in its EPIPEN® mark. Except as described in Paragraph 6, below, all of these proceedings ended either with cancellation of an existing registration or abandonment of a pending application:

a. Mylan, Inc. v. Brian Klughaupt Kaplan, Cancellation No.92051946 (EPIDRYL). See Exhibit 27.

b. Mylan, Inc. v. Intelliject, Inc., Cancellation No. 92051951 (EPICARD). See Exhibit 28.

c. Mylan, Inc. v. Teva Pharmaceuticals USA, Inc., Opposition No.91194703 (EPINOW and EPIZIP). See Exhibit 29.

d. Mylan, Inc. v. Brian K. Kaplan, Opposition No. 91199177. See Exhibit 30 (EPIDRYL).

4

e. Mylan, Inc. v. Pernix Therapeutics, Opposition No. 91202308. See Exhibit 31 (EPI-TWIN).

f. Mylan, Inc. v. Osagie O. Imasogie, Opposition No. 91202440. See Exhibit 32 (EPIDRYL).

g. Mylan, Inc. v. Epimed International, Inc., Opposition No. 91204718 (EPIMED). See Exhibit 33.

6. Stipulated Motion to Amend Identification of Goods in Application Serial Nos. 85/328,059 and 85/328,075. See Exhibit 34. In the opposition proceeding identified in Paragraph 5.g., above, the applicant agreed to amend its identification of goods to specifically exclude "prefilled epinephrine auto-injectors and syringes."

Applicant's Answers to Opposer's First Set of Interrogatories. See Exhibit
 35. The Answers are offered to establish the following matters:

a. Territorial scope of Applicant's intended use of its mark (No. 4(d)).

b. Proposed channels of trade of products sold under Applicant's

mark (No. 7).

McNEES WALLACE & NURICK LLC

By:<u>/s/ Harvey Freedenberg</u> Harvey Freedenberg <u>hfreeden@mwn.com</u> 100 Pine Street P.O. Box 1166 Harrisburg, PA 17108-1166 Phone: 717-232-8000 Facsimile: 717-237-5300

Attorneys for Opposer Mylan, Inc.

Dated: September 21, 2012

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on this date a true and correct copy of the

foregoing OPPOSER MYLAN, INC.'S NOTICE OF RELIANCE was served by first

class mail upon the following:

Anthony Verna III, Esquire Kravitz & Verna LLC 160 West End Avenue New York, NY 10023 averna@kravitzverna.com

> /s/ Harvey Freedenberg Harvey Freedenberg

Of Counsel for Opposer Mylan, Inc.

Dated: September 21, 2012

EXHIBIT 1

Generated on: This page was generated by TSDR on 2012-09-04 9:39:51 EST

Mark: EPIPEN

EPIPEN

US Serial Number:	73183957	Application Filing Date:	Aug. 30, 1978
US Registration Number:	1124454	Registration Date:	Aug. 28, 1979
Register:	Principal		
Mark Type:	Trademark		
Status:	The registration has been a	renewed.	
Status Date:	Dec. 01, 2008		
- · · · ·	Mark	(Information	
Mark Literal Elements:	EPIPEN		

Standard
Character Claim:NoMark Drawing
Type:1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S)

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- • Brackets [..] indicate deleted goods/services;
- • Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- • Asterisks *..* identify additional (new) wording in the goods/services.

For:	HYPODERMIC INJECTORS		
International Class:	010 - Primary Class	U.S Class:	044
Class Status:	ACTIVE		

Basis:	1(a)	
First Use:	Aug. 17, 1978	Use in Commerce: Aug. 17, 1978

Basis Information (Case Level)

Filed Use:	Yes	Currently Use:	Yes	Amended Use:	No
Filed ITU:	No	Currently ITU:	No	Amended ITU:	No
Filed 44D:	No	Currently 44D:	No	Amended 44D:	No
Filed 44E:	No	Currently 44E:	No	Amended 44E:	No
Filed 66A:	No	Currently 66A:	No		
Filed No Basis:	No	Currently No Basis:	No		

Current Owner(s) Information

Owner Name:	Mylan Inc.
Owner Address:	1500 Corporate Drive Suite 400 Canonsburg, PENNSYLVANIA 15317 UNITED STATES

Legal Entity
Type:State or CountryCORPORATIONWherePENNSYLVANIAOrganized:

Attorney/Correspondence Information

Attorney of Record

Attorney Name:	Michael A. Doctrow	Docket Number:	24406-0007
----------------	--------------------	----------------	------------

Correspondent

Correspondent e- mail:	trademarks@mwn.com	Correspondent e- mail Authorized:	Yes
Phone:	717-232-8000	Fax:	717-237-5300
Correspondent Name/Address:	Michael A. Doctrow McNees Wallace & Nurick 100 Pine Street Harrisburg, PENNSYLVANIA 1 UNITED STATES	7108	

Domestic Representative - Not Found

Prosecution History Proceeding Date Description Number ASSIGNMENT OF OWNERSHIP NOT UPDATED Feb. 01, 2012 AUTOMATICALLY ASSIGNMENT OF OWNERSHIP NOT UPDATED Jan. 04, 2012 AUTOMATICALLY ASSIGNMENT OF OWNERSHIP NOT UPDATED Jan. 04, 2012 AUTOMATICALLY ASSIGNMENT OF OWNERSHIP NOT UPDATED Dec. 07, 2011 AUTOMATICALLY **REGISTERED AND RENEWED (SECOND RENEWAL -**68973 Dec. 01, 2008 10 YRS) REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 Dec. 01, 2008 **GRANTED** 68973 Dec. 01, 2008 ASSIGNED TO PARALEGAL **TEAS SECTION 8 & 9 RECEIVED** Nov. 04, 2008 ASSIGNMENT OF OWNERSHIP NOT UPDATED May 07, 2008 AUTOMATICALLY Jan. 22, 2008 CASE FILE IN TICRS **REGISTERED AND RENEWED (FIRST RENEWAL - 10** Mar. 15, 2000 YRS) **REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR** Mar. 15, 2000 SEC. 8 **REGISTERED - COMBINED SECTION 8 (10-YR) & SEC.** Oct. 18, 1999 9 FILED **REGISTERED - COMBINED SECTION 8 (10-YR) & SEC.** Oct. 18, 1999 9 FILED **REGISTERED - SEC. 9 FILED/CHECK RECORD FOR** Aug. 18, 1999 **SEC. 8** REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 Dec. 23, 1985 ACK. POST REGISTRATION ACTION MAILED - SEC. 8 & 15 Nov. 18, 1985 REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED Aug. 22, 1985

Maintenance Filings or Post Registration Information

Affidavit of Continued Use:	Section 8 - Accepted
Affidavit of Incontestability:	Section 15 - Accepted
Renewal Date:	Aug. 28, 2009

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: POST REGISTRATION

Date in Location: Dec. 01, 2008

Assignment Abstract of Title Information

Summary

Total Assignments:	5	Registrant:	SURVIVAL TECHNOLOGY, INC.
Assignment 1 of 5			
Conveyance:	ASSIGNS THE ENTIRE INTER	REST AND THE C	GOODWILL
Reel/Frame:	0381/0538	Pages:	3
Date Recorded:	Dec. 18, 1980		
Supporting Documents:	No Supporting Documents		
	Assigr	nor	
Name:	<u>SURVIVAL TECHNOLOGY,</u> <u>INC.</u>	Execution Date:	Dec. 05, 1980
Legal Entity Type:	UNKNOWN	State or Country Where Organized:	No Place Where Organized Found
Assignee			
Name:	EM INDUSTRIES, INCORPORATED		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	NEW YORK
Address:	500 EXECUTIVE BLVD. ELMSFORD, NEW YORK 105	23	

Correspondent

Correspondent Name:	STEPHENS AND BUDERWITZ
Correspondent	NORTHCOURT BLDG.
Address:	WHITE PLAINS, NY 10601

Domestic Representative - Not Found

Assignment 2 of 5			
Conveyance:	CHANGE OF NAME		
Reel/Frame:	2560/0677	Pages:	3
Date Recorded:	Aug. 19, 2002		
Supporting Documents:	assignment-tm-2560-0677.	pdf	
	A	ssignor	
Name:	<u>EM INDUSTRIES,</u> INCORPORATED	Execution Date:	Jun. 27, 2002
Legal Entity Type:	CORPORATION	State or Country Where Organized:	No Place Where Organized Found
	A	ssignee	
Name:	EMD CHEMICALS INC.		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	NEW YORK
Address:	480 S. DEMOCRAT ROA GIBBSTOWN, NEW JERS		
	Corr	espondent	
Correspondent Name:	EMD CHEMICALS INC.		
Correspondent Address:	SUSANNE F. DEAL, ESQ 480 S. DEMOCRAT ROA GIBBSTOWN, NJ 06027	-	
	Domestic Repre	esentative - Not Four	nd
Assignment 3 of 5			
Conveyance:	ASSIGNS THE ENTIRE I	NTEREST	
Reel/Frame:	3772/0028	Pages:	10
Date Recorded:	May 06, 2008		

,

Supporting Documents:	assignment-tm-3772-0028.pdf		
	Assign	ior	
Name:	EMD CHEMICALS, INC.	Execution Date:	Oct. 02, 2007
Legal Entity Type:	CORPORATION	State or Country Where Organized:	NEW YORK
	Assign	ee	
Name:	MYLAN LABORATORIES, IN	<u>C.</u>	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Address:	1500 CORPORATE DRIVE SUITE 400 CANONSBURG, PENNSYLVA	ANIA 15317	
	Correspo	ndent	
Correspondent Name:	SUE HEBERLIG		
Correspondent Address:	100 PINE STREET HARRISBURG, PA 17108		
	Domestic Represent	ative - Not Foun	d
Assignment 4 of 5			
Conveyance:	CHANGE OF NAME		
Reel/Frame:	3772/0082	Pages:	7
Date Recorded:	May 06, 2008		
Supporting Documents:	assignment-tm-3772-0082.pdf		
	Assigr	nor	
Name:	<u>MYLAN LABORATORIES,</u> <u>INC.</u>	Execution Date:	Oct. 02, 2007
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
	Assigr	nee	
Name:	<u>MYLAN INC.</u>		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA

	1500 CORPORATE DRIVE
Address:	SUITE 400
	CANONSBURG, PENNSYLVANIA 15317

Correspondent

Correspondent Name:	SUE HEBERLIG		
Correspondent	100 PINE STREET		
Address:	HARRISBURG, PA 17108		

Domestic Representative - Not Found

			-
Assignment 5 of 5			
Conveyance:	SECURITY AGREEMENT		
Reel/Frame:	4704/0376	Pages:	26
Date Recorded:	Nov. 21, 2011		
Supporting Documents:	assignment-tm-4704-0376.pdf		
	Assigr	or	
Name:	DEY PHARMA, L.P.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	LIMITED PARTNERSHIP	State or Country Where Organized:	DELAWARE
Name:	<u>MYLAN INSTITUTIONAL</u> <u>INC., (F/K/A UDL</u> <u>LABORATORIES, INC.)</u>	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	ILLINOIS
Name:	<u>MYLAN</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA
Name:	<u>MYLAN BERTEK</u> <u>PHARMACEUTICALS INC.</u> <u>(F/K/A BERTEK</u> <u>PHARMACEUTICALS, INC.)</u>	Execution Date:	Nov. 14, 2011

Legal Entity Type:	CORPORATION	State or Country Where Organized:	TEXAS
Name:	<u>MYLAN INC. (F/K/A MYLAN</u> LABORATORIES INC.)	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Name:	<u>SOMERSET</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	DELAWARE
Name:	<u>MYLAN TECHNOLOGIES,</u> INC.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA
	Assigr	nee	
Name:	BANK OF AMERICA, N.A., A	S ADMINISTRAT	TIVE AGENT
Legal Entity Type:	ASSOCIATION	State or Country Where Organized:	UNITED STATES
Address:	101 N TRYON STREET, NC1-0 ONE INDEPENDENCE CENTI CHARLOTTE, NORTH CARO	ER	-0001
	Correspo	ndent	
Correspondent Name:	MICHAEL VIOLET		
Correspondent Address:	CT LIEN SOLUTIONS 4400 EASTON COMMONS W. COLUMBUS, OH 43219	AY, SUITE 125	
		C Not Farm	. al

Domestic Representative - Not Found

EXHIBIT 2

Generated on: This page was generated by TSDR on 2012-09-04 10:01:19 EST Mark: **EPIPEN Application Filing** Jun. 18, 1987 US Serial Number: 73666943 Date: US Registration 1479294 **Registration Date:** Mar. 08, 1988 Number: **Register:** Principal

Mark Type: Trademark

The registration has been renewed. Status:

Jul. 30, 2008 Status Date:

Publication Date: Dec. 15, 1987

Mark Information

Mark Literal **EPIPEN** Elements:

Standard No Character Claim:

Mark Drawing 1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S)

Type:

Related Properties Information

Claimed Ownership of US Registrations: <u>1124454</u>, and others

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [..] indicate deleted goods/services; •
- • Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *..* identify additional (new) wording in the goods/services.

INJECTABLE PHARMACEUTICALS FOR TREATMENT OF For: ANAPHYLACTIC REACTIONS TO INSECT STINGS

International Class:	005 - Prim	ary Class	U.S Class:	018	
Class Status:	ACTIVE				
Basis:	1(a)				
First Use:	Aug. 17, 1	978	Use in Commerc	ce: Aug. 17, 1978	3
······································	Ba	asis Informatio	on (Case Lev	(el)	
Filed Use:	Yes	Currently Use:	Yes	Amended Use:	No
Filed ITU:	No	Currently ITU:	No	Amended ITU:	No
Filed 44D:	No	Currently 44D:	No	Amended 44D:	No
Filed 44E:	No	Currently 44E:	No	Amended 44E:	No
Filed 66A:	No	Currently 66A:	No		

Current Owner(s) Information

No

Currently No

Basis:

Filed No Basis: No

Owner Name:	MYLAN INC.		
Owner Address:	SUITE 400 1500 CORPOATE DRIVE CANONSBURG, PENNSY UNITED STATES	LVANIA 15317	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
	Attorney/Corres	pondence Inforr	nation
	Attor	ney of Record	
Attorney Name:	Michael A. Doctrow		
	Cor	respondent	
Correspondent Name/Address:		-	

Harrisburg, PENNSYLVANIA 17108

UNITED STATES

Phone: 717-232-8000

Fax: 717-237-5300

Correspondent email:

trademarks@mwn.com

Correspondent email Authorized:

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
Feb. 01, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Dec. 07, 2011	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jul. 30, 2008	REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)	60132
Jul. 30, 2008	REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED	
Jul. 22, 2008	ASSIGNED TO PARALEGAL	60132
Jul. 10, 2008	TEAS SECTION 8 & 9 RECEIVED	
May 07, 2008	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Apr. 30, 2007	CASE FILE IN TICRS	
Jun. 21, 1994	REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.	
Mar. 01, 1994	REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED	
Mar. 08, 1988	REGISTERED-PRINCIPAL REGISTER	
Dec. 15, 1987	PUBLISHED FOR OPPOSITION	
Nov. 13, 1987	NOTICE OF PUBLICATION	
Oct. 15, 1987	APPROVED FOR PUB - PRINCIPAL REGISTER	
Sep. 28, 1987	CORRESPONDENCE RECEIVED IN LAW OFFICE	
Sep. 10, 1987	NON-FINAL ACTION MAILED	
Sep. 03, 1987	ASSIGNED TO EXAMINER	61700

Maintenance Filings or Post Registration Information

Affidavit of Sec

Section 8 - Accepted

Affidavit of Section 15 - Accepted

Renewal Date: Mar. 08, 2008

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: POST REGISTRATION

Date in Location: Jul. 30, 2008

Assignment Abstract of Title Information

Summary

Total Assignments:	4	Registrant:	EM INDUSTRIES, INC.	
Assignment 1 of 4				
Conveyance:	CHANGE OF NAME			
Reel/Frame:	2560/0677	Pages:	3	
Date Recorded:	Aug. 19, 2002			
Supporting Documents:	assignment-tm-2560-0677.pdf			
	Assign	or		
Name:	<u>EM INDUSTRIES,</u> INCORPORATED	Execution Date:	Jun. 27, 2002	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	No Place Where Organized Found	
Assignee				
Name:	EMD CHEMICALS INC.			
Legal Entity Type:	CORPORATION	State or Country Where Organized:	NEW YORK	

	480 S. DEMOCRAT ROAD
Address:	GIBBSTOWN, NEW JERSEY 08027

Correspondent

Correspondent Name:	EMD CHEMICALS INC.
Correspondent Address:	SUSANNE F. DEAL, ESQ. 480 S. DEMOCRAT ROAD GIBBSTOWN, NJ 06027

Domestic Representative - Not Found

Assignment 2 of 4			
Conveyance:	ASSIGNS THE ENTIRE INTE	REST	
Reel/Frame:	3772/0028	Pages:	10
Date Recorded:	May 06, 2008		
Supporting Documents:	assignment-tm-3772-0028.pdf		
	Assig	nor	
Name:	EMD CHEMICALS, INC.	Execution Date:	Oct. 02, 2007
Legal Entity Type:	CORPORATION	State or Country Where Organized:	NEW YORK
	Assig	nee	
Name:	MYLAN LABORATORIES, IN	I <u>C.</u>	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Address:	1500 CORPORATE DRIVE SUITE 400 CANONSBURG, PENNSYLVA	ANIA 15317	
	Correspo	ondent	
Correspondent Name:	SUE HEBERLIG		
Correspondent Address:	100 PINE STREET HARRISBURG, PA 17108		
Domestic Representative - Not Found			
Assignment 3 of 4			
Conveyance:	CHANGE OF NAME		
Reel/Frame:	3772/0082	Pages:	7

Date Recorded:	May 06, 2008			
Supporting Documents:	assignment-tm-3772-0082.pdf			
	Assigr	nor		
Name:	<u>MYLAN LABORATORIES,</u> <u>INC.</u>	Execution Date:	Oct. 02, 2007	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA	
	Assigr	iee		
Name:	MYLAN INC.			
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA	
Address:	1500 CORPORATE DRIVE SUITE 400 CANONSBURG, PENNSYLVA	ANIA 15317		
	Correspo	ndent		
Correspondent Name:	SUE HEBERLIG			
Correspondent Address:	100 PINE STREET HARRISBURG, PA 17108			
	Domestic Represent	ative - Not Foun	d	
Assignment 4 of 4				
Conveyance:	SECURITY AGREEMENT			
Reel/Frame:	4704/0376	Pages:	26	
Date Recorded:	Nov. 21, 2011			
Supporting Documents:	assignment-tm-4704-0376.pdf			
	Assig	nor		
Name:	DEY PHARMA, L.P.	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	LIMITED PARTNERSHIP	State or Country Where Organized:	DELAWARE	

MYLAN INSTITUTIONAL INC., (F/K/A UDL

Name:

Execution Date: Nov. 14, 2011

	LABORATORIES, INC.)		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	ILLINOIS
Name:	<u>MYLAN</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA
Name:	<u>MYLAN BERTEK</u> <u>PHARMACEUTICALS INC.</u> (F/K/A BERTEK PHARMACEUTICALS, INC.)	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	TEXAS
Name:	<u>MYLAN INC. (F/K/A MYLAN</u> LABORATORIES INC.)	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Name:	<u>SOMERSET</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	DELAWARE
Name:	<u>MYLAN TECHNOLOGIES,</u> <u>INC.</u>	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA
	Assigr	nee	
Name:	BANK OF AMERICA, N.A., A	S ADMINISTRAT	TIVE AGENT
		State or Country	

Legal Entity Type:	ASSOCIATION	Where Organized:	UNITED STATES
Address:	101 N TRYON STREET, NC1-00 ONE INDEPENDENCE CENTER CHARLOTTE, NORTH CAROLI	Ł	-0001
	Correspon	dent	
Correspondent Name:	MICHAEL VIOLET		

Correspondent
Address:CT LIEN SOLUTIONS
4400 EASTON COMMONS WAY, SUITE 125
COLUMBUS, OH 43219

Domestic Representative - Not Found

EXHIBIT 3

Generated on: This page was generated by TSDR on 2012-09-04 10:04:04 EST

Mark: EPIPEN JR. 2-PAK

EPIPEN JR. 2-PAK

US Serial Number:	76286512	Application Filing Date:	Jul. 17, 2001
US Registration Number:	2576013	Registration Date:	Jun. 04, 2002
Register:	Principal		
Mark Type:	Trademark		
Status:	The registration has been r	enewed.	
Status Date:	Sep. 13, 2011		
Publication Date:	Mar. 12, 2002		
	Mark	Informatio	

Mark Literal Elements:	EPIPEN JR. 2-PAK
Standard Character Claim:	No
Mark Drawing Type:	1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S)
Disclaimer:	"JR. 2 PACK"

Related Properties Information

Claimed Ownership of US Registrations: <u>1124454,1479294</u>

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- • Brackets [..] indicate deleted goods/services;
- • Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and

• • Asterisks *..* identify additional (new) wording in the goods/services.

For:	INJECTABLE PHARMACEUTICALS FOR TREATMENT OF ANAPHYLACTIC REACTIONS TO INSECT STINGS				
International Class:	005 - Primary	v Class	U.S Class:	006, 018, 044,	046, 051, 052
Class Status:	ACTIVE				
Basis:	1(a)				
First Use:	Apr. 02, 2001	l	Use in Commerc	e: Apr. 02, 2001	
For:	HYPODERM	1IC INJECTORS			
International Class:	010 - Primary	y Class	U.S Class:	026, 039, 044	
Class Status:	ACTIVE				
Basis:	1(a)				
First Use:	Apr. 02, 2001	1	Use in Commerc	e: Apr. 02, 2001	
					· · · · · · · ·
	Bas	is Information	on (Case Leve	el)	
Filed Use:	Yes	Currently Use:	Yes	Amended Use:	No
Filed ITU:	No	Currently ITU:	No	Amended ITU:	No
Filed 44D:	No	Currently 44D:	No	Amended 44D:	No
Filed 44E:	No	Currently 44E:	No	Amended 44E:	No
Filed 66A:	No	Currently 66A:	No		
Filed No Basis:	No	Currently No Basis:	No		
	Cu	rrent Owner	(s) Informatio	n	
Owner Name:	MYLAN INC.				
Owner Address:	1500 CORPOR SUITE 400	G, PENNSYLVA	ANIA 15317		
Legal Entity Type:	CORPORATIO		State or Country Where Organized:	PENNSYLVAN	ΙΑ

	Attorney/Correspon	dence Informatio)n
	Attorney o	f Record	
Attorney Name:	Michael A. Doctrow	Docket Number:	24406-0007
	Correspo	ondent	
Correspondent Name/Address:		A 17108	
Phone:	717-232-8000	Fax:	717-237-5300
Correspondent e mail:	trademarks@mwn.com	Correspondent e- mail Authorized:	Yes
	Domestic Represen	tative - Not Found	
	Prosecutio	n History	
Date	Description		Proceeding Number
Feb. 01, 2012	ASSIGNMENT OF OWNERSHI AUTOMATICALLY	P NOT UPDATED	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHI AUTOMATICALLY	P NOT UPDATED	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHI AUTOMATICALLY	P NOT UPDATED	
Dec. 07, 2011	ASSIGNMENT OF OWNERSHI AUTOMATICALLY	P NOT UPDATED	
Sep. 13, 2011	REGISTERED AND RENEWED YRS)) (FIRST RENEWAL -	10 59136
Sep. 13, 2011	REGISTERED - SEC. 8 (10-YR) GRANTED	ACCEPTED/SEC. 9	59136
Jul. 15, 2011	TEAS SECTION 8 & 9 RECEIV	ED	
Nov. 18, 2008	REGISTERED - SEC. 8 (6-YR) ACK.	ACCEPTED & SEC. 1:	5 59136
Nov. 04, 2008	TEAS SECTION 8 & 15 RECEIV	VED	
May 07, 2008	ASSIGNMENT OF OWNERSHI	IP NOT UPDATED	

- Sep. 06, 2007 CASE FILE IN TICRS
- Jun. 04, 2002 REGISTERED-PRINCIPAL REGISTER
- Mar. 12, 2002 PUBLISHED FOR OPPOSITION
- Feb. 20, 2002 NOTICE OF PUBLICATION
- Nov. 30, 2001 APPROVED FOR PUB PRINCIPAL REGISTER
- Oct. 29, 2001 EXAMINERS AMENDMENT MAILED
- Sep. 05, 2001 NON-FINAL ACTION MAILED
- Aug. 31, 2001ASSIGNED TO EXAMINER76629

Maintenance Filings or Post Registration Information

Affidavit of Continued Use:	Section 8 - Accepted
Affidavit of	

Affidavit of	Section 15 - Accepted
Incontestability:	Section 15 - Accepted

Renewal Date: Jun. 04, 2012

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: Not Found

Date in Location: Sep. 13, 2011

Assignment Abstract of Title Information

Summary

Total Assignments:	4	Registrant:	EM Industries, Incorporated
Assignment 1 of 4			
Conveyance:	CHANGE OF NAME		
Reel/Frame:	2560/0677	Pages:	3
Date Recorded:	Aug. 19, 2002		
Supporting Documents:	assignment-tm-2560-0677.pdf		

Assignor

Name:	EM INDUSTRIES, INCORPORATED	Execution Date:	Jun. 27, 2002
Legal Entity Type:	CORPORATION	State or Country Where Organized:	No Place Where Organized Found
	Assign	iee	
Name:	EMD CHEMICALS INC.		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	NEW YORK
Address:	480 S. DEMOCRAT ROAD GIBBSTOWN, NEW JERSEY 0	08027	
	Correspo	ndent	
Correspondent Name:	EMD CHEMICALS INC.		
Correspondent Address:	SUSANNE F. DEAL, ESQ. 480 S. DEMOCRAT ROAD GIBBSTOWN, NJ 06027		
	Domestic Representa	ative - Not Foun	d
Assignment 2 of 4			
Conveyance:	ASSIGNS THE ENTIRE INTER	REST	
Reel/Frame:	3772/0028	Pages:	10
Date Recorded:	May 06, 2008		
Supporting Documents:	assignment-tm-3772-0028.pdf		
	Assigr	nor	
Name:	EMD CHEMICALS, INC.	Execution Date:	Oct. 02, 2007
Legal Entity Type:	CORPORATION	State or Country Where Organized:	NEW YORK
	Assigr	nee	
Name:	MYLAN LABORATORIES, IN	<u>'C.</u>	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Address:	1500 CORPORATE DRIVE SUITE 400 CANONSBURG, PENNSYLVA	ANIA 15317	

Correspondent

	•		
Correspondent Name:	SUE HEBERLIG		
Correspondent Address:	100 PINE STREET HARRISBURG, PA 17108		
	Domestic Represent	ative - Not Foun	d
Assignment 3 of 4			
Conveyance:	CHANGE OF NAME		
Reel/Frame:	3772/0082	Pages:	7
Date Recorded:	May 06, 2008		
Supporting Documents:	assignment-tm-3772-0082.pdf		
	Assig	nor	
Name:	<u>MYLAN LABORATORIES,</u> <u>INC.</u>	Execution Date:	Oct. 02, 2007
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
	Assig	nee	
Name:	<u>MYLAN INC.</u>		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Address:	1500 CORPORATE DRIVE SUITE 400 CANONSBURG, PENNSYLVA	ANIA 15317	
	Correspo	ondent	
Correspondent Name:	SUE HEBERLIG		
Correspondent Address:	100 PINE STREET HARRISBURG, PA 17108		
	Domestic Represent	tative - Not Foun	d
Assignment 4 of 4			
Conveyance:	SECURITY AGREEMENT		
Reel/Frame:	4704/0376	Pages:	26

Date Recorded: Nov. 21, 2011

Supporting Documents:	assignment-tm-4704-0376.pdf				
Assignor					
Name:	DEY PHARMA, L.P.	Execution Date:	Nov. 14, 2011		
Legal Entity Type:	LIMITED PARTNERSHIP	State or Country Where Organized:	DELAWARE		
Name:	<u>MYLAN INSTITUTIONAL</u> <u>INC., (F/K/A UDL</u> <u>LABORATORIES, INC.)</u>	Execution Date:	Nov. 14, 2011		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	ILLINOIS		
Name:	<u>MYLAN</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA		
Name:	<u>MYLAN BERTEK</u> <u>PHARMACEUTICALS INC.</u> (F/K/A BERTEK PHARMACEUTICALS, INC.)	Execution Date:	Nov. 14, 2011		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	TEXAS		
Name:	<u>MYLAN INC. (F/K/A MYLAN</u> LABORATORIES INC.)	Execution Date:	Nov. 14, 2011		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA		
Name:	<u>SOMERSET</u> <u>PHARMACEUTICALS, INC.</u>	Execution Date:	Nov. 14, 2011		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	DELAWARE		

	MYLAN TECHNOLOGIES,				
Name:	<u>INC.</u>	Execution Date:	Nov. 14, 2011		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA		
Assignee					
Name:	BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT				
Legal Entity Type:	ASSOCIATION	State or Country Where Organized:	UNITED STATES		
Address:	101 N TRYON STREET, NC1-001-05-45 ONE INDEPENDENCE CENTER CHARLOTTE, NORTH CAROLINA USA 28255-0001				
Correspondent					
Correspondent Name:	MICHAEL VIOLET				
Correspondent Address:	CT LIEN SOLUTIONS 4400 EASTON COMMONS WA COLUMBUS, OH 43219	AY, SUITE 125			
Domestic Representative - Not Found					

EXHIBIT 4

Generated on: This page was generated by TSDR on 2012-09-04 10:06:50 EST

Mark: EPIPEN 2-PAK

EPIPEN 2-PAK

US Serial Number:	76286513	Application Filing Date:	Jul. 17, 2001		
US Registration Number:	2576014	Registration Date:	Jun. 04, 2002		
Register:	Principal				
Mark Type:	Trademark				
Status:	The registration has been	renewed.			
Status Date:	Sep. 06, 2011				
Publication Date:	Mar. 12, 2002				
	Mark	(Information	··· •••••••••••		
Mark Literal Elements:	EPIPEN 2-PAK				
Standard Character Claim	No :				
Mark Drawing Type:	1 - TYPESET WORD(S)/LETTER(S)/	NUMBER(S)		
Disclaimer:	"2 PACK"				

Related Properties Information

Claimed Ownership of US Registrations: <u>1124454,1479294</u>

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [..] indicate deleted goods/services;
- • Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit

of incontestability; and
Asterisks *..* identify additional (new) wording in the goods/services.

For:	INJECTABLE PHARMACEUTICALS FOR TREATMENT OF ANAPHYLACTIC REACTIONS TO INSECT STINGS						
International Class:	005 - Primary Class		U.S Class:	006, 018, 044,	046, 051, 052		
Class Status:	ACTIVE						
Basis:	1(a)						
First Use:	Apr. 02, 200	1	Use in Commerc	e: Apr. 02, 2001			
For:	HYPODERM	4IC INJECTORS	5				
International Class:	010 - Primary	y Class	U.S Class:	026, 039, 044			
Class Status:	ACTIVE						
Basis:	1(a)						
First Use:	Apr. 02, 200	1	Use in Commerc	e: Apr. 02, 2001			
Basis Information (Case Level)							
Filed Use:	Yes	Currently Use:	Yes	Amended Use:	No		
Filed ITU:	No	Currently ITU:	No	Amended ITU:	No		
Filed 44D:	No	Currently 44D:	No	Amended 44D:	No		
Filed 44E:	No	Currently 44E:	No	Amended 44E:	No		
Filed 66A:	No	Currently 66A:	No				
Filed No Basis:	No	Currently No Basis:	No				
	Cu	rrent Owner	(s) Informatio	on			
Owner Name:	MYLAN INC.						
Owner Address:	Suite 400 1500 Corporate Canonsburg, Pl UNITED STAT	ENNSYLVANIA	15317				
Legal Entity	CORPORATIO	DN	State or Country Where	PENNSYLVANI	A		

Organized:

Attorney/Correspondence Information

Attorney of Record

Attorney Name:	Michael A. Doctrow	24406-0007				
	Correspondent					
Correspondent Name/Address:	Michael A. Doctrow McNees Wallace & Nurick 100 Pine Street Harrisburg, PENNSYLVANIA 17108 UNITED STATES					
Phone:	717-232-8000	Fax:	717-237-5300			
Correspondent e- mail:	trademarks@mwn.com	Correspondent e- mail Authorized:	Yes			

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
Feb. 01, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Dec. 07, 2011	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Sep. 06, 2011	REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)	59136
Sep. 06, 2011	REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED	59136
Jul. 15, 2011	TEAS SECTION 8 & 9 RECEIVED	
Nov. 25, 2008	REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.	59136
Nov. 04, 2008	TEAS SECTION 8 & 15 RECEIVED	

Type:

May 07, 2008	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Sep. 06, 2007	CASE FILE IN TICRS	
Jun. 04, 2002	REGISTERED-PRINCIPAL REGISTER	
Mar. 12, 2002	PUBLISHED FOR OPPOSITION	
Feb. 20, 2002	NOTICE OF PUBLICATION	
Nov. 30, 2001	APPROVED FOR PUB - PRINCIPAL REGISTER	
Oct. 29, 2001	EXAMINERS AMENDMENT MAILED	
Sep. 05, 2001	NON-FINAL ACTION MAILED	
Aug. 31, 2001	ASSIGNED TO EXAMINER	76629

Maintenance Filings or Post Registration Information

Affidavit of Continued Use:	Section 8 - Accepted
Affidavit of Incontestability:	Section 15 - Accepted
Renewal Date:	Jun. 04, 2012

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: Not Found

Date in Location: Sep. 06, 2011

Assignment Abstract of Title Information

Summary

Total Assignments:	4	Registrant:	EM Industries, Incorporated
Assignment 1 of 4			
Conveyance:	CHANGE OF NAME		
Reel/Frame:	2560/0677	Pages:	3
Date Recorded:	Aug. 19, 2002		
Supporting Documents:	assignment-tm-2560-0677.pdf		

Λc	C 1	~	n	^r
As	31	ч		01

Name:EM INDUSTRIES,
INCORPORATED

Execution Date: Jun. 27, 2002

State or Country Where Organized: No Place Where Organized Found

Legal Entity Type: CORPORATION

Assignee

Name: <u>H</u>	MD CHEMICALS INC.
----------------	-------------------

Legal Entity Type: CORPORATION

State or Country Where NEW YORK Organized:

Address: 480 S. DEMOCRAT ROAD GIBBSTOWN, NEW JERSEY 08027

Correspondent

- Correspondent EMD CHEMICALS INC.
- Correspondent
Address:SUSANNE F. DEAL, ESQ.
480 S. DEMOCRAT ROAD
GIBBSTOWN, NJ 06027

Domestic Representative - Not Found

Assignment 2 of 4	A	ssi	gn	m	ent	2	of	4
-------------------	---	-----	----	---	-----	---	----	---

Conveyance:	ASSIGNS THE ENTIRE INTEREST					
Reel/Frame:	<u>3772/0028</u> Pages: 10					
Date Recorded:	May 06, 2008					
Supporting Documents:	assignment-tm-3772-0028.pdf					
Assignor						
Name:	EMD CHEMICALS, INC.	Execution Date:	Oct. 02, 2007			
Legal Entity Type:		State or Country Where Organized:	NEW YORK			
	Assign	ee				
Name:	MYLAN LABORATORIES IN	C				

Name: <u>MYLAN LABORATORIES, I</u>

Legal Entity Type: CORPORATION

State or Country Where PENNSYLVANIA Organized:

1500 CORPORATE DRIVE

Address:	SUITE 400
	CANONSBURG, PENNSYLVANIA 15317

Correspondent

Correspondent	SUE HEBERLIG		
Name:			
Correspondent Address:	100 PINE STREET HARRISBURG, PA 17108		
	Domestic Represent	ative - Not Foun	d
Assignment 3 of 4			
Conveyance:	CHANGE OF NAME		
Reel/Frame:	3772/0082	Pages:	7
Date Recorded:	May 06, 2008		
Supporting Documents:	assignment-tm-3772-0082.pdf		
	Assig	nor	
Name:	<u>MYLAN LABORATORIES,</u> <u>INC.</u>	Execution Date:	Oct. 02, 2007
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
	Assig	nee	
Name:	MYLAN INC.		
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Address:	1500 CORPORATE DRIVE SUITE 400 CANONSBURG, PENNSYLVA	ANIA 15317	
	Correspo	ondent	
Correspondent Name:	SUE HEBERLIG		
Correspondent Address:	100 PINE STREET HARRISBURG, PA 17108		
	Domestic Represent	tative - Not Foun	d
Assignment 4 of 4			
Conveyance:	SECURITY AGREEMENT		
Reel/Frame:	4704/0376	Pages:	26

Date Recorded:	Nov. 21, 2011			
Supporting Documents:	assignment-tm-4704-0376.pdf			
	Assign	or		
Name:	DEY PHARMA, L.P.	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	LIMITED PARTNERSHIP	State or Country Where Organized:	DELAWARE	
Name:	MYLAN INSTITUTIONAL INC., (F/K/A UDL LABORATORIES, INC.)	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	ILLINOIS	
Name:	<u>MYLAN</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA	
Name:	<u>MYLAN BERTEK</u> <u>PHARMACEUTICALS INC.</u> (F/K/A BERTEK <u>PHARMACEUTICALS, INC.)</u>	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	TEXAS	
Name:	<u>MYLAN INC. (F/K/A MYLAN</u> <u>LABORATORIES INC.)</u>	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA	
Name:	<u>SOMERSET</u> <u>PHARMACEUTICALS, INC.</u>	Execution Date:	Nov. 14, 2011	

Legal Entity Type: CORPORATION

Legal Entity Type: CORPORATION

State or Country Where DELAWARE Organized:

Name: <u>MYLAN TECHNOLOGIES,</u> IN<u>C.</u>

Execution Date: Nov. 14, 2011

State or Country Where WEST VIRGINIA Organized:

Assignee

Name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT

Legal Entity Type: ASSOCIATION State or Country UNITED STATES Organized:

101 N TRYON STREET, NC1-001-05-45Address:ONE INDEPENDENCE CENTER
CHARLOTTE, NORTH CAROLINA USA 28255-0001

Correspondent

Correspondent MICHAEL VIOLET

Correspondent Address: CT LIEN SOLUTIONS 4400 EASTON COMMONS WAY, SUITE 125 COLUMBUS, OH 43219

Domestic Representative - Not Found

EXHIBIT 5

Generated on: This page was generated by TSDR on 2012-09-04 10:09:09 EST

Mark: EPIPEN-READY

EPIPEN-READY

US Serial Number:	77919265	Application Filing Date:	Jan. 25, 2010	
Filed as TEAS Plus:	Yes	Currently TEAS Plus:	Yes	
Register:	Principal			
Mark Type:	Trademark			
Status:	A second request for ext	ension of time to fi	le a Statement of Use has been granted.	
Status Date:	May 01, 2012			
Publication Date:	Feb. 08, 2011	Notice of Allowance Date:	Apr. 05, 2011	
	Ма	rk Informatior		
Mark Literal Elements:	EPIPEN-READY			
Standard Character Claim			cters without claim to any particular	
Mark Drawing Type:	4 - STANDARD CHA	ARACTER MARK		
Related Properties Information				
Claimed Ownersl of US Registratio	• 11/44/4/4/9/94 /	576013, and others		
	Good	ds and Servic	es	

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- • Brackets [..] indicate deleted goods/services;
- • Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and

• • Asterisks *..* identify additional (new) wording in the goods/services.

For:	Injectable pl	Injectable pharmaceuticals for treatment of anaphylactic reactions			
International Clas	s: 005 - Prima	ry Class	U.S Class:	006, 018, 044,	046, 051, 052
Class Status:	ACTIVE				
Basis:	1(b)				
For:	Medical flui	d injectors			
International Clas	s : 010 - Prima	ry Class	U.S Class:	026, 039, 044	
Class Status:	ACTIVE				
Basis:	1(b)				
	Bas	sis Informatio	on (Case Lev	el)	
Filed Use:	No	Currently Use:	No	Amended Use:	No
Filed ITU:	Yes	Currently ITU:	Yes	Amended ITU:	No
Filed 44D:	No	Currently 44D:	No	Amended 44D:	No
Filed 44E:	No	Currently 44E:	No	Amended 44E:	No
Filed 66A:	No	Currently 66A:	No		
Filed No Basis:	No	Currently No Basis:	No		
	Cu	rrent Owner(s) Informatio)n	
Owner Name:	Mylan Inc.				
Owner Address:	Suite 400 1500 Corporate Canonsburg, P UNITED STA	ENNSYLVANIA	15317		
Legal Entity Type:	CORPORATIO		State or Country Where Organized:	PENNSYLVAN	IA
	Attorne	ey/Correspon	idence Inforr	nation	

Attorney of Record

Attorney Name:	Michael A. Doctrow	Docket Number:	24406-0007
	Correspondent		
Correspondent Name/Address:	MICHAEL A. DOCTROW MCNEES WALLACE & NURICK 100 PINE ST HARRISBURG, PENNSYLVANIA 17101-1200 UNITED STATES		
Phone:	717-232-8000	Fax:	717-237-5300
Correspondent e- mail:	trademarks@mwn.com	Correspondent e- mail Authorized:	Yes

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
May 02, 2012	NOTICE OF APPROVAL OF EXTENSION REQUEST E- MAILED	
May 01, 2012	EXTENSION 2 GRANTED	66530
Apr. 03, 2012	EXTENSION 2 FILED	66530
Apr. 27, 2012	CASE ASSIGNED TO INTENT TO USE PARALEGAL	66530
Apr. 03, 2012	TEAS EXTENSION RECEIVED	
Feb. 01, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Dec. 07, 2011	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Oct. 06, 2011	NOTICE OF APPROVAL OF EXTENSION REQUEST E- MAILED	
Oct. 04, 2011	EXTENSION 1 GRANTED	98765
Oct. 04, 2011	EXTENSION 1 FILED	98765
Oct. 04, 2011	TEAS EXTENSION RECEIVED	
Apr. 05, 2011	NOA E-MAILED - SOU REQUIRED FROM APPLICANT	

Feb. 08, 2011	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E- MAILED	
Feb. 08, 2011	PUBLISHED FOR OPPOSITION	
Jan. 03, 2011	LAW OFFICE PUBLICATION REVIEW COMPLETED	67287
Dec. 26, 2010	APPROVED FOR PUB - PRINCIPAL REGISTER	
Nov. 16, 2010	AMENDMENT FROM APPLICANT ENTERED	67287
Nov. 16, 2010	CORRESPONDENCE RECEIVED IN LAW OFFICE	67287
Nov. 16, 2010	ASSIGNED TO LIE	67287
Oct. 27, 2010	PAPER RECEIVED	
Apr. 25, 2010	NOTIFICATION OF NON-FINAL ACTION E-MAILED	6325
Apr. 25, 2010	NON-FINAL ACTION E-MAILED	6325
Apr. 25, 2010	NON-FINAL ACTION WRITTEN	59851
Apr. 22, 2010	ASSIGNED TO EXAMINER	59851
Jan. 29, 2010	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	
Jan. 28, 2010	NEW APPLICATION ENTERED IN TRAM	

TM Staff and Location Information

TM Staff Information

TM Attorney:	FISHER, HANNAH M	Law Office Assigned:	LAW OFFICE 111
File Location			

File Location

Current Location: INTENT TO USE SECTION Date in Location: Apr. 27, 2012

Assignment Abstract of Title Information

Summar	V
--------	---

Applicant: Mylan Inc.

26

Assignments:

Total

Pages:

Assignment 1 of 1

Conveyance: SECURITY AGREEMENT

Reel/Frame: 4704/0376

Date Recorded: Nov. 21, 2011

1

Supporting Documents:	assignment-tm-4704-0376.pdf		
	Assign	or	
Name:	DEY PHARMA, L.P.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	LIMITED PARTNERSHIP	State or Country Where Organized:	DELAWARE
Name:	<u>MYLAN INSTITUTIONAL</u> <u>INC., (F/K/A UDL</u> <u>LABORATORIES, INC.)</u>	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	ILLINOIS
Name:	<u>MYLAN</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA
Name:	<u>MYLAN BERTEK</u> <u>PHARMACEUTICALS INC.</u> (F/K/A BERTEK PHARMACEUTICALS, INC.)	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	TEXAS
Name:	<u>MYLAN INC. (F/K/A MYLAN</u> LABORATORIES INC.)	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Name:	<u>SOMERSET</u> <u>PHARMACEUTICALS, INC.</u>	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	DELAWARE

Name:	INC.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA
	Assig	nee	
Name:	BANK OF AMERICA, N.A., A	S ADMINISTRAT	TIVE AGENT
Legal Entity Type:	ASSOCIATION	State or Country Where Organized:	UNITED STATES
Address:	101 N TRYON STREET, NC1- ONE INDEPENDENCE CENT CHARLOTTE, NORTH CARC	ER	-0001
	Correspo	ondent	
Correspondent Name:	MICHAEL VIOLET		
Correspondent Address:	CT LIEN SOLUTIONS 4400 EASTON COMMONS W COLUMBUS, OH 43219	AY, SUITE 125	

Execution Date: Nov. 14, 2011

MYLAN TECHNOLOGIES,

Name:

Domestic Representative - Not Found

EXHIBIT 6

Generated on: This page was generated by TSDR on 2012-09-04 10:10:48 EST

Mark: EPIPEN PREPARED

EPIPEN PREPARED

US Serial Number:	77919257	Application Filing Date:	Jan. 25, 2010
Filed as TEAS Plus:	Yes	Currently TEAS Plus:	Yes
Register:	Principal		
Mark Type:	Trademark		
Status:	A fourth request for exter	nsion of time to fil	e a Statement of Use has been granted.
Status Date:	Aug. 09, 2012		
Publication Date:	Jun. 08, 2010	Notice of Allowance Date:	Aug. 03, 2010

Mark Information

Mark Literal EPIPEN PREPARED Elements:

Standard Yes. The mark consists of standard characters without claim to any particular font style, size, or color.

Mark Drawing Type: 4 - STANDARD CHARACTER MARK

Related Properties Information

Claimed Ownership of US Registrations: <u>1124454,1479294,2576013</u>, and others

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- • Brackets [..] indicate deleted goods/services;
- • Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and

• • Asterisks *..* identify additional (new) wording in the goods/services.

For:	Injectable ph	Injectable pharmaceuticals for treatment of anaphylactic reactions			
International Clas	s : 005 - Primar	y Class	U.S Class:	006, 018, 044,	046, 051, 052
Class Status:	ACTIVE				
Basis:	l(b)				
For:	Medical fluid	d injectors			
International Clas	s : 010 - Primar	y Class	U.S Class:	026, 039, 044	
Class Status:	ACTIVE				
Basis:	1(b)				
	Bas	is Informatio	on (Case Lev	^{wester west}	
Filed Use:	No	Currently Use:	No	Amended Use:	No
Filed ITU:	Yes	Currently ITU:	Yes	Amended ITU:	No
Filed 44D:	No	Currently 44D:	No	Amended 44D:	No
Filed 44E:	No	Currently 44E:	No	Amended 44E:	No
Filed 66A:	No	Currently 66A:	No		
Filed No Basis:	No	Currently No Basis:	No		
	Cu	rrent Owner	(s) Informatio	n	
Owner Name:	Mylan Inc.				
Owner Address:		Drive, Suite 400 ENNSYLVANIA FES			
Legal Entity Type:	CORPORATIC		State or Country Where Organized:	PENNSYLVAN	IA

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Michael A. Doctrow

Docket Number: 24406-0007

Correspondent

Corresponden Name/Address		-		
Phone:	717-232-8000	Fax:	717-237-5300	
Correspondent mail:	e- <u>trademarks@mwn.com</u>	Correspondent e- mail Authorized:	Yes	
Domestic Representative - Not Found				
	Prosecution	History		
Date	Description		Proceeding Number	
Aug. 10, 2012	NOTICE OF APPROVAL OF EXT MAILED	ENSION REQUEST	'E-	
Aug. 09, 2012	EXTENSION 4 GRANTED		70565	

- Aug. 03, 2012 EXTENSION 4 FILED
- Aug. 03, 2012 TEAS EXTENSION RECEIVED
- Feb. 01, 2012ASSIGNMENT OF OWNERSHIP NOT UPDATED
AUTOMATICALLY
- Jan. 24, 2012 NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- Jan. 21, 2012
 EXTENSION 3 GRANTED
 70565
- Jan. 19, 2012EXTENSION 3 FILEDJan. 19, 2012TEAS EXTENSION RECEIVED
- Jan. 04, 2012 ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- Jan. 04, 2012 ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- Dec. 07, 2011 ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- Aug. 09, 2011 NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- Aug. 08, 2011 EXTENSION 2 GRANTED

70565

70565

Total	1	Applicant:	Mylan Inc.
	Sum	mary	
	Assignment Abstrac	t of Title Inform	nation
Current Locatior	: INTENT TO USE SECTION	Date in Location:	Feb. 16, 2011
	File Lo	cation	
TM Attorney:	FISHER, HANNAH M	Law Office Assigned:	LAW OFFICE 111
	TM Staff Ir	formation	
·····	TM Staff and Loc	ation Informat	ion
Jan. 28, 2010	NEW APPLICATION ENTERE	D IN TRAM	
Jan. 29, 2010	ENTERED IN TRAM		
Apr. 22, 2010	ASSIGNED TO EXAMINER NEW APPLICATION OFFICE	SUPPLIED DATA	59851
Apr. 24, 2010	APPROVED FOR PUB - PRING	CIPAL REGISTER	60051
May 05, 2010	ASSIGNED TO LIE		66213
May 05, 2010	LAW OFFICE PUBLICATION	REVIEW COMPLI	
Jun. 08, 2010	PUBLISHED FOR OPPOSITIO		
Jun. 08, 2010	OFFICIAL GAZETTE PUBLIC E-MAILED	ATION CONFIRM	ATION
Aug. 03, 2010	NOA E-MAILED - SOU REQU	IRED FROM APPI	JCANT
Jan. 28, 2011	TEAS EXTENSION RECEIVED	C	
Feb. 16, 2011	CASE ASSIGNED TO INTENT	TO USE PARALE	GAL 70565
Jan. 28, 2011	EXTENSION 1 FILED		70565
Feb. 16, 2011	EXTENSION 1 GRANTED		70565
Feb. 17, 2011	NOTICE OF APPROVAL OF E MAILED	XTENSION REQU	EST E-
Aug. 02, 2011	TEAS EXTENSION RECEIVED	D	
Aug. 02, 2011	EXTENSION 2 FILED		70565

Assignments: Assignment 1 of 1

Reel/Frame:	<u>4704/0376</u>	Pages:	26
Date Recorded:	Nov. 21, 2011		
Supporting Documents:	assignment-tm-4704-0376.pdf		
	Assign	or	
Name:	DEY PHARMA, L.P.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	LIMITED PARTNERSHIP	State or Country Where Organized:	DELAWARE
Name:	<u>MYLAN INSTITUTIONAL</u> INC., (F/K/A UDL LABORATORIES, INC.)	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	ILLINOIS
Name:	<u>MYLAN</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA
Name:	<u>MYLAN BERTEK</u> <u>PHARMACEUTICALS INC.</u> (F/K/A BERTEK <u>PHARMACEUTICALS, INC.)</u>	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	TEXAS
Name:	<u>MYLAN INC. (F/K/A MYLAN</u> <u>LABORATORIES INC.)</u>	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Name:	<u>SOMERSET</u>	Execution Date:	Nov. 14, 2011

PHARMACEUTICALS, INC.

Legal Entity Type: CORPORATION

State or Country Where DELAWARE Organized:

Name: <u>MYLAN TECHNOLOGIES,</u> <u>INC.</u>

Execution Date: Nov. 14, 2011

Legal Entity Type: CORPORATION State or Organized:

Assignee

Name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT

State or Country Where UNITED STATES Organized:

	101 N TRYON STREET, NC1-001-05-45
Address:	ONE INDEPENDENCE CENTER
	CHARLOTTE, NORTH CAROLINA USA 28255-0001

Correspondent

Correspondent MICHAEL VIOLET

Legal Entity Type: ASSOCIATION

Correspondent Address: CT LIEN SOLUTIONS 4400 EASTON COMMONS WAY, SUITE 125 COLUMBUS, OH 43219

Domestic Representative - Not Found

EXHIBIT 7

Generated on: This page was generated by TSDR on 2012-09-04 10:14:20 EST

Mark: EPI-PREPARED

EPI-PREPARED

US Serial Number:	77919269	Application Filing Date:	Jan. 25, 2010
Filed as TEAS Plus:	Yes	Currently TEAS Plus:	Yes
Register:	Principal		
Mark Type:	Trademark		
Status:	A fourth request for e	extension of time to file	e a Statement of Use has been granted.
Status Date:	Aug. 09, 2012		
Publication Date:	Jun. 08, 2010	Notice of Allowance Date:	Aug. 03, 2010
		Mark Informatior	······································
·		a a an ann an	ann ann annsaichteann a' ann annsaichteanna ann an annsaichteanna
Mark Literal Elements:	EPI-PREPARED		
Standard Character Claim			cters without claim to any particular
Mark Drawing Type:	4 - STANDARD C	CHARACTER MARK	
maariya ya maraasa	Related	Properties Info	
Claimed Owners of US Registratio	• • • • • • • • • • • • • • • • • • • •	4,2576013,and others	
	Go	oods and Service	
Note: The following syr	nbols indicate that the	registrant/owner has a	mended the goods/services:
	-	· ·	not claimed in a Section 15 affidavit

• • Asterisks *..* identify additional (new) wording in the goods/services.

For:	Injectable p	Injectable pharmaceuticals for treatment of anaphylactic reactions			
International Clas	ss : 005 - Prima	: 005 - Primary Class		006, 018, 044,	046, 051, 052
Class Status:	ACTIVE				
Basis:	l(b)				
For:	Medical flu	id injectors			
International Clas	ss: 010 - Prima	ary Class	U.S Class:	026, 039, 044	
Class Status:	ACTIVE				
Basis:	1(b)				
	Ba	sis Informatio	on (Case Lev	el)	
Filed Use:	No	Currently Use:	No	Amended Use:	No
Filed ITU:	Yes	Currently ITU:	Yes	Amended ITU:	No
Filed 44D:	No	Currently 44D:	No	Amended 44D:	No
Filed 44E:	No	Currently 44E:	No	Amended 44E:	No
Filed 66A:	No	Currently 66A:	No		
Filed No Basis:	No	Currently No Basis:	No		
	Cı	urrent Owner(s) Informatio)n	
Owner Name:	Mylan Inc.				
Owner Address:	Suite 400 1500 Corporat Canonsburg, F UNITED STA	PENNSYLVANIA	15317		
Legal Entity Type:	CORPORATI		State or Country Where Organized:	PENNSYLVAN	IA
Attorney/Correspondence Information					

Attorney of Record

Attorney Name:	Michael A. Doctrow Docket Number:		24406-0007
	Correspondent		
Correspondent Name/Address:	MICHAEL A. DOCTROW MCNEES WALLACE & NURIC 100 PINE ST HARRISBURG, PENNSYLVAN UNITED STATES		
Phone:	717-232-8000	Fax:	717-237-5300
Correspondent e- mail:	trademarks@mwn.com	Correspondent e- mail Authorized:	Yes

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
Aug. 10, 2012	NOTICE OF APPROVAL OF EXTENSION REQUEST E- MAILED	
Aug. 09, 2012	EXTENSION 4 GRANTED	70565
Aug. 03, 2012	EXTENSION 4 FILED	70565
Aug. 03, 2012	TEAS EXTENSION RECEIVED	
Feb. 01, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 25, 2012	NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED	
Jan. 21, 2012	EXTENSION 3 GRANTED	70565
Jan. 19, 2012	EXTENSION 3 FILED	70565
Jan. 19, 2012	TEAS EXTENSION RECEIVED	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Aug. 09, 2011	NOTICE OF APPROVAL OF EXTENSION REQUEST E- MAILED	
Aug. 08, 2011	EXTENSION 2 GRANTED	70565
Aug. 02, 2011	EXTENSION 2 FILED	70565

Aug. 02, 2011	TEAS EXTENSION RECEIVED	
Feb. 17, 2011	NOTICE OF APPROVAL OF EXTENSION REQUEST E- MAILED	
Feb. 16, 2011	EXTENSION 1 GRANTED	70565
Jan. 28, 2011	EXTENSION 1 FILED	70565
Feb. 16, 2011	CASE ASSIGNED TO INTENT TO USE PARALEGAL	70565
Jan. 28, 2011	TEAS EXTENSION RECEIVED	
Aug. 03, 2010	NOA E-MAILED - SOU REQUIRED FROM APPLICANT	
Jun. 08, 2010	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	
Jun. 08, 2010	PUBLISHED FOR OPPOSITION	
May 05, 2010	LAW OFFICE PUBLICATION REVIEW COMPLETED	66213
May 05, 2010	ASSIGNED TO LIE	66213
Apr. 24, 2010	APPROVED FOR PUB - PRINCIPAL REGISTER	
Apr. 22, 2010	ASSIGNED TO EXAMINER	59851
Jan. 29, 2010	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	
Jan. 28, 2010	NEW APPLICATION ENTERED IN TRAM	

TM Staff and Location Information

TM Staff Information

IN ANOTHEV: FISHER HANNAH M	Law Office Assigned:	LAW OFFICE 111
-----------------------------	-------------------------	----------------

File Location

Current Location: INTENT TO USE SECTION Date in Location: Feb. 16, 2011

Assignment Abstract of Title Information

Summary

Total Assignments:	1	Applicant:	Mylan Inc.
Assignment 1 of 1			
Conveyance:	SECURITY AGREEMENT		
Reel/Frame:	4704/0376	Pages:	26

Date Recorded:	Nov. 21, 2011			
Supporting Documents:	assignment-tm-4704-0376.pdf			
	Assign	or		
Name:	<u>DEY PHARMA, L.P.</u>	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	LIMITED PARTNERSHIP	State or Country Where Organized:	DELAWARE	
Name:	<u>MYLAN INSTITUTIONAL</u> <u>INC., (F/K/A UDL</u> <u>LABORATORIES, INC.)</u>	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	ILLINOIS	
Name:	<u>MYLAN</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA	
Name:	<u>MYLAN BERTEK</u> <u>PHARMACEUTICALS INC.</u> (F/K/A BERTEK PHARMACEUTICALS, INC.)	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	TEXAS	
Name:	<u>MYLAN INC. (F/K/A MYLAN</u> LABORATORIES INC.)	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA	
Name:	<u>SOMERSET</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011	

Legal Entity Type: CORPORATION

State or Country Where DELAWARE Organized:

Name: <u>MYLAN TECHNOLOGIES,</u> INC.

Execution Date: Nov. 14, 2011

Legal Entity Type: CORPORATION

State or Country Where WEST VIRGINIA Organized:

Assignee

Name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT

Legal Entity Type: ASSOCIATION State or Organized:

Address:101 N TRYON STREET, NC1-001-05-45Address:ONE INDEPENDENCE CENTER
CHARLOTTE, NORTH CAROLINA USA 28255-0001

Correspondent

Correspondent MICHAEL VIOLET

Correspondent Address: CT LIEN SOLUTIONS 4400 EASTON COMMONS WAY, SUITE 125 COLUMBUS, OH 43219

Domestic Representative - Not Found

EXHIBIT 8

Generated on: This page was generated by TSDR on 2012-09-04 10:16:52 EST

Mark: EPI-SET

EPI-SET

US Serial Number:	77919271	Application Filing Date:	Jan. 25, 2010	
Filed as TEAS Plus:	Yes	Currently TEAS Plus:	Yes	
Register:	Principal			
Mark Type:	Trademark			
Status:	A second request	t for extension of time to fi	le a Statement of Use has been granted.	
Status Date:	May 01, 2012			
Publication Date:	Feb. 08, 2011	Notice of Allowance Date:	Apr. 05, 2011	
		Mark Information		
Mark Literal Elements:	EPI-SET			
Standard Character Claim			ecters without claim to any particular	
Mark Drawing Type:	4 - STANDAI	RD CHARACTER MARK		
Related Properties Information				
Claimed Ownership of US Registrations: <u>1124454,1479294,2576013</u> ,and others				
Goods and Services				
Note:				

The following symbols indicate that the registrant/owner has amended the goods/services:

- • Brackets [..] indicate deleted goods/services;
- • Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and

• • Asterisks *..* identify additional (new) wording in the goods/services.

For:	Injecta	Injectable pharmaceuticals for treatment of anaphylactic reactions			
International Clas	s: 005 - I	Primary Class	U.S Class:	006, 018, 044,	046, 051, 052
Class Status:	ACTIV	νE			
Basis:	1(b)				
For:	Medic	al fluid injectors			
International Clas	s: 010 - I	Primary Class	U.S Class:	026, 039, 044	
Class Status:	ACTIV	VЕ			
Basis:	1(b)				
		Basis Informatio	on (Case Lev	el)	
Filed Use:	No	Currently Use:	No	Amended Use:	No
Filed ITU:	Yes	Currently ITU:	Yes	Amended ITU:	No
Filed 44D:	No	Currently 44D:	No	Amended 44D:	No
Filed 44E:	No	Currently 44E:	No	Amended 44E:	No
Filed 66A:	No	Currently 66A:	No		
Filed No Basis:	No	Currently No Basis:	No		
		Current Owner(s) Informatio)n	
Owner Name:	Mylan In	с.			
Owner Address:	Canonsb	porate Drive 1rg, PENNSYLVANIA STATES	15317		
Legal Entity Type:	CORPOR		State or Country Where Organized:	PENNSYLVAN	ΊΑ
Attorney/Correspondence Information					

Attorney of Record

Attorney Name:	Michael A. Doctrow	ichael A. Doctrow Docket Number:		
	Correspondent			
Correspondent Name/Address:	MICHAEL A. DOCTROW MCNEES WALLACE & NURIC 100 PINE ST HARRISBURG, PENNSYLVAN UNITED STATES			
Phone:	717-232-8000	Fax:	717-237-5300	
Correspondent e- mail:	trademarks@mwn.com	Correspondent e- mail Authorized:	Yes	

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
May 02, 2012	NOTICE OF APPROVAL OF EXTENSION REQUEST E- MAILED	
May 01, 2012	EXTENSION 2 GRANTED	66530
Apr. 03, 2012	EXTENSION 2 FILED	66530
Apr. 27, 2012	CASE ASSIGNED TO INTENT TO USE PARALEGAL	66530
Apr. 03, 2012	TEAS EXTENSION RECEIVED	
Feb. 01, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Dec. 07, 2011	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Oct. 06, 2011	NOTICE OF APPROVAL OF EXTENSION REQUEST E- MAILED	
Oct. 04, 2011	EXTENSION 1 GRANTED	98765
Oct. 04, 2011	EXTENSION 1 FILED	98765
Oct. 04, 2011	TEAS EXTENSION RECEIVED	
Apr. 05, 2011	NOA E-MAILED - SOU REQUIRED FROM APPLICANT	

Feb. 08, 2011	OFFICIAL GAZETTE PUBLICA MAILED	ATION CONFIRM	ATION E-	
Feb. 08, 2011	PUBLISHED FOR OPPOSITION	J		
Jan. 03, 2011	LAW OFFICE PUBLICATION I	ETED 67287		
Dec. 26, 2010	APPROVED FOR PUB - PRINC	IPAL REGISTER		
Nov. 16, 2010	AMENDMENT FROM APPLIC	67287		
Nov. 16, 2010	CORRESPONDENCE RECEIVE	ED IN LAW OFFIC	CE 67287	
Nov. 16, 2010	ASSIGNED TO LIE		67287	
Oct. 27, 2010	PAPER RECEIVED			
Apr. 25, 2010	NOTIFICATION OF NON-FINA	AL ACTION E-MA	ILED 6325	
Apr. 25, 2010	NON-FINAL ACTION E-MAIL	ED	6325	
Apr. 25, 2010	NON-FINAL ACTION WRITTE	ΣN	59851	
Apr. 22, 2010	ASSIGNED TO EXAMINER	59851		
Jan. 29, 2010	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM			
Jan. 28, 2010	NEW APPLICATION ENTERE	D IN TRAM		
	TM Staff and Loca TM Staff In		ion	
TM Attorney:	FISHER, HANNAH M	Law Office Assigned:	LAW OFFICE 111	
	File Lo	cation		
Current Locatio	n: INTENT TO USE SECTION	Date in Location:	Apr. 27, 2012	
·	Assignment Abstrac	t of Title Infor		
Summary				
Total Assignments:	. 1	Applicant:	Mylan Inc.	
Assignment 1 o	f 1			
Conveyance:	SECURITY AGREEMENT			
Reel/Frame:	<u>4704/0376</u>	Pages:	26	
Date Recorded	d : Nov. 21, 2011			

Supporting Documents:	assignment-tm-4704-0376.pdf			
Assignor				
Name:	DEY PHARMA, L.P.	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	LIMITED PARTNERSHIP	State or Country Where Organized:	DELAWARE	
Name:	<u>MYLAN INSTITUTIONAL</u> <u>INC., (F/K/A UDL</u> <u>LABORATORIES, INC.)</u>	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	ILLINOIS	
Name:	<u>MYLAN</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA	
Name:	<u>MYLAN BERTEK</u> <u>PHARMACEUTICALS INC.</u> <u>(F/K/A BERTEK</u> <u>PHARMACEUTICALS, INC.)</u>	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	TEXAS	
Name:	<u>MYLAN INC. (F/K/A MYLAN</u> LABORATORIES INC.)	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA	
Name:	<u>SOMERSET</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	DELAWARE	

Name:	<u>MYLAN TECHNOLOGIES,</u> <u>INC.</u>	Execution Date:	Nov. 14, 2011	
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA	
	Assign	ee		
Name:	BANK OF AMERICA, N.A., AS	S ADMINISTRAT	TIVE AGENT	
Legal Entity Type:	ASSOCIATION	State or Country Where Organized:	UNITED STATES	
Address:	101 N TRYON STREET, NC1-0 ONE INDEPENDENCE CENTE CHARLOTTE, NORTH CARO	ER	-0001	
Correspondent				
Correspondent Name:	MICHAEL VIOLET			
Correspondent Address:	CT LIEN SOLUTIONS 4400 EASTON COMMONS WA COLUMBUS, OH 43219	AY, SUITE 125		

Domestic Representative - Not Found

Generated on: This page was generated by TSDR on 2012-09-04 10:18:24 EST

Mark: EPICARD

EPICARD

US Serial Number:	77927738	Application Filing Date:	Feb. 04, 2010
Register:	Principal		
Mark Type:	Trademark		
Status:	A first request for extension	n of time to file	a Statement of Use has been granted.
Status Date:	Apr. 30, 2012		
Publication Date:	Sep. 06, 2011	Notice of Allowance Date:	Nov. 01, 2011

Mark Information

Mark Literal EPIC

EPICARD

Standard Yes. The mark consists of standard characters without claim to any particular **Character Claim**: font style, size, or color.

Mark Drawing Type: 4 - STANDARD CHARACTER MARK

Related Properties Information

Claimed Ownership of US Registrations: <u>1124454,1479294,2576013</u>, and others

Goods and Services

Note:

The following symbols indicate that the registrant/owner has amended the goods/services:

- • Brackets [..] indicate deleted goods/services;
- • Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- • Asterisks *..* identify additional (new) wording in the goods/services.

printed multilingual instructional material regarding the purpose and use of For: epinephrine auto injectors 002, 005, 022, 023, 029, 037, International Class: 016 - Primary Class U.S Class: 038,050 ACTIVE **Class Status:** 1(b)Basis: **Basis Information (Case Level)** No **Currently Use:** No Amended Use: No Filed Use: Filed ITU: Yes **Currently ITU:** Yes Amended ITU: No Filed 44D: No Currently 44D: No Amended 44D: No Amended 44E: No Filed 44E: Currently 44E: No No Currently 66A: No Filed 66A: No **Currently No** No Filed No Basis: No Basis: **Current Owner(s) Information** Owner Name: Mylan Inc. 1500 Corporate Drive **Owner Address:** Canonsburg, PENNSYLVANIA 15317 UNITED STATES State or Country Legal Entity PENNSYLVANIA CORPORATION Where Type: Organized: **Attorney/Correspondence Information** Attorney of Record Michael A. Doctrow **Docket Number:** 24406-0001 **Attorney Name:** Correspondent MICHAEL A. DOCTROW MCNEES WALLACE & NURICK Correspondent 100 PINE ST Name/Address: HARRISBURG, PENNSYLVANIA 17101-1200 UNITED STATES

Fax: 717-237-5300

Correspondent email: <u>trademarks@mwn.com</u> Correspondent email Authorized:

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
May 02, 2012	NOTICE OF APPROVAL OF EXTENSION REQUEST E- MAILED	
Apr. 30, 2012	EXTENSION 1 GRANTED	98765
Apr. 30, 2012	EXTENSION 1 FILED	98765
Apr. 30, 2012	TEAS EXTENSION RECEIVED	
Feb. 01, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Jan. 04, 2012	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Dec. 07, 2011	ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY	
Nov. 01, 2011	NOA E-MAILED - SOU REQUIRED FROM APPLICANT	
Sep. 06, 2011	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E- MAILED	
Sep. 06, 2011	PUBLISHED FOR OPPOSITION	
Aug. 03, 2011	LAW OFFICE PUBLICATION REVIEW COMPLETED	66213
Jul. 28, 2011	APPROVED FOR PUB - PRINCIPAL REGISTER	
Jul. 01, 2011	AMENDMENT FROM APPLICANT ENTERED	66213
Jul. 01, 2011	CORRESPONDENCE RECEIVED IN LAW OFFICE	66213
Jun. 29, 2011	PAPER RECEIVED	
Dec. 26, 2010	NOTIFICATION OF FINAL REFUSAL EMAILED	
Dec. 26, 2010	FINAL REFUSAL E-MAILED	
Dec. 26, 2010	FINAL REFUSAL WRITTEN	59851
Nov. 16, 2010	AMENDMENT FROM APPLICANT ENTERED	66213

Nov. 16, 2010	CORRESPONDENCE RECEIVED IN LAW OFFICE	66213
Nov. 16, 2010	ASSIGNED TO LIE	66213
Oct. 27, 2010	PAPER RECEIVED	
Apr. 26, 2010	NOTIFICATION OF NON-FINAL ACTION E-MAILED	6325
Apr. 26, 2010	NON-FINAL ACTION E-MAILED	6325
Apr. 26, 2010	NON-FINAL ACTION WRITTEN	59851
Apr. 22, 2010	ASSIGNED TO EXAMINER	59851
Feb. 13, 2010	NOTICE OF PSEUDO MARK MAILED	
Feb. 12, 2010	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	
Feb. 08, 2010	NEW APPLICATION ENTERED IN TRAM	

TM Staff and Location Information

TM Staff Information

TM Attorney:	FISHER, HANNAH M	Law Office Assigned:	LAW OFFICE 111
		Assigned	

File Location

Current Location: INTENT TO USE SECTION Date in Location: Nov. 01, 2011

Assignment Abstract of Title Information

Summary

Total Assignments:	1	Applicant:	Mylan Inc.
Assignment 1 of 1			
Conveyance:	SECURITY AGREEMENT		
Reel/Frame:	4704/0376	Pages:	26
Date Recorded:	Nov. 21, 2011		
Supporting Documents:	assignment-tm-4704-0376.pdf		
	Assigr	or	
Name:	DEY PHARMA, L.P.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	LIMITED PARTNERSHIP	State or Country Where	DELAWARE

		Organized:	
Name:	<u>MYLAN INSTITUTIONAL</u> <u>INC., (F/K/A UDL</u> <u>LABORATORIES, INC.)</u>	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	ILLINOIS
Name:	<u>MYLAN</u> PHARMACEUTICALS, INC.	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA
Name:	<u>MYLAN BERTEK</u> <u>PHARMACEUTICALS INC.</u> (F/K/A BERTEK PHARMACEUTICALS, INC.)	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	TEXAS
Name:	<u>MYLAN INC. (F/K/A MYLAN</u> LABORATORIES INC.)	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	PENNSYLVANIA
Name:	<u>SOMERSET</u> <u>PHARMACEUTICALS, INC.</u>	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	DELAWARE
Name:	<u>MYLAN TECHNOLOGIES,</u> <u>INC.</u>	Execution Date:	Nov. 14, 2011
Legal Entity Type:	CORPORATION	State or Country Where Organized:	WEST VIRGINIA

Assignee

Name:	BANK OF AMERICA, N.A.	, AS ADMINISTRAT	IVE AGENT
Legal Entity Type:	ASSOCIATION	State or Country Where Organized:	UNITED STATES
Address:	101 N TRYON STREET, NO ONE INDEPENDENCE CEI CHARLOTTE, NORTH CA	NTER	-0001
	Corres	pondent	
Correspondent Name:	MICHAEL VIOLET		
Correspondent Address:	CT LIEN SOLUTIONS 4400 EASTON COMMONS COLUMBUS, OH 43219	WAY, SUITE 125	

Domestic Representative - Not Found

٠

•

THOMAS C. BELLER DISCOVERY DEPOSITION FEBRUARY 13, 2012 (EXCERPTS)

Page 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

MYLAN, INC.,

Opposer,

vs.

بر. ز

: :...

 $(1,\ldots, n, n)$

لمستحمة

OPPOSITION NUMBER 91195868

BEAUFORT COUNTY ALLERGY,

Applicant.

------/

The deposition of THOMAS CHARLES BELLER, M.D., a witness in the above-entitled cause, taken pursuant to Notice and agreement, before Kyle J. Saniga, Certified Court Reporter and Notary Public, at the Offices of Raymond James, 27 Towne Drive, Suite 202, Hilton Head, South Carolina 29910, on the 13th day of February 2012, commencing at or about the hour of 10:30 a.m.

		Page 2		
2 AP			1	Page 4
	PEARANCES OF COUNSEL:		2	DOCUMENTARY EVIDENCE
4	FOR THE OPPOSER: HARVEY FREEDENBERG, ESOUIRE		3	NUMBER DESCRIPTION PAGE
	McNees, Wallace & Nurick, L.L.C.		4	
5	100 Pine Street Harrisburg, Pennsylvania 17108-1166		5	OX-18 Email of 1/15/12 TriE Medical Followup 74
6	hfreedenberg@mwn.com		6	OX-19 Email of 1/15/12 Epi-Key
7	717.237.5267			Proposal 74
	OR THE APPLICANT:		7	
9	ANTHONY M. VERNA, III, ESQUIRE Anthony M. Verna, III, Esquire		8	OX-20 Email of 1/15/12 Epi-Key Proposal-1 ATT00057 74
10	160 West End Avenue		9	OX-21 Email of 1/15/12 Epi-Key
11	New York, New York 10023 averna@kravitzverna.com		-	Proposal-1 ATT00051 74
12	212.729.5651		10	
			11 12	
13	INDEX		13	
14			14	
15	PAGE		15	
16 EX	HIBIT INDEX 3		16 17	
17 OP	ENING REMARKS AND STIPULATIONS		18	
18 19			19	
20			20	
21 DIF	RECT EXAMINATION: by Mr. Freedenberg 5		21 22	
22	y with Theodenberg		23	
23 24			24	
	RTIFICATE 113		25	
		Page 3		Page 5
1			1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
	DOCUMENTARY EVIDENCE MBER DESCRIPTION PAGE		2	THOMAS CHARLES BELLER, M.D.,
4 OX	7 Notice of Deposition 7		3	having been produced and first duly sworn as a
5 OX	-2 Email of 1/15/12 Epi-Key Timeline 17		4	witness, testified as follows:
6			5	DIRECT EXAMINATION
	-3 Combined Declaration and POA for Patent Application 23		6 7	BY MR. FREEDENBERG:
	-4 Email of 1/15/12		8	Q Could you state your full name and your business address for the record, please.
9	Trademark Question 47		9	A Thomas Charles Beller. My business
	-5 Federal Registered Trademarks 52		10	address is 60 Main Street, Suite D, Hilton Head
	-6 Applicant's Answers to Opposer's		11	South, Carolina, 29926.
11 12 OX	First Set of Interrogatories 68 -7 Answers 68		12	Q Dr. Beller, my name is Harvey
13 OX	-8 Expert Report of Myron Zitt 74		13	Freedenberg.
	-9 Expert Report of Kevin Murphy 74 -10 Expert Report of Martha White 74		14	As you know, I'm an attorney
16 OX	-11 Expert Report of Ray Davis 74		15	representing Mylan Incorporated in a trademark
	-12 Expert Report of Phil Lieberman 74 -13 Applicant's Expert Report of		16 17	proceeding in which an entity with which you're
	Thomas Murphy, M.D. 74		18	involved, Beaufort County Allergy, is the respondent or the trademark applicant. Have you
19 OX	-14 Applicant's Expert Report		19	ever had your deposition taken before?
20	of Rajit Abrol, M.D. 74		20	A I've been deposed for other you
21 OX	-15 Applicant's Expert Report of Andrew Rubin, M.D. 74		21	know, for not for cases concerning myself.
			22	Q Okay.
22	16 Applicantle Europet Benort			
	-16 Applicant's Expert Report of Amin Mery, M.D. 74		23	A But for cases of like workman's
OX 23			23 24 25	 A But for cases of like workman's compensation, things like that. Q Okay. So you've testified in

2 (Pages 2 to 5)

	Page 18		Page 20
1 1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
	e-mail, an attachment that I received from Mr.	2	A I'm not sure I understand your
	Verna on Friday afternoon.	3	question.
4	The first page is an e-mail that you	4	Q What were you – in creating this
5	sent to him on January 15th, a covered e-mail,	5	timeline, what were you trying to capture?
	and the second page, which you have the document	6	A I was trying to let you know exactly
	open to, is something called pertinent timeline	7	how the whole thing evolves. I prepared the
	involving Epi-Key trademark, is that correct?	8	timeline for Anthony to pass it on to you.
9	A Yes.	9	Q Okay, all right. You're obviously
10	Q Did you prepare this timeline?	101	familiar with the device called the Epi-Key?
11	A Yes, I did.	11	A Yes, sir.
12	Q Now, you had mentioned, in your	12	Q Okay. What is it?
	previous answer, that you, referring to this,	13	A It's a key-shaped device that contains
	might refresh your recollection about when TCB	14	epi.
	Medical Devices was formed. Does it, in fact,	15	Q And when you use the term "epi" you're
	do that?	16	referring to epinephrine?
17	A Let me see. You know, I'm going to say	17	A Yes.
	I as far as I recall it was February 2010, if	18	Q What's the purpose of the device?
	it wasn't it might have been March but it was	19	A It's for patients to carry who are at
		20	risk of anaphylaxis.
	somewhere right in that timeline.	21	Q Okay. And what is anaphylaxis?
21	Q Okay. And if you look at the I	22	A It's a severe allergic reaction.
	guess the fourth entry from the bottom, it's	23	Q Okay. And what are some of the causes
	dated 2-15-10, it says; e-mailed, Mark Foreman.	24	of anaphylaxis?
24	A Yes.	25	A Food allergy, insect allergy, allergy
25	Q Now, a large shareholder in TCB Medical	2.5	Page 21
	Page 19	-	
	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
	Devices about potentially investing in my	2	shot reactions, idiopathic exercise-induced.
	product project; that's the same Mark Foreman	4	Q What was the reason for developing this device?
	that you mentioned a few minutes ago?	5	
5	A Yes.	6	A Well, because I treat patients who are at risk of this condition
6	Q What's his business or profession?	7	O Uh-huh.
7	A He's a software consultant.	8	A I recognize that there's a big
8	Q Is he a personal friend of yours?	g	market for these devices and I thought I could
9	A Yes.		
10	Q Is there any legal relationship or	10 11	have some financial gain.
	business relationship between TCB and we'll call	1	Q Okay. When did that idea first occur
	BCA, Beaufort County Allergy?	12 13	to you?
13	A No, only that they're both related to	13	A 2008.
	me and I control and own both companies.	14 15	Q Okay. If you look at the timeline, that's the first entry where it says you
15	Q Okay. Did you prepare the chronology	15	conceptualized the idea of making a smaller
	that's on the second page of Exhibit 2 about the	10	device to contain epi that could attach to a key
	time that you sent it to Mr. Verna in the middle	18	•
	of January?	18 19	chain, is that correct?
19	A Do you mean did I prepare this		A Yes, sir.
	timeline?	20	Q Is that the time period, 2008, when you
21	Q Yes.	21	came up with this name, Epi-Key?
22	A Yes.	22	A Probably.
23	Q Does this timeline set forth the	23	Q And it says in that first entry that
	significant dates relating to the development of	24	you shared your idea, verbally, with a Twinject
25	the Epi-Key trademark?	25	rep, who is Twinject?

 $(1, \dots, n)$

6 (Pages 18 to 21)

÷

.

	Page 26	Γ	Page 28
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
2	Q Okay. But he doesn't have any medical	2	few weeks ago, December 29th 2011.
3	background has he ever worked on designing a	3	Were you aware that this application
4	medical device, to your knowledge?	4	had been published sometime after December of
5	A Well, other than this one.	5	last year?
6	MR. VERNA: Objection, relevancy.	6	A You know, my understanding was we
	THE WITNESS: He did help develop	7	initially filed a you know, there's a new
8	this device, you know, as far as how	8	category of patents that you have one year to
9	should it function, you know, where	9	change it, I forget the exact name.
10	should the safety buttons go, that kind	10	Q Does the term "provisional patent"
11	of thing.	11	A Provisional, yes. So we initially
12	BY MR. FREEDENBERG:	12	filed a provisional patent I believe in 2010.
13		13	Q If you look at the first page of the
14	Q Okay. My question was, other than this device has he ever worked on	14	application, I'll direct your attention to
15	A No, other than this device, no.	15	something there. Do you see where it says;
16	O There's another name listed below Mr.	16	related U.S. application data?
17	Foreman as Matthew Morton.	17	A Yes.
18	A Yes.	18	Q And it says; professional application,
19		19	and then there's a number filed on
20	Q Who's Matthew? A He works for TriE Medical. He was one	20	A Yes.
20		21	O - June 23rd?
22	of the engineers.	22	Q = June 25rd: A Yes.
	Q And what was his role?	23	
23	MR. VERNA: Objection can I	24	Q So that's consistent with your recollection?
24	preserve an objection over everything?	25	
25	I'm going to	25	A Yes, absolutely.
	Page 27		Page 29
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
2	MR. FREEDENBERG: Sure.	2	Q And then do you recall that there was a
3	MR. VERNA: I'm going to object to	3	formal patent application filed a year later?
4	everything on this exhibit as	4	A Yes.
5	irrelevant so we'll just not waste our	5	Q And then, according to this
6	time.	6	information, that application was published on
7	MR. FREEDENBERG: Okay, thanks.	7	December 29th 2011?
8	MR. VERNA: Go ahead.	8	A Okay.
9	THE WITNESS: So Matt is one of	9	Q Now, if you would, look, you can skip
10	the engineers. You know, when I	10	over the drawings. Do you recall reviewing this
11	mentioned, on the timeline, that I	11	patent application before it was filed?
12	contacted TriE Medical, he's one of the	12	A Yes.
13	engineers that works for TriE Medical.	13	Q Okay. If you go to the section of the
14	BY MR. FREEDENBERG:	14	application, it's entitled, Background of the
15	Q Again, we'll get back to TriE Medical	15	Invention; do you see that?
16	in a little bit.	16	MR. VERNA: Right there.
17	And would that also be true of Amanda,	17	THE WITNESS: Yes.
18	if I'm pronouncing this correctly, Bedsaul.	18	BY MR. FREEDENBERG:
19	A Yes.	19	Q If you go to the - there are numbered
20	Q She's also an engineer with TriE?	20	paragraphs here, which makes it easier to refer
0.1	A Yes.	21	to, but if you look at paragraph 0005.
21		22	A Uh-huh.
22	Q Looks like this application was filed		
22 23	on June 23, 2011. And from the information we	23	Q I'm going to read the page sentence
22			Q I'm going to read the page sentence to you, actually two sentences and ask if you agree with these two sentences; The most common

••• • •

() | |

• •

8 (Pages 26 to 29)

	Page 30		Page 3
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
2	automatic emergency epinephrine injector	2	of the patent?
3	apparatus is the EPI-PEN – that word is all	3	A Well, when you say 'talked to about
4	capped and then there's an R in a circle	4	potential license', I mean we certainly never
5	following that auto-injector distributed by	5	sat down and said, 'We're going to make an
6	Mylan Inc. I'll stop at that, do you agree with	6	agreement' but we presented our idea with the
7	that statement?	7	hopes of making an agreement. We spoke with
8	A Yes.	8	I mean I still have all their business cards at
9	Q Second sentence says; The EPI-PEN,	9	home.
10	again all capped with the R in the circle,	10	Q Uh-hub.
11	injector is designed to rapidly inject an adult	11	A John Wilmot is the name that comes to
12	• • • •	12	mind.
	dose of about 0.30 milligrams of epinephrine. Do	13	Q Can you spell, W-i-l-m
13	you agree with that statement?	14	A M-o-t.
14	A Yes.	15	
15	Q The spelling of epinephrine is	16	
16	e-p-i-n-e-p-h-r-i-n-e.		A W-i-l-m-o-t.
17	If you go to the paragraph labeled	17	Q Okay.
18	0006, which is in the second column of the first	18	A He's with Meridian. He was the main
19	page.	19	person we communicated with.
20	A Uh-huh.	20	My initial contact was at Mylan and his
21	Q I'll read that statement to you, I'll	21	name was Drew, I think his full name is Andrew,
22	read it for the record and then ask if you	22	it's either Cuney or McCuney, I can't remember.
23	agree.	23	Q Okay.
24	"It would be desirable to provide a	24	A I think it's Cuney.
25	more compact, easier to use injector which	25	Q C-o-o-n-e-y?
	Page 31		Page 3
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
2	patients are more likely to carry on their	2	A I think it's C-u-n-e-y but I'm not
3	person for rapid transcutaneous administration	3	positive.
4	of a predetermined dose of medication. It would	4	Q Okay. Did you ever meet with Mr. Cuney
5	also be desirable to provide an injector which	5	or Mr. Wilmot?
6	can be unlocked, activated and administered with	6	A Yes.
7	the use of only one hand."	7	Q Where did the meetings take place?
8	Is that — do you believe that's an	8	A First meeting took place in Connecticut
9	accurate statement in describing your Epi-Key	9	at King Pharmaceutical's offices.
10	auto injector?	10	Q Okay. And who was present at that
	A Yes.	11	meeting?
			0
11		12	A Well, John
11 12	Q And were those at least some of the	12 13	 Well, John MR. VERNA: Objection, again, on
11 12 13		1	
11 12 13 14	Q And were those at least some of the advantages that you believed existed or believe	13	MR. VERNA: Objection, again, on
11 12 13 14 15	Q And were those at least some of the advantages that you believed existed or believe existed in this device over other devices? A Yes.	13 14	MR. VERNA: Objection, again, on relevance to this entire can we
11 12 13	 Q And were those at least some of the advantages that you believed existed or believe existed in this device over other devices? A Yes. Q Have you had any discussions with any 	13 14 15	MR. VERNA: Objection, again, on relevance to this entire can we preserve that for this entire line
11 12 13 14 15 16 17	 Q And were those at least some of the advantages that you believed existed or believe existed in this device over other devices? A Yes. Q Have you had any discussions with any third parties about licensing the patent if and 	13 14 15 16	MR. VERNA: Objection, again, on relevance to this entire can we preserve that for this entire line then?
11 12 13 14 15 16 17 18	 Q And were those at least some of the advantages that you believed existed or believe existed in this device over other devices? A Yes. Q Have you had any discussions with any third parties about licensing the patent if and when it eventually issues? 	13 14 15 16 17	MR. VERNA: Objection, again, on relevance to this entire can we preserve that for this entire line then? MR. FREEDENBERG: Uh-huh, sure.
11 12 13 14 15 16 17 18 19	 Q And were those at least some of the advantages that you believed existed or believe existed in this device over other devices? A Yes. Q Have you had any discussions with any third parties about licensing the patent if and when it eventually issues? A Yes. 	13 14 15 16 17 18	MR. VERNA: Objection, again, on relevance to this entire can we preserve that for this entire line then? MR. FREEDENBERG: Uh-huh, sure. MR. VERNA: Okay.
11 12 13 14 15 16 17 18 19 20	 Q And were those at least some of the advantages that you believed existed or believe existed in this device over other devices? A Yes. Q Have you had any discussions with any third parties about licensing the patent if and when it eventually issues? A Yes. Q Who have you talked to about that? 	13 14 15 16 17 18 19	MR. VERNA: Objection, again, on relevance to this entire can we preserve that for this entire line then? MR. FREEDENBERG: Uh-huh, sure. MR. VERNA: Okay. THE WITNESS: So Drew Cuney, John
11 12 13 14 15 16 17 18 19 20 21	 Q And were those at least some of the advantages that you believed existed or believe existed in this device over other devices? A Yes. Q Have you had any discussions with any third parties about licensing the patent if and when it eventually issues? A Yes. Q Who have you talked to about that? A Every one associated with EpiPen, so 	13 14 15 16 17 18 19 20	MR. VERNA: Objection, again, on relevance to this entire can we preserve that for this entire line then? MR. FREEDENBERG: Uh-huh, sure. MR. VERNA: Okay. THE WITNESS: So Drew Cuney, John Wilmot, the President of I'm trying to think who was the company that
11 12 13 14 15 16 17 18 19 20 21 22	 Q And were those at least some of the advantages that you believed existed or believe existed in this device over other devices? A Yes. Q Have you had any discussions with any third parties about licensing the patent if and when it eventually issues? A Yes. Q Who have you talked to about that? A Every one associated with EpiPen, so Mylan, King, Meridian. We also had discussions 	13 14 15 16 17 18 19 20 21	MR. VERNA: Objection, again, on relevance to this entire can we preserve that for this entire line then? MR. FREEDENBERG: Uh-huh, sure. MR. VERNA: Okay. THE WITNESS: So Drew Cuney, John Wilmot, the President of I'm trying
11 12 13 14 15 16	 Q And were those at least some of the advantages that you believed existed or believe existed in this device over other devices? A Yes. Q Have you had any discussions with any third parties about licensing the patent if and when it eventually issues? A Yes. Q Who have you talked to about that? A Every one associated with EpiPen, so 	13 14 15 16 17 18 19 20 21 22	MR. VERNA: Objection, again, on relevance to this entire can we preserve that for this entire line then? MR. FREEDENBERG: Uh-huh, sure. MR. VERNA: Okay. THE WITNESS: So Drew Cuney, John Wilmot, the President of I'm trying to think who was the company that Dey.

100

9 (Pages 30 to 33)

	Page 62		Page 64
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
2	MR. FREEDENBERG: In other words,	2	A Sometimes, yes, and if I think of it I
3	you can tell me and I'm not	3	try and train them as often as possible.
4	THE WITNESS: You're not going to	4	Q What's the risk of someone not being
5	go tell Meridian and Mylan what I said?	5	trained in using the device?
6	BY MR. FREEDENBERG:	6	MR. VERNA: Objection, relevancy.
7	Q No, no.	7	THE WITNESS: That they use it
8	A Yeah, we considered Medi Key.	8	improperly.
9	O M-e-d-i?	9	BY MR. FREEDENBERG:
10	A M-e-d-i-Key, Allergi-Key.	10	Q And if they use it improperly, then the
11		11	device may not serve its intended purpose?
12	Q Okay. A-I-I-e-r-g-i? A Yeah.	12	A Exactly.
13		13	Q And I assume when people are prescribed
14	Q And these have hyphens in them?	14	this device they may go many months or years
15	A In both, Allergy, as well	15	without ever having to use it unless they
	Q Okay.	16	-
16	A hyphen Key.	17	A Correct.
17	Q Any others?		Q have a situation where they need it,
18	A Adrena-Key.	18	correct?
19	Q Okay. Is that it?	19	A Yes.
20	A That's it.	20	Q Do you have or have you, in your
21	Q Did you do trademark searches for any	21	practice, ever prescribed any other epinephrine
22	of those names or ask anyone to do searches for	22	auto injectors other than EpiPen?
23	them?	23	A Yes.
24	A Nothing official. I may have searched	24	Q The EpiPen auto injector?
25	Google but nothing beyond that.	25	A Yes.
	Page 63		Page 65
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
2	Q You're obviously familiar, in your	2	Q Which ones?
3	practice, as an allergist, with the EpiPen	3	A Twinject and a generic device, you
4	injector?	4	know. It I don't really know what the name
5	A Yes.	5	of it is, I think it's just called generic
6	Q Is that a device that you prescribe for	6	epinephrine auto injector.
7	your patients?	7	Q Okay.
8	A Yes.	8	A It was made by Creanstone and I'm not
			A It was made by Greenstone and I'm not
9	Q And would you agree that for someone	9	sure that it's still available but it would also
-		9 10	•
10	who is at risk of anaphylaxis, that this can be		sure that it's still available but it would also
10 11		10	sure that it's still available but it would also be autoswitched if you write Adrenaclick.
10 11 12	who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes.	10 11	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever
9 10 11 12 13 14	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you 	10 11 12	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device.
10 11 12 13	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you train, you or someone on your staff train your 	10 11 12 13	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes.
10 11 12 13 14 15	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you 	10 11 12 13 14	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes. Q What's Adrenaclick?
10 11 12 13 14	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you train, you or someone on your staff train your patients in how to use it? A Yes. 	10 11 12 13 14 15	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes. Q What's Adrenaclick? A It's a Twinject without the second
10 11 12 13 14 15 16 17	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you train, you or someone on your staff train your patients in how to use it? A Yes. Q Describe that training for me. 	10 11 12 13 14 15 16	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes. Q What's Adrenaclick? A It's a Twinject without the second injection.
10 11 12 13 14 15 16 17 18	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you train, you or someone on your staff train your patients in how to use it? A Yes. Q Describe that training for me. A I have a training device. I show them 	10 11 12 13 14 15 16 17	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes. Q What's Adrenaclick? A It's a Twinject without the second injection. Q And who's the manufacturer of the
10 11 12 13 14 15 16 17 18 19	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you train, you or someone on your staff train your patients in how to use it? A Yes. Q Describe that training for me. A I have a training device. I show them you pull off the safety, the button goes against 	10 11 12 13 14 15 16 17 18	 sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes. Q What's Adrenaclick? A It's a Twinject without the second injection. Q And who's the manufacturer of the Twinject injector, the Adrenaclick? A I believe it's now used to be
10 11 12 13 14 15 16 17 18 19 20	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you train, you or someone on your staff train your patients in how to use it? A Yes. Q Describe that training for me. A I have a training device. I show them you pull off the safety, the button goes against the leg, press, click, count to ten. Then I 	10 11 12 13 14 15 16 17 18 19	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes. Q What's Adrenaclick? A It's a Twinject without the second injection. Q And who's the manufacturer of the Twinject injector, the Adrenaclick? A I believe it's now used to be Sciele. I think it's now Shionogi.
10 11 12 13 14 15 16 17 18 19 20 21	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you train, you or someone on your staff train your patients in how to use it? A Yes. Q Describe that training for me. A I have a training device. I show them you pull off the safety, the button goes against the leg, press, click, count to ten. Then I have the patient demonstrate back to me. 	10 11 12 13 14 15 16 17 18 19 20	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes. Q What's Adrenaclick? A It's a Twinject without the second injection. Q And who's the manufacturer of the Twinject injector, the Adrenaclick? A I believe it's now used to be Sciele. I think it's now Shionogi. Q Do the Twinject and the Adrenaclick
10 11 12 13 14 15 16 17 18 19 20 21 22	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you train, you or someone on your staff train your patients in how to use it? A Yes. Q Describe that training for me. A I have a training device. I show them you pull off the safety, the button goes against the leg, press, click, count to ten. Then I have the patient demonstrate back to me. Q Is it necessary to train someone more 	10 11 12 13 14 15 16 17 18 19 20 21	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes. Q What's Adrenaclick? A It's a Twinject without the second injection. Q And who's the manufacturer of the Twinject injector, the Adrenaclick? A I believe it's now used to be Sciele. I think it's now Shionogi. Q Do the Twinject and the Adrenaclick auto injectors operate differ differently
10 11 12 13 14 15 16 17 18 19 20 21	 who is at risk of anaphylaxis, that this can be a lifesaving device? A Yes. Q When you prescribe this device, did you train, you or someone on your staff train your patients in how to use it? A Yes. Q Describe that training for me. A I have a training device. I show them you pull off the safety, the button goes against the leg, press, click, count to ten. Then I have the patient demonstrate back to me. 	10 11 12 13 14 15 16 17 18 19 20 21 22	sure that it's still available but it would also be autoswitched if you write Adrenaclick. Q I was going to ask you if you've ever heard of that device. A Yes. Q What's Adrenaclick? A It's a Twinject without the second injection. Q And who's the manufacturer of the Twinject injector, the Adrenaclick? A I believe it's now used to be Sciele. I think it's now Shionogi. Q Do the Twinject and the Adrenaclick

.

·····

17 (Pages 62 to 65)

	Page 66		Page 68	
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	
2	A The Twinject and Adrenaclick both have	2	Numbers 6 and 7 were marked for	
3	two covers that need to be removed, so there's a	3	identification.)	
4	cover over the needle portion of the device	4	BY MR. FREEDENBERG:	
5	-		Q Okay. Dr. Beller, I've put before you	
6	Q Okay. Anything else?	5	a document we've marked as Exhibit 6.	
7	A Well, the Twinject device, once you've	7	Exhibit 6 is a document entitled.	
8			Applicant's Answers to Opposer's First Set of	
9	the top, take out the syringe and manually	8 9	Interrogatories. Do you see that?	
10	inject the second injection.	10	A Yes.	
11	Q Okay. And that would be if a second	11	Q Have you seen this document before	
12	injection is needed?	12	today?	
13	A Correct.	13	A Yes.	
14		14	Q Were you consulted in preparing the	
15	Q When you have prescribed those, those	15		
15	auto injectors in the past, do you also train A Yes.	16	answers to interrogatories? A Yes.	
17		17	Q Okay. If you would take a look,	
18	Q patients in how to use those?	18	please, at Exhibit or I'm sorry, excuse me,	
18 19	A Yes.	$10 \\ 19$	Interrogatory Number 29.	
20	Q Today, what percentage of your patients	20		
	are prescribed — if any, are prescribed the	21	The other thing I'm going to ask you to	
21	EpiPen auto injector?	22	do, if you would, is take a look at Exhibit 7,	
22	A 99 percent.	22	which is the answer to the Notice of Opposition	
23	Q Has that been true in the six or seven		that was filed on behalf of Beaufort County	
24	years that you've been in practice?	24 25	Allergy.	
25	A No.	25	If you go to page two of that document,	
	Page 67		Page 69	
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	
2	Q Was it 11?	2	please, and specifically under the heading,	
· 3	A There was one point when I prescribed	3	"Applicant's Application Will Not Cause	
4	virtually 100 percent Twinject.	4	Confusion." Do you see that?	
5	Q Okay. And what was the reason for	5	A Yes.	
6	moving over to the EpiPen injector?	6	Q Were you involved in formulating any of	
7	A Availability.	7	the reasons that are set forth under that	
8	Q Okay.	8	heading as to why Beaufort County Allergy	
9	A I just became frustrated with the	9	believes that there will not be confusion	
10	pharmacies calling me and saying, 'We just don't	10	between Epi-Key and EpiPen?	
11	have any right now, we have EpiPen.'	11	A In discussions, yes, but I didn't write	
12	Q Okay. Do patients ever come in and ask	12	the document, but yeah, in discussions, yes.	
13	for one device or the other if they're familiar	13	Q It was written by Mr. Verna	
14	with what these devices do?	14	A Yes.	
15	A No.	15	Q - or someone in his office?	
16	Q The Epi Key device that you have	16	If you look at I'll read to you	
17	developed, you've said that that's intended and	17	paragraph number five, it says; EpiPen, words	
18	it's in the patent application it's intended to	18	are in quote; "EpiPen" bas become a colloquial,	
	be an alternative to the EpiPen auto injector,	19	common generally accepted term for any	
19	is that correct?	20	epinephrine auto injectors. And then there's a	
20		21	footnote to wikipedia and I apologize for making	
20 21	A Yes.			
20 21 22	A Yes. Q Is it also intended as an alternative	22	you jump back and forth but these are related.	
20 21 22 23		22 23	If you look at answer to Interrogatory	
19 20 21 22 23 24 25	Q Is it also intended as an alternative	22		

18 (Pages 66 to 69)

	Page 102	Τ	Page 104
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
2	shareholder and you're 42 percent and then some	2	Q Okay. And finally, Exhibit 21 was an
3	family members have chipped in the rest?	3	e-mail you sent to a Kevin G.
4	A Correct.	4	A Kevin is my brother-in-law. Krg is his
5	Q Who are the officers of that company?	5	initials, I guess.
6	A Myself and Mark Foreman.	6	Q Okay. And what's his last name?
7	Q Okay. You said that Mr. Foreman is a	7	A Grenier, G-r-e-n-i-e-r?
8	software consultant. What type of work does he	8	Q What does he do?
9	do, generally?	9	A He's an architect.
10	A I know very little about it but I know	10	Q Okay. And David Mellor, M-e-l-l-o-r?
11	he works with software like Oracle, you know,	11	A That's my father-in-law.
12	and he primarily consults with Campbell Soup	12	Q Did they also contribute?
13	Company, so, you know, that's really all I know.	13	A Kevin did not but we decided to gift
14	I'm not a software person so that's the extent	14	him one percent, so we kicked in his one
15	of my knowledge of what he does.	15	percent, but Dave, my father-in-law, and Meg, my
16	O Where is he located?	16	mother-in-law, yeah, they jointed.
17	A In New York. Actually he lives in	17	Q Have any of these folks, other than Mr.
18	Phili now.	18	Foreman, have anything more than a passive role
19	Q And he's an he was acquaintance of	19	in this project?
20	yours or a friend of yours?	20	A No.
21	A He and I went to college together.	21	O Has TCB Medical Devices done or
22	Q Okay. In looking at exhibit well,	22	commissioned any type of marketing surveys to
23	before we get to Exhibit 20, did Mr. Foreman	23	
24	immediately respond to this indicating he was	24	determine what the sales potential would be for this device?
25	interested in getting in on the ground floor of	25	A No.
25	······································	25	
	Page 103		Page 105
1	FREEDENBERG - BELLER (DIRECT EXAMINATION)	1	FREEDENBERG - BELLER (DIRECT EXAMINATION)
2	this project, so to speak?	2	Q Has anyone on your behalf or on behalf
3	A Yes.	3	of the company done any such surveys?
4	Q Exhibit 20 is the an e-mail that you	4	A No.
5	sent to some family members?	5	Q What's your understanding of how the
6	A Correct.	6	• device would be sold? Where would the device be
7	Q For the record we need to identify	7	sold?
8	these people, so who are Bob and Karen Beller?	8	A It would be marketed like any drug to
9	A My mom and dad.	9	physicians.
10	Q And Bob Beller is the same Bob Beller?	10	Q Okay. And dispensed through physicians
11	A My brother, Bob.	11	through prescriptions and physicians offices?
12	Q And then there is a C I just have an	12	A Through prescriptions and dispensive
13	e-mail address.	13	pharmacies.
14	A CGRI, oh, C.	14	Q Have you had any discussion with anyone
15	Q Cbell8040@aol.com.	15	about preparing any type of marketing materials
16	A That's my sister, Cheri.	16	that would be used in connection with the sale?
17	Q Okay.	17	MR. VERNA: Objection, asked and
18	A C-h-e-r-i.	18	answered.
19	Q And Jim is another brother?	19	THE WITNESS: No.
20	A That's my brother.	20	BY MR. FREEDENBERG:
21	Q Okay. Did all of your family members	21	Q And would it be fair to say that
22	who were approached	22	you haven't when I say "you" I'm referring to
23	A Contribute?	23	TCB hasn't spent any money on developing such
24	Q Yes.	24 25	materials, any marketing materials?
25	A Yes.	2 F	A We have not.

د . ا

.*

hine and

لمستحدث

27 (Pages 102 to 105)

COASTAL COURT REPORTING & VIDEO SERVICES SCHEDULE@COASTALCOURT.COM

Like 3k

EpiPen medical definition

A trademark for a self-injection kit containing epinephrine, used

intramuscularly for anaphylactic shock.

The American Heritage® Medical Dictionary Copyright © 2010 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

ł

Feedback

-1



An A-Z of Medicinal Drugs

(d) adrenaline (b)

A CROSS-REFERENCE

E PRINT THIS ENTRY

In this entry adrenaline Side effects: Interactions with other drugs: Proprietary preparations:

See also adrenoceptors anaphylaxis arrhythmia glaucoma local anaesthetics prescription

Adjacent entries Adenoscan adenosine Adipine MR, Adipine XL Adizem-XL, Adizem-SR adjunct adrenaline adrenoceptors Adult Meltus Chesty Coughs with Congestion Advagraf aerosol Afinitor

adrenaline (epinephrine) A hormone that is secreted by the centre (medulla) of the adrenal glands into the bloodstream in conditions of stress. It acts on adrenoceptors to cause constriction of some blood vessels and dilatation of others, increasing blood flow to the heart and skeletal muscles. The heart rate is increased, while the muscles of the intestine and airways relax. As a drug, adrenaline is available in various forms on prescription only. It is given by intramuscular injection to relieve the effects of anaphylactic shock (an extreme and potentially fatal allergic reaction; see anaphylaxis) and by intravenous injection to treat cardiac arrest. It is given with local anaesthetic preparations because it constricts blood vessels and thus confines the local anaesthetic to the area of application. It is also available as eye drops to treat glaucoma, in which it reduces the production of aqueous fluid in the eye and increases its outflow.

Side effects:

when adrenaline is given by injection side effects include dry mouth, palpitation, cold hands and feet, nervousness, tremor, and headache; there may be stomach pain after inhalation. Side effects with eye drops include smarting and redness of the eye and headache.

Interactions with other drugs:

Anaesthetics:

irregular heartbeats (arrhythmias) may occur if adrenaline is given with certain anaesthetics. Antidepressants: hypertension (raised blood pressure) and arrhythmias may occur if adrenaline is given with tricyclic antidepressants. Beta blockers: severe hypertension may occur if these drugs are given with adrenaline. Clonidine: hypertension may occur if this drug is given with adrenaline. Dopexamine: may increase the effects of adrenaline. Entacapone: may increase the effects of adrenaline. Rasagiline: should not be used with adrenaline.

Proprietary preparations:

Anapen and Anapen Junior (disposable pens for self-injection); Epipen and Epipen Junior (disposable pens for self-injection); Minijet Adrenaline (injection).

How to cite this entry: "adrenaline" An A-Z of Medicinal Drugs. Ed Elizabeth Martin. Oxford University Press 2010

٢

.

۰, ۰

Oxford Reference Online. Oxford University Press. Free Library of Philadelphia. 6 December 2011 http://www.oxfordreference.com/views/ENTRY.html?subview=Main&entry=t61.e66>

•, •

 \odot

/

Your subscription to Oxford Reference Online is brought to you by: FREE LIBRARY OF PHILADELPHIA

Copyright © Oxford University Press 2011. All Rights Reserved Privacy Policy and Legal Notices

Oxford Reference Online Premium

* A Dictionary of Dentistry

EpiPen® (Trade name) n. A preassembled syringe containing 300 micrograms of adrenaline for intramuscular injection carried by patients at risk of anaphylaxis for self or third-party injection.

How to cite this entry:

"EpiPen®" A Dictionary of Dentistry, by Robert Ireland. Oxford University Press 2010. Oxford Reference Online. Oxford University Press. Free Library of Philadelphia. 6 December 2011 <http://www.oxfordreference.com/views/ENTRY.html? subview=Main&entry=t305.e1463>

ł


Your subscription to Oxford Reference Online is brought to you by: FREE LIBRARY OF PHILADELPHIA

Copyright © Oxford University Press 2011. All Rights Reserved Privacy Policy and Legal Notices


Epinephrine autoinjector

From Wikipedia, the free encyclopedia

An epinephrine autoinjector is a medical device used to deliver a measured dose (or doses) of epinephrine (also known as adrenaline) using autoinjector technology, most frequently for the treatment of acute allergic reactions to avoid or treat the onset of anaphylactic shock.



Trade names for this device include **EpiPen**, **Twinject**, **Adrenaclick**, **Anapen**, **Jext**, and **Auvi-Q**. The EpiPen was originally derived from the ComboPen, a product developed for the military for treating exposure to nerve agents.^[1]



Design

The devices contain a spring-loaded needle that exits the tip of the device (in some cases through a sterile membrane) and into the recipient's body to deliver the medication.

http://en_wikipedia_org/wiki/Enipenhrine_autoinjector

Epinephrine autoinjectors contain a pre-determined dose of epinephrine, usually between 300 $\mu g^{[2][3]}$ and 500 $\mu g^{[2][4]}$ of active ingredient at a concentration of 1:1000. They typically contain more medication than the amount needed for a single dose, but any extra amount is not intended for use and is inaccessible without destroying the device. Manufacturers have also made pediatric dosed versions available at 150 μg of active ingredient,^{[2][5]} and there is also a version which contains two individual doses (in case a repeated application is required) sold under the trade name Twinject.^[6]

On August 13th, 2012, the US FDA approved a new version of epinephrine auto-injector made by Intelliject and Sanofi called the Auvi-Q.^[7] It is rectangular in shape, 3.5 inches by 2 inches by 0.5 inch. It has a soundchip in it to give audio cues to a patient or caregiver to aid in the proper use of the device.^[8]

In most countries, epinephrine is a prescription drug, and therefore obtaining the device requires a prescription from a doctor. However, in some jurisdictions, epinephrine autoinjectors are an over-the-counter drug and may be purchased from a pharmacy counter.

Usage

After activation the patient holds the device in place for 10 seconds as the epinephrine is delivered. This gives the drug enough time to be absorbed by the body's muscles and diffused into the bloodstream. Using the device intravenously is highly discouraged, and can even be lethal as epinephrine is a local vascular constrictor, and used intravenously can restrict blood flow to the area of the injection site, causing subsequent damage to extremities. Additionally, intravenous administration of the epinephrine can cause ventricular tachycardia, or dangerously rapid heartbeat.^[9] After administering the device, patients are advised to seek immediate medical attention.

Effectiveness

None of these devices prevent future episodes of anaphylaxis, but patients who experience severe or life-threatening reactions may be treated with a series of allergy injections composed of increasing concentrations of naturally occurring substances such as venom to provide excellent and usually lifelong protections against adverse effects of future insect stings: the initial injections have a very low concentration, usually 1 ppb or less.^[10]

On May 8, 1998, a voluntary Class I recall took place in a number of countries (the United States, Germany, Israel, Denmark, Canada, Turkey, Australia, Greece and South Africa). Epipen (0.3 mg) and Epipen Jr. (0.15 mg) epinephrine auto-injectors were recalled because certain devices originating from specific production lots were found to be ineffective in delivering medication and treating anaphylaxis.^[11] This issue was resolved within the same year.

See also

Anaphylaxis

Notes

- "EpiPen inventor helped millions and died in obscurity" (http://www.tampabay.com/news/humaninterest/epipen-inventorhelped-millions-and-died-in-obscurity/1038756). St. Petersburg Times. http://www.tampabay.com/news/humaninterest/epipen-inventor-helped-millionsand-died-in-obscurity/1038756. Retrieved 2010-07-07.
- 2. ^ *a b c* "Epipen and Epipen Jr; Dosing | Epinephrine Dose | Anaphylaxis" (http://www.epipen.com/epipen_dosing.aspx). EpiPen. http://www.epipen.com/epipen_dosing.aspx. Retrieved 2010-07-07.
- * "Anapen 300 product information sheet" (http://www.anapen.co.uk/downloads/SUMMARY%20OF% 20PRODUCT%20CHARACTERISTICS%20ANAPEN%20300.doc). Lincoln Medical Ltd. http://www.anapen.co.uk/downloads/SUMMARY%20OF% 20PRODUCT%20CHARACTERISTICS%20ANAPEN%20300.doc.

- 4. ^ "Anapen 500 product information sheet" (http://www.anapen.co.uk/downloads/SUMMARY%20OF% 20PRODUCT%20CHARACTERISTICS%20ANAPEN%20500.doc) . Lincoln Medical Ltd. http://www.anapen.co.uk/downloads/SUMMARY%20OF% 20PRODUCT%20CHARACTERISTICS%20ANAPEN%20500.doc.
- 5. ^ "Anapen 150 product information sheet" (http://www.anapen.co.uk/downloads/SUMMARY%20OF% 20PRODUCT%20CHARACTERISTICS%20ANAPEN%20150.doc) . Lincoln Medical Ltd. http://www.anapen.co.uk/downloads/SUMMARY%20OF% 20PRODUCT%20CHARACTERISTICS%20ANAPEN%20150.doc.
- 6. Verus Pharmaceuticals Announces U.S. Launch of Twinject for Anaphylaxis (http://www.veruspharm.com/news_releases_08_16_2005.htm)
- 7. ^ "Sanofi Announces FDA Approval for Auvi-Q" (http://en.sanofi.com/Images/30999_20120813_EAI_FDA_APPROVAL_en.p(http://en.sanofi.com/Images/30999_20120813_EAI_FDA_APPROVAL_en.pdf. Retrieved 18 August 2012.
- * "Auvi-Q Fact Sheet" (http://www.multivu.com/assets/57459/documents/Auvi-Q-Fact-Sheet-original.pdf). http://www.multivu.com/assets/57459/documents/Auvi-Q-Fact-Sheet-original.pdf. Retrieved 18 August 2012.
- 9. http://www.bmj.com/cgi/content/full/326/7389/589
- 10. ^ Resiman, R (August 1994). "Insect Stings". New England Journal of Medicine
 26: 523–7. doi:10.1056/NEJM199408253310808(http://dx.doi.org/10.1056%
 2FNEJM199408253310808). PMID 8041420
 (//www.ncbi.nlm.nih.gov/pubmed/8041420).
- 11. ^ [1] (http://www.fda.gov/MEDWATCH/safety/1998/epipen.htm)

References

- The Anaphylaxis Campaign (http://www.anaphylaxis.org.uk/information/adrenaline.html). Accessed on March 19, 2007.
- BMJ Clinical Review of Epinephrine Administration (http://www.bmj.com/cgi/content/full/326/7389/589). Accessed on March 19, 2007.

External links

- US EpiPen information (http://www.epipen.com/)
- US Twinject information (http://www.twinject.com/)

http://en.wikipedia.org/wiki/Epinephrine autoinjector

- US Adrenaclick information (http://www.adrenaclick.com/)
- Anapen website (http://www.anapen.com/)
- Training video for EpiPen and Anapen from the Anaphylaxis Campaign (UK) (http://www.anaphylaxis.org.uk/information/healthprofessionals/administering-adrenaline.aspx)
- Twinject training video (http://www.twinject.com/injector-allergytreatment/twinject-injector-training.html)

Retrieved from "http://en.wikipedia.org/w/index.php? title=Epinephrine_autoinjector&oldid=507925624" Categories: First aid Drug delivery devices

- This page was last modified on 18 August 2012 at 02:11.
- Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. See Terms of use for details.
 Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.

Oxford English Dictionary | The definitive record of the English language

EpiPen, n.

Pronunciation: Brit. /'ɛpi,pɛn/, U.S. /'ɛpi'pɛn/

```
Etymology:  < epi - (in EPINEPHRINE n.) + PEN n.<sup>2</sup>
```

Med.

A proprietary name for: a hypodermic device that administers a dose of epinephrine, used for the emergency treatment of anaphylaxis.

- 1979 Official Gaz. (U.S. Patent Office) 5 June TM7/2 EpiPen. · · For hypodermic injectors.
- 1989 *N.Y. Times Mag.* 2 July 28/4 Although I have no allergies, I usually bring along an EpiPen when I travel to the countryside, a practice I always attributed to paranoia.
- 1996 Independent (Nexis) 7 Sept. 11 His next attack, again caused by peanut butter, came at a birthday party when he was three. He travels with an EpiPen which can be used to deliver a life-saving adrenalin injection.
- 2003 A. HOFFMAN *Probable Future* 259 He was so allergic, Liza had convinced him to carry an EpiPen in his pocket when he went out running, in case he met up with a bee.

EpiPen, n.

Third edition, August 2006; online version September 2011. <http://www.oed.com/view/Entry/262201>; accessed 06 December 2011.

Oxford University Press Copyright © 2011 Oxford University Press . All rights reserved.



Cilation HTML Full Text

`

Print F-mail Save

Title: Epinephrine. Lexi-PALS Drug Guide, Nov2011 Database: Consumer Health Complete

	Epinephrine
En Español (Spar	nish Version)
Last modified: 03/	/28/2011
conditions or trea	prmation is an educational aid only. It is not intended as medical advice for individual atments. Talk to your doctor, nurse or pharmacist before following any medical it is safe and effective for you.
Pronunciation (ep i NEF rin)	
Pharmacologic C Alpha/Beta Agoni	<u>ategory</u> st
<u>U.S. Brand Names</u> Adrenaclick™ [D Primatene® Mist	<u>s</u> SC], Adrenalin®, EpiPen 2-Pak®, EpiPen Jr 2-Pak®, EpiPen®, EpiPen® Jr., [OTC], S2® [OTC], Twinject®
Canadian Brand N Adrenalin®, EpiPe	<u>Names</u> en®, EpiPen® Jr, Twinject®
 This medicine of 	as should I know about before taking this medicine? does not mix well with some medicines. Serious reactions may occur. Check all ealthcare provider.
Reasons not to ta	ke this medicine
 Tell healthcat how it affected 	an allergy to epinephrine or any other part of this medicine. are provider if you are allergic to any medicine. Make sure to tell about the allergy and d you. This includes telling about rash; hives; itching; shortness of breath; wheezing; g of face, lips, tongue, or throat; or any other symptoms involved.
Inhaler:	
oxidase inhibitors	en isocarboxazid, phenelzine, or tranylcypromine in the last 14 days. Monoamine s (eg, isocarboxazid, phenelzine, and tranylcypromine) must be stopped 14 days ne is started. Taking the two together could cause dangerously high blood pressure.
What is this medie	cine used for?
• This modiair	ne is used to treat severe allergic reactions. ne is used to open the airways in lung diseases where spasm may cause breathing

How does it work?

Injection:

- EpiPen®, EpiPen® Jr: This medicine blocks the allergic reaction by minimizing or preventing the body's reaction to the allergen.
- · Adrenalin®: This medicine excites the heart.

Inhaler:

• This medicine works to open the airways in lung diseases where spasms may cause breathing problems.

How is it best taken?

EpiPen®, EpiPen® Jr:

- · Read directions before an emergency occurs.
- Use this medicine for emergencies which may include insect stings or bites, food, drug, latex allergies, and ones caused by exercise.
- · Keep this medicine with you at all times. Can keep extra ones at work, school, and home.
- Never put fingers, or hand over tip.
- · Do not remove safety release until ready to use.
- Do not use if solution is not clear or if red flag is in window.
- When ready to use, remove pen from case.
- · Hold pen with tip pointing down.
- Make a fist around pen.
- Pull off safety release.
- Jab straight into the outer thigh until it clicks and hold for 10 seconds.
- · Remove and massage area where shot was given.
- Get medical attention now.
- · Call the emergency department. Do not drive yourself to the hospital.
- Replace in storage case.
- Take it with you to the hospital.

Adrenalin®:

· Your healthcare provider will give this medicine.

Inhaler:

- For inhaling (puffing) only by an inhaler or as a liquid (solution) through a special machine (nebulizer) into the lungs.
- Inhale once, may repeat in 1 minute if symptoms are not relieved. Wait at least 3 hours before using again.

What do I do if I miss a dose? (does not apply to patients in the hospital)

Many times this medicine is taken on an as needed basis.

What are the precautions when taking this medicine?

- If you have heart disease, talk with healthcare provider.
- If you have thyroid disease, talk with healthcare provider.
- · Check medicines with healthcare provider. This medicine may not mix well with other medicines.
- · Tell healthcare provider if you are pregnant or plan on getting pregnant.
- · Tell healthcare provider if you are breast-feeding.

What are some possible side effects of this medicine?

- · Feeling dizzy. Rise slowly over several minutes from sitting or lying position. Be careful climbing.
- Irritation where the shot is given.
- · Flushing.
- Nausea or vomiting. Small frequent meals, frequent mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.
- Dry mouth. Frequent mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.

Nervous and excitable.

What should I monitor?

- Change in condition being treated. Is it better, worse, or about the same?
- Take good care of your teeth. See a dentist regularly.
- · Follow up with healthcare provider.

Reasons to call healthcare provider immediately

- · If used for allergy emergency, go to an emergency room immediately after use.
- If you suspect an overdose, call your local poison control center or emergency department immediately.
- Signs of a life-threatening reaction. These include wheezing; chest tightness; fever; itching; bad cough; blue skin color; fits; or swelling of face, lips, tongue, or throat.
- · Unable to get breathing attack under control. Get emergency medical care right away.
- Fast heartbeat.
- Severe nausea or vomiting.
- · Feeling extremely tired or weak.
- Any rash.
- No improvement in condition or feeling worse.

How should I store this medicine?

Store at room temperature.

EpiPen®, EpiPen® Jr:

· Protect from light.

Primatene® Mist:

• Protect from heat or open flame.

General statements

- · If you have a life-threatening allergy, wear allergy identification at all times.
- Do not share your medicine with others and do not take anyone else's medicine.
- · Keep all medicine out of the reach of children and pets.

• Most medicines can be thrown away in household trash after mixing with coffee grounds or kitty litter and sealing in a plastic bag.

• In Canada return any unused drugs back to the pharmacy. Also, visit <u>http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th</u> for more facts about the right way to get rid of unused drugs.

• Keep a list of all your medicines (prescription, natural products, supplements, vitamins, over-thecounter) with you. Give this list to healthcare provider (doctor, nurse, nurse practitioner, pharmacist, physician assistant).

• Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800 -FDA-1088 or in Canada to Health Canada's Canada Vigilance Program at 1-866-234-2345.

• Talk with healthcare provider before starting any new medicine, including over-the-counter, natural products, or vitamins.

Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.

Last modified: 03/28/2011

Copyright of Lexi-PALS Drug Guide is the property of Lexi-Comp, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.

Safety Information: It is recommended that research for treatment and drug safety should be complemented with information from additional sources. Please see the <u>CHC Resources</u> page for organizations providing this information.

Cilation HIML Full Text

Print F-mail Save

EXHIBIT 17



Gitation HTML Full Text

Print E-mail Save

Title: *EpiPen*. Royal Society of Medicine: Medicines, 2002 Database: *Consumer Health Complete*


piPen (ALK-Abel	EpiPen lo) is a proprietary, prescription-only preparation of adrenaline acid tartrate (epinephrine). It is a and drug in emergency treatment of acute and severe bronchoconstriction and other
symptoms	of acute anaphylaxis (allergic reaction; eg an insect sting). It is available as an auto- hich delivers a single intramuscular dose, and also as a version for children, Epipen Jr Auto
See.	
© Bloomst	bury Publishing 2002
	formation: It is recommended that research for treatment and drug safety should be nted with information from additional sources. Please see the <u>CHC Resources</u> page for providing this information.

Citation HTML Full Text

Print F-mail Save

EXHIBIT 18





Hot Topics

Downloads Contact Us : Español

Shop | Recipes Donate | Calendar | Alerts Log In | Join Us

ABOUT US | EDUCATION | AWARENESS | RESEARCH | ADVOCACY | ALLERGENS | FUNDRAISING | MEDIA CENTER

Search

1È

Media Center

Media Kit

Hot Topics

Video Gallery

News Releases

FOR IMMEDIATE RELEASE Subscribe | Receive hot topics by e-mail

Epinephrine Auto-injectors - Patients May Need Re-training

🖒 Like

You like Epinephrine Auto-injectors - Patients May Need Re-training - FAAN, · Add Comment · Admin RETWEET This page has 3 tweets.

Celebrity Ambassadors Who Care

FAAN in the News

Our Experts



Recently, a generic epinephrine auto-injector became available on the market. This may result in pharmacies substituting the generic auto-injector for a brand-name auto-injector, or vice-versa.

If you or someone you know has been prescribed an epinephrine auto-injector, please be aware that specific brand-name epinephrine auto-injectors, such as Adrenaclick[®], EpiPen[®] or Twinject[®], as well as the generic version, each have their own unique instructions for proper administration.

Families may have been trained by their pediatricians or allergists on the use of one type of autoinjector, then receive another type from the pharmacy on which they have received no training. It is important to have a clear understanding of the training instructions for the auto-injector obtained at the pharmacy.

For more information on epinephrine auto-injectors, visit the American Academy of Pediatrics Allergy and Immunology section of the AAP website. Similar information can be found on the websites of the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology.

About FAAN

Founded in 1991, The Food Allergy & Anaphylaxis Network (FAAN) is the world leader in information, resources, and programs for food allergy, a potentially life-threatening medical condition that afflicts as many as 15 million Americans including almost 6 million children. A nonprofit organization based in Fairfax, Va., FAAN has approximately 22,000 members in the U.S., Canada, and 58 other countries. It is dedicated to increasing public awareness of food allergy and its consequences, to educating people about the condition, and to advancing research on behalf of all those affected by it. FAAN provides information and educational resources about food allergy to patients, their families, schools, health professionals, pharmaceutical companies, the food industry, and government officials. To become a member or for more information, please visit FAAN at www.foodallergy.org.

Media Contact

Jennifer Roeder Director, Marketing and Media Communications Direct: (703) 563-3061 Cell: (301) 639-4811 E-mail: jroeder@foodallergy.org Twitter: @JenRoeder

Last updated: May 24, 2010

FAAN Walk for Food Allergy FAAN Events FAAN Kids FAAN Teen FAAN College Network Food Allergy & Anaphylaxi

Alliance

Copyright © 2011, The Food Allergy & Anaphylaxis Network

EXHIBIT 19

Home > Health > Food Allergies

Abeut.com. Food Allergies

Food Allergies

Symptoms / Treatment




Advertisement

When is an Epi-Pen Not an Epi-Pen? By Jeanette Bradley, About.com Guide June 24, 2010

By Allergy

Coping

My Bio | Headlines | Forum | 🖾 RSS



Sponsored Links

Symptoms Of Mold Allergy Learn About Your Indoor Allergies See How Claritin ® Can Help www.Claritin.com

Stylish Epi-Pen Carriers Fashionable Epi-pen carriers that are great for kids. Free S & H www.AllergyHaven.com

20 Ways To Stop Allergies Want To Know How To Get Rid Of Your Allergies? We Give You The Answers. www.health.com

An Epi-Pen is prescribed as emergency treatment for severe food allergies that include anaphylactic shock as a symptom. Epi-Pen is actually a brand name, like Kleenex. There is now a generic epinephrine auto-injector on the market.

The good news is that generic drugs are less expensive, which is particularly good for people without insurance. Epi-Pens are not cheap, and you need to replace them every year.

The bad news is that the generic auto-injector is different from either of the most commonly prescribed brand names, Epi-Pen and Twinject. Your doctor may have prescribed one of these brand name injectors to you and trained you how to use it. Your pharmacy (or rather, your insurance company) may give you the generic injector instead.

Check your injector to see what brand it is, and then look up the instructions for its use. Ask your doctor to prescribe a "trainer" pen - a fake pen used for educational purposes - with each new prescription.

Having a trainer pen is especially important if you have a child with food allergies who has multiple caregivers - babysitters, grandparents, teachers, and the parents of his friends. Everyone who takes care of your child should be trained how to use his injector.

Instructions for each type of injector:

Adrenaclick (makers of the generic injector, distributed by Greenstone) Epi-Pen Twintect

More About Anaphylaxis and Epinephrine:

First Aid for Anaphylaxis

	SEARCH		
💽 S	hare	i,	Print

Free Food Allergies Newsletter!	
Enter email address	Sign Up
Discuss in my forum	

Advertisement

Fix Your Thyroid = Lose Weight!

Dr. Andrew Jones M.D. of the Women's Health Institute of Texas reports that most women who struggle with weight loss after pregnancy or can't lose weight no matter what diet they try actually suffer from a thyroid condition that is simple to fix with a proven natural remedy.

More from this article

Food Allergies Ads

- » Food Allergies
- Epi Pen

Q

- Brand Name Wholesale
- Pen Factory
- Buy Pen Holder

Related Blogs

Parenting a Child with a Food Allergy Alleraic Child Please Don't Pass the Nuts Alleraizer Allergy Moms Allerieez! Peanut Free Mama

Readers Respond

Share Your Favorite Allergy Recipes Add Your Response

When is an Epi-Pen Not an Epi-Pen?

How to Use an Epi-Pen

Anaphylaxis

Epinephrine Auto-Injector

Source:

American Academy of Pediatrics. Availability of Generic Epinephrine Auto-Injector. Accessed June 23, 2010. http://www.aap:org/sections/allergy/new.cfm#new

Comments (0) | See All Posts | 🐳 Share

< Prev Next >

Comments

No comments yet. Leave a Comment

Related Articles

- Epinephrine Auto-Intector
- Sulfite Allergy and Epi-Pens Allergies to Sulfites and the Epi-Pen
- Lie Down After Using Epi-Pen Why Should You Lie Down After Using Epi-Pen
- Where to Cut Corners Meals on a Budget
- Over-the-Counter Medications Arthritis

Sponsored Links

Find generic Cozaar.

Learn the generic names of all your family's prescriptions, and save. smart-health.com

Child-Safe EpiPen Carrier

Great for School, Day Care, Camp, Sleepovers, Babysitters, Vacations. www.SafetvSack.com

Medicare Part D in PA

Compare All Medicare Part D Plans in PA. Compare & Enroll Today! PlanPrescriber.com/PartD

Bi Polar Illness Signs

Learn About The Signs Of Bi Polar. Discover Your Options Today. healthynow.com/Bi-Polar-Illness

ITT Technical Institute

Attend Class in Harrisburg Official Site. Learn more today! www.ITT-Tech.edu/Pennsylvania

AARP® Medicare Part D

Plans Insured by UnitedHealthcare. Enroll in a New 2012 Part D Plan! AARPMedicarePlans.com/Rx

Related Searches Epinephrine Auto Injector Epi Pen Food Allergies Anaphylaxis Generic Drugs Kleenex

Explore Food Allergies

Free Food Allergies Newsletter!

Enter email address	Sign Up

By Category

- Allergies Age By Age
- Food Allergy Basics
- Reading Labels
- Diagnosing Food Allergies
- Allergy Recipes Common Food Allergies
 - Glossary
 Giossary
 Giossary

Must Reads

- First Steps: Food Allergies
- Anaphylaxis: What You
- Need to Know Most Common Food
- Allergies
 - Food Allergy Signs and Symptoms
 - · Safety Tips for Kids with Food Allergies

About.com Special Features

Is Fruit Juice Bad?

Find out if juice is a healthy way to get your daily dose of fruit. More >

How Alcohol Affects Diabetes

Be aware of the 4 major ways alcohol can affect your health if you have diabetes. More >

Cooking Tips

Living with Food Allergies

Emergency Treatment

When is an Epi-Pen Not an Epi-Pen?

- Treatment
- Blogs

Most Popular

- Shellfish Allergy
- Alcohol
- Allergies/Intolerances
- Egg Allergies
- Microwave Spaghetti
 - Squash
- Infant Milk Allergies

About.com Food Allergies

Home > Health > Food Allergies

Most Popular | Latest Articles | 🖾 RSS

Also from About.com: Calorie Count - Nutrition Database Advertise on About.com | Our Story | News & Events | Work at About | SiteMap | All Topics | Reprints | Help

Write for About | User Agreement | Ethics Policy | Patent Info. | Privacy Policy | Your Ad Choices

©2011 About.com. All rights reserved. A part of The New York Times Company.

We comply with the HONcode standard for trustworthy health information: verify here.

EXHIBIT 20



🚍 Print this page 🔄 Close

Teen dies after eating cookie containing peanut

By Alexis Stevens The Atlanta Journal-Constitution

7:46 p.m. Thursday, August 18. 2011

While his aunt shopped Tuesday, 15-year-old Jharell Dillard ran outside to grab a snack from the car. He remembered there were cookies and he grabbed one, his father told the AJC Thursday night.

But the chocolate chip cookie also contained traces of peanuts, sending Jharell's body into shock. Jharell's allergy caused his tongue and throat to swell and restricted his breathing, Charles Dillard said.

The teen was transported Walton County Medical Center Tuesday, then flown Wednesday to Children's Healthcare of Atlanta at Egleston, where he died.

"This was one of those freak accidents," Dillard told the AJC. "He was very, very careful about what he ate."

When he realized the cookie contained nuts, Jharell ran to a nearby McDonald's, where he tried to rinse his mouth out, his father said. The teen also took an over-the-counter allergy medication, but the reaction continued. A family member called 911 and Jharell was transported to the hospital, but it was too late.

Jharell, who was in the 11th grade at Central Gwinnett High School, normally didn't carry an injection of epinephrine, known by the brand name EpiPen, because he was aware of his allergy and generally cautious. After his death, Jharell's parents decided to donate their sons' organs.

"He has already saved seven other lives," his father said.

Jharell was very involved in his church, family friend Roland Pinder told the AJC.

"Jharell was a soft-spoken, low-key kid, but he didn't go unnoticed," Pinder said.

In addition to his parents, Jharell is also survived by two sisters.

Funeral arrangements are tentatively scheduled for Aug. 28 at Stone Mountain Seventh-day Adventist Church.

Find this article at: http://www.ajc.com/news/gwinnett/teen-dies-after-eating-1120883.html 🚍 Print this page 🔄 Close

EXHIBIT 21

🛱 Print this page 🕘 Close



Food allergies can be deadly

By Alexis Stevens The Atlanta Journal-Constitution

7:16 p.m. Friday, August 19, 2011

Four out of 100 children have a food allergy and the number of those diagnosed continues to rise, experts say.

Though the exact cause of the increase isn't known, children with allergies and their parents must scrutinize food carefully to avoid potentially deadly situations. The death of a 15-year-old metro Atlanta boy this week has made more people aware of the severity of allergies.

Jharell Dillard, an 11th grader at Central Gwinnett High School, was well aware of his peanut allergy and had had a reaction before, his father, Charles Dillard, told the AJC. Jharell, a soft-spoken teen, loved basketball and had NBA dreams, his father said. Had Jharell known the store-bought cookie he took a bite of contained traces of nuts, he wouldn't have eaten it.

"This was one of those freak accidents," Dillard told the AJC. "He was very, very careful about what he ate."

While family, friends, classmates and teachers mourn Jharell's death, others hope the tragedy serves as an eye-opening lesson. Each year, about 150 people die from an allergic reaction to food, according to the Centers for Disease Control.

"Being prepared for accidents is key," Dr. Karen DeMuth, a pediatric allergy and immunology specialist, told the AJC. "You need to know what to do and how to react when you have an accident."

When a person with a food allergy accidentally ingests the allergen, several symptoms can occur, DeMuth said. Skin rashes, swelling, respiratory distress, coughing, wheezing, sneezing and vomiting are all possible, she said.

If a child is having a severe allergic reaction, also called anaphylaxis, there is one treatment: Epinephrine.

The medication, which is injected, is often dispensed under the brand name EpiPen, DeMuth said. Once injected, it works immediately to stop the reaction and lasts only about 10-15 minutes, allowing enough time to make an emergency call to 911, she said.

Having an EpiPen nearby, and knowing how to use, can relieve some of the stress that a food allergy can bring for both parents and children, said DeMuth, who works at both Emory University and Children's

Healthcare of Atlanta.

There is currently no cure for food allergies. But still, many allergy sufferers don't carry the injection, relying instead on the belief that they can avoid the allergen, which may not always be possible. Doctors refer to this as "risk drift," DeMuth said.

"This happens to every one of us," DeMuth said. "You just have to remind yourself every day of why it's so important."

Education about the dangers of food allergies is key to preventing tragedies, such as Jharell's death, according to Aleasa Word, a mother of a child with eight food allergies and an advocate. Word's daughter has twice been the victim of "peanut bullying," where another child has tried to force peanut butter on her daughter's face.

"Kids don't understand that someone could really get sick," Word said.

As the executive director of the Food Allergic Multi-Cultural Society of Delaware, Word said people must realize allergies cross all races. The group plans to reach out to Jharell's family by sending flowers for the teen's funeral, she said.

"People need to understand that this affects everyone," Word said. "We're all one big family with one problem."

Not everyone with food allergies will have a severe reaction, such as the one Jharell suffered. For most people with food allergies, sitting next to someone eating the allergen isn't enough to cause a problem. Soap and water are enough to remove the peanut allergen, DeMuth said.

The Food Allergy Kids of Atlanta group offers support and educational opportunities for families dealing with food allergies.

"There is no way to know how severe a reaction will be," DeMuth said. "If you're being careful and you're prepared, you're in control. You're always ready."

Find this article at: http://www.ajc.com/news/food-allergies-can-be-1124064.html 🚍 Print this page 🔄 Close

EXHIBIT 22

H

Expert Report from Ray S. Davis, MD

INTRODUCTION:

My name is Ray S. Davis, M.D., and I have been asked to provide an expert witness report in a trademark dispute between Dey Pharmaceuticals, Inc. and Mylan Labs and TCB Medical Devices over the proposed Epi-Key name vs. EpiPen® for autoinjectors. I was asked to give my opinion regarding several issues and concerns which are being addressed in this case from my perspective in practicing as a specialist in clinical allergy and immunology for the past 30 years.

My preparation for this report is based upon 30 years of experience in private practice as a specialist who is board certified in both pediatrics and allergy/immunology and who has seen thousands of patients with food allergies, drug allergies and insect venom allergies and anaphylaxis as well as cases of anaphylaxis of unknown causes (idiopathic). I not only teach regularly as a full Professor in Clinical Pediatrics in the Division of Allergy Immunology and Pulmonary Medicine, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, Missouri, but I also have lectured all over this country and outside it to other healthcare professionals on these subjects scores of times.

QUALIFICATIONS:

My background is initial training in general pediatrics at Washington University School of Medicine and St. Louis Children's Hospital (1978-1980) followed by specialty training in allergy & immunology at the consistently number 1 ranked respiratory hospital in this country—the National Jewish Hospital/National Asthma Center now called National Jewish Health (1980-1982), <u>www.nationaljewish.org</u>.

I have worked at multiple hospitals and Emergency Rooms in Louisville, Denver & St. Louis. I am a "Fellow" of both the American Academy of Allergy Asthma and Immunology and the American College of Allergy Asthma and Immunology and have been chosen to speak at their annual continuing education meetings (CME) multiple times. I also give many other talks at national and regional CME meetings in my field.

My curriculum vitae is attached to this report. See Exhibit A.

BACKGROUND:

As a pediatric resident in training in the 1970s, the only "kit" available for patients who needed to have aqueous epinephrine available to treat a severe potentially fatal allergic reaction was the Ana-KitTM. This syringe of epinephrine with instructions on how a patient should give a self injection proved to be awkward and difficult for most patients seeing an exposed needle. Despite that, it is still an available choice by prescription today. Thankfully, EpiPen® autoinjector was developed and over the next 3 decades, with its hidden needle and "automatic" injector mechanism, it has become the treatment of choice widely accepted for virtually all patients who need this form of treatment. EpiPen® represents a brand of autoinjector that has been counted upon by most allergists for decades despite attempts to develop other autoinjectors such as Twin-Ject® and Adrenaclick®, each of which has had its problems. Each time a new device was introduced, specialists referred to it by its specific brand name and no one called it an "Epipen." Furthermore, when "EpiPen" is prescribed or used in conversation, everyone in the field, as well as patients, understands that it is the original brand of the product made and quality controlled by Mylan Labs. The name EpiPen® is synonymous with a famous brand of epinephrine autoinjector which is unique in its mechanism and has withstood the test of time and many thousands of uses. Although some may claim that "epi" or "epipen" refers to ALL self injectable aqueous epinephrine medications, "EpiPen" stands apart as the brand of choice and is NOT a generic word for ALL other self injectable epinephrine medications.

"Epi" or "epipen" should not be confused with the utilization of aqueous epinephrine injectable solutions drawn up at hospitals for intracardiac injections during cardiac arrests. This "epi" given stat (immediately) is either aqueous adrenaline 1:1,000 USP in a sterile vial for intramuscular, subcutaneous or intravenous use or if the "epi" is to be injected into the heart of a dying patient, it is a 1:10,000 concentration called Adrenaline (Epinephrine) 1:10,000 Sterile Solution MinijetTM and is used during codes at most hospitals. In fact, autoinjectors are generally not used in most hospitals or emergency rooms around this country since health care professionals are trained to draw up the correct dose and inject it properly either intracardiac, intravenously, or intramuscularly; they do not need the convenience of the autoinjector, which most patients and lay people do. Thus, what may be referred to as "epi" in a hospital setting should not be confused with an EpiPen® autoinjector.

In teaching a Continuing Medical Education course on food allergies and anaphylaxis at the Eastern Allergy Conference several years ago in Palm Beach, Florida, I presented a real case to a group of over 100 allergy and asthma specialists from all over the U.S. The discussion led to a specific individualized treatment plan for the patient and as such, a discussion occurred about whether or not it mattered which brand of epinephrine autoinjector should be recommended. Although some admitted to having tried other brands on some patients in the past for various reasons, the group believed, almost without exception, that the EpiPen® autoinjector was the only device and brand they trusted. In my opinion, from these observations and many others, it is clear that specialists in the field of allergy and immunology do not refer to ALL selfadministered epinephrine autoinjectors as "epipens." If referring to an alternative autoinjector, they specifically mention, e.g., Twin-Ject® or Ana-KitTM, by their brand names.

In my office, at every new patient visit or routine yearly check up for a patient with food allergies or anaphylaxis (or for any other reason), we go over a check list, emphasizing the newly updated Food Allergy and Anaphylaxis Guidelines published in 2010. For all of my patients, I prescribe EpiPen® autoinjectors and no other brands. The proper technique of injection must be demonstrated to my nurses or medical assistants by either the patient or a parent. I would personally hate to think that if I had prescribed an EpiPen® autoinjector, demonstrated the proper technique and the patient received a different device and tried to use it, the confusion could be potentially fatal. Or, if another device had a similar name, such as Epi-Key, there could be confusion by the patient or pharmacist about which device to dispense or use, which again could lead to a fatal result.

CONCLUSION:

EpiPen®, in my opinion, is a famous name brand for a device that dispenses aqueous epinephrine. That device has been utilized for many years by many thousands of patients who need a reliable, life saving device and medication to carry on a daily basis. Among physicians, the trademark is as recognizable as Coke® and iPhone®. There will always be those who attempt to copy others' work, but the name EpiPen® is unique and should not be generalized to mean, and other device names should not be allowed to be confused with anything but the original device.

Most sincerely,

Ray Sociomo

Ray S. Davis, M.D. Professor in Clinical Pediatrics Division of Allergy Immunology and Pulmonary Medicine St. Louis Children's Hospital Washington University School of Medicine And Private Practice with Allergy Consultants, P.C.

EXHIBIT A

Date: Nov. 2011



Personal Information:

Sex: Male Born: January 5, 1953 Place of Birth: Louisville, Kentucky

Citizenship:

United States of America

Address and Telephone Number:

Home: NA

Office: Allergy Consultants 456 North New Ballas Road Suite 129 St. Louis, MO 63141 314-569-1881(pvt.lines 569-1444 or 1448) Email <u>ahchu1@aol.com</u>

Present Position:

Private Practice - Allergy Consultants, P.C. (President and Senior partner)

Education:

Undergraduate:

University of Louisville, no degree obtained due to early acceptance to medical school after 97 credit hours; grade point average 3.95

Graduate:

5-14-78 M.D.: University of Louisville School of Medicine

Postgraduate:

6-23-78 to 6-30-79	Internship - Pediatrics, Washington University School of Medicine, St. Louis Children's 7-1-79 to 6-30-80 Residency - Pediatrics, Washington University
	School of Medicine
	St. Louis Children's Hospital
7-1-80 to 6-30-82	Fellowship - Allergy/Immunology National Jewish Hospital and Research Center, the National Asthma Center, and the University of Colorado Medical Center, Denver, Colorado

Academic Positions/Employment:

Professor of Clinical Pediatrics, St. Louis Children's Hospital; Washington University School of Medicine, St. Louis, MO - Division of Allergy and Pulmonary Medicine, Washington University School of Medicine

University and Hospital Appointments and Committees:

Professor of Clinical Pediatrics, St. Louis Children's Hospital - Division of Allergy and Pulmonary Medicine, Washington University School of Medicine

Medical Licensure and Hospital Appointments and Committees:

State of Missouri - #R9698 - 8-3-79 7-2-79 - National Board of Medical Examiners #194924 10-17-82 - American Board of Pediatrics #28242 10-3-83 - American Board of Allergy/Immunology #2328

Military Services:

N/A

Honors and Awards:

Academic scholarships awarded 1971, 1972, 1973, and 1974 A.O.A. Outstanding Senior Student of the Class of 1978

Professional Societies and Organizations:

Fellow, American Academy of Allergy, Asthma & Immunology Fellow, American College of Allergy Asthma and Immunology Missouri State Allergy Society Southern Medical Association Joint Council of Allergy & Immunology

Major Invited Professorships and Lectureships:

N/A

Consulting Relationship and Board Memberships:

N/A

Research Support (role, title, duration, amount):

Governmental N/A

Non-Governmental N/A

Clinical Title and Responsibilities:

Professor of Clinical Pediatrics, St. Louis Children's Hospital, Division of Allergy Immunology and Pulmonary Medicine Washington University School of Medicine, St. Louis, MO Teaching Title and Responsibilities:

- -

Same

<u>Reviewer</u> for the Annals of Allergy Asthma and Immunology Journal 2006-11. <u>Reviewer</u> for the Journal of Allergy & Clinical Immunology 2009. <u>Reviewer</u> for the Allergy & Asthma Proceedings 2008-2011.

Bibliography:

Lang D, Davis RS. The long acting beta agonist controversy: A clinical dilemma. Allergy Asthma Proc. 28:136-144, 2007.

Davis RS, Larsen G. Use of videography in the diagnosis of exercise-induced vocal cord dysfunction: A case report with video clip. J Allergy Clin Immunol 119:1329-31,2007.

Davis RS, Settipane R, et.al . Problem-based learning: Chronic cough—an interactive case discussion. Allergy Asthma Proceedings 2006:27;17-20

Davis RS, Vanderwalker ML, Slavin RG, et al. Facial angioedema in children Due to ladybug (Harmonia axyridis) contact: 2 case reports. Ann Allergy Asthma Immunol. 2006;97:440-442.

Bukstein DA, Gepner A, Luskin A, Davis RS. Proactive education for asthma Patients. International Review of Asthma (Japanese) 2006:8(1);48-57.

Ray S. Davis, M.D., Don A. Bukstein, M.D., Allan T. Luskin, M.D., JA Kailin, G.Goodenow, R.N. Changing Physician Prescribing Patterns Through Problembased Learning: an Interactive Case-based Education Program. Ann Allergy Asthma Immunol. 2004;93:237-242.

In Bukstein, D.A., Strunk, R.C., eds. Manual of Clinical Problems in Allergy Related Disorders. Little Brown and Company, Boston, 1984. Author of the following chapters:

Outpatient Treatment of Asthma Urticaria Antihistamines Allergic Rhinitis

Davis, R.S., Larsen, G.L., Grunstein, M.M. : Respiratory response to intra esophageal acid infusion in asthmatic children during sleep. J Allergy Clin Immunol 72:393, 1983.

Davis, R.S., Remigio, L.K., Schochet, A.L., Bock, S.A. : Evaluation of a patient with both aquagenic and cholinergic urticaria. J Allergy Clin Immunol 68:479,1981.

Davis, R.S., Strunk, R. : Auriculotemporal syndrome in childhood. Am J Dis Child <u>135</u>:832, 1981.

Cook, L.N., Davis, R.S., Stover, B.H. : Outbreak of amikacin resistant enterobacteria-ceae in an intensive care nursery. Pediatrics <u>65</u>:264, 1980.

Davis, R.S., Stoler, B.S. : Febrile reactions to Isoniazid. N Engl J Med 297:337, 1977.

Davis, R.S., Flynn, M.B., Moore, C: An unusual presentation of carcinoma of the lung - 26 cases of cervical lymph node metastases, J Surg Oncol <u>9</u>:503-507, 1977.

Stoler, B.S., Davis, R.S.: Corticosteroids in postinfluenzal respiratory distress syndrome. J Kentucky Med Assoc <u>75</u>:367-371, 1977.

Presentations:

I have been asked to create a 4 hour workshop to train allergists in PBL facilitation skills chosen from each Committee of the AAAAI at the upcoming annual meeting in Orlando in March 2011. The AAAAI executives want more PBL talks to be done at annual meetings.

I was the speaker/facilitator at a luncheon workshop for the AAAAI Annual Meeting in Miami, FL in March 2006. I taught a workshop on how to become a skilled facilitator of PBL (Problem-based learning) to a small group of allergists.

Davis, R.S., Larsen, G.L., Grunstein, M.M.: Esophageal acid infusion during sleep in asthmatic children with gastroesophageal reflux. Presented to the Pediatric Section, American Thoracic Society's Annual Meeting, Los Angeles, CA, May 17, 1982.

Andrews, B.F., Davis, R.S.: Decreasing Mortality and morbidity in infants of diabetic mothers (presented to the XV International Congress of Pediatrics, New Delhi, India, on October 25, 1977, by B.F. Andrews, M.D., Chairman, Department of Pediatrics, University of Louisville School of Medicine).

Abstracts:

Davis, R.S., et al.: Esophageal acid infusion during sleep in asthmatic children with gastroesophageal reflux. Am Rev Resp Dis <u>125</u>:190, 1982.

Davis, R.S., et al.: An unusual presentation of carcinoma of the lung. JAMA 239:662, 1978.

Andrews, B.F., Davis, R.S.: Decreasing mortality and morbidity in infants of diabetic mothers. Ped Res $\underline{12}(4)$: 518, 1978.

SPEAKER'S BUREAUS:

For the past 20 years I have been on the Speaker's Bureau for various pharmaceutical companies including Merck, Genentech, Novartis, Glaxo Smith Kline, MEDA, Alcon, Dey & AstraZeneca. I have led over fifty conferences per year (some were for CME) on allergies, asthma and food allergies & anaphylaxis for the past fifteen years. They have virtually <u>ALL</u> been by <u>PROBLEM-BASED LEARNIING (PBL)</u>, also known as interactive case discussions. Most of these conferences have been in small groups of between five to fifteen participants. Most have been comprised of primary care physicians (pediatricians, internists and family physicians), nurse practitioners, physician assistants, nurses, pharmacists or pharmacy doctoral students and even specialist groups of allergists and pulmonologists. Moreover, I have been in charge of setting up the PBL faculty and cases to be presented in several national conferences in the last few years mainly involving specialists.

Teaching other specialists to become skilled facilitators in Problem-based learning:

I have trained over 300 specialists in how to become <u>"skilled facilitators"</u> of Problem-based learning (PBL) workshops/seminars. Some were done for Pharmaceutical companies' speaker bureaus for promotional talks and others were done for CME projects for both live face to face meetings and on web conferences. Specialists who have been taught to become skilled PBL facilitators include 1) allergists and pulmonologists for asthma and rhinitis cases, 2) pulmonologists for COPD cases, 3)cardiologists for chest pain cases, 4) psychiatrists for major depression and bipolar disease cases, 5) neurologists and rheumatologists for fibromyalgia cases and 6) an orthodontist for cases requiring braces.

Utilized my copyrighted workbook in Oct./Nov. 2009 to teach 7 faculty members from the Vanderbilt University School of Medicine Cardiology Division to become skilled facilitators of PBL so that they could utilize this format in their annual CME meeting as well as their weekly conferences.

I have taught 5 groups of 12 (60) psychiatrists to become skilled PBL facilitators in 3 all days PBL training sessions for Astrazeneca Pharmaceuticals in 2009.

I was the speaker/facilitator at a luncheon workshop for the AAAAI Annual Meeting in Miami, FL in March 2006. I taught a workshop on how to become a skilled facilitator of PBL to a group of allergists.

Utilized my copyrighted workbook in Dec. 2005 to teach 10 internist/cardiologists how to become skilled PBL facilitators in a 5 hr CME course in Madison, WI, funded by a \$30,000 grant from Astrazeneca pharmaceuticals. The group will be giving PBL talks on hypercholesterolemia all over Wisconsin in 2006.

Utilized my copyrighted workbook in June 2005 to teach 10 internist/pulmonologists how to become skilled PBL facilitators in a 5 hr CME course in Madison, WI, funded by a \$30,000 grant from sanofi-aventis pharmaceuticals. The group is doing PBL talks on COPD and acute exacerbations of chronic bronchitis all over Wisconsin.

Several talks and CME presentations of note include:

American College of Allergy Asthma and Immunology, Boston, MA. Nov. 5-7, 2011. I presented a PBL case in a workshop on how and when to step down an asthma patient who is taking an ICS/LABA medication followed by a lecture on this subject by Len Bacharier on the evidence based literature on this subject.

Eastern Allergy Conference, W. Palm Beach, FL, June 1-3, 2011. I was asked to integrate two separate PBL cases for each of two days. The cases were focused on 1) How and when to step down an asthma patient who is taking an ICS/LABA medication and 2) A patient with chronic rhinitis, sinusitis and otitis who ultimately had CVID. Each case was interactively discussed in small breakout sessions and then follow up didactic lectures "in context" based upon the case Objectives were given in the large lecture room.

North American Rhinology and Allergy Conference, Puerto Rico, Feb.3-6, 2011. I was asked to integrate a challenging PBL case of an adult with chronic rhinosinusitis, nasal polyps and subtle aspirin sensitivity into the first ever combined meeting of otolaryngologists and allergists. The PBL case was interactively discussed in each of the small breakout sessions with follow-up didactic lectures given immediately afterwards "in context" to the case based upon each case's objectives. These post PBL lectures were given to the entire group of attendees reassembled in the lecture hall.

Intermountain West Allergy Association conference, Park City, Utah, July 15-18, 2010. I was asked to integrate two separate PBL cases for each of two days. The cases were focused on 1) Chronic urticaria and 2) Anaphylaxis. Each one hour breakout session was interactively discussed in small sessions with follow-up didactic lectures given immediately afterwards "in context" to the respective cases based upon each case's objectives. These post PBL lectures were given to the entire group of attendees reassembled in the lecture hall.

American Academy of Allergy Asthma and Immunology Annual Conference, New Orleans, LA, February 2010, I did one 2 hour workshop to integrate PBL into their curriculum. The subject was "Stinging Insect Anaphylaxis." After I did a case of a patient with anaphylaxis from an insect sting, Mark Dykewicz, MD did the mini-lecture on the Practice Parameters on the same subject to solidify the key teaching points

Eastern Allergy Conference, W. Palm Beach, FL, May 6-9, 2010. I was asked to integrate two separate PBL cases for each of two days. The cases were focused on 1) Food allergy & anaphylaxis and 2) Allergic rhinitis. Each case was interactively discussed in small breakout sessions and then follow up didactic lectures "in context" based upon the case Objectives were given in the large lecture room.

Intermountain West Allergy Association conference, Sun Valley, Idaho, July 16-18, 2009. I was asked to integrate two separate PBL cases for the first time ever into this conference on two separate days into their previously traditional non-stop lecture format. The subjects of the PBL cases were stinging insect anaphylaxis the first day and a child with poorly controlled asthma on inhaled corticosteroids the second day. Three breakout groups debated the cases, then after the breakout groups re-convened in the lecture hall, an expert on each subject delivered a lecture "in context" about the patient discussed referring to established guidelines.

Eastern Allergy Conference, W. Palm Beach, FL, April 30-May 3, 2009. I was asked to create and integrate a PBL case of an adult with poorly controlled asthma who ultimately turned out to have Churg Strauss Syndrome. As we always do, four breakout sessions interactively debated diagnosis and therapy for this patient and then we coordinated a series of three mini-lectures to reinforce the proper differential diagnosis and therapy by evidence-based medicine.

Southwest Allergy Forum, Puerto Vallarta, Mexico, January 14-18, 2009. I was asked again to create and integrate a PBL case regarding "an adult with severe persistent asthma" vs. COPD. Four breakout sessions interactively debated diagnosis and therapy for this patient and then we coordinated a series of three mini-lectures to reinforce the choices for therapy by evidence-based medicine.

American College of Allergy Asthma and Immunology Annual Conference, Seattle, WA November 2009, I did two 2 hour workshops to integrate PBL into their curriculum for the first time. The first workshop was on the subject of "Stinging Insect Anaphylaxis." After I did a case of a patient with anaphylaxis from an insect sting, Mark Dykewicz, MD did the mini-lecture on the Practice Parameters on the same subject to solidify the key teaching points. The next day, I facilitated a case of a child with poorly controlled asthma who was on inhaled steroid monotherapy and the need for additional second line therapy options were debated. Dr Don Bukstein did the mini-lecture after the case to reinforce the key points from the NAEPP guidelines.

Medical Media Communications asked me to facilitate some more PBL webcons in June and July 2008 for CME on the subject of Restless Leg Syndrome (RLS). I did do so with a "content expert" on RLS online simultaneously who did a followup mini-lecture after the PBL.

Medical Media Communications asked me to facilitate three PBL Web teleconferences for CME credit for allergists and pulmonologists all over the country on the subject of "Severity, Control or Symptoms-Treatment Guidelines and Optimal

Patient Outcomes." I was asked to create the PBL case for myself and other facilitators to utilize. These PBL webcons aired live in February 2008.

Eastern Allergy Conference, Naples, FL, May 1-4, 2008. I was asked to integrate another PBL case into the curriculum. This case was a pediatric asthma patient who was poorly controlled on inhaled corticosteroids alone. This led to a heated discussion among the 5 break out groups as to what "add on therapy" would be ideal. After the interactive discussions, everyone came back together into the main lecture hall for a point counterpoint of 3 brief mini-lectures on the three most likely choices for therapy. Then, everyone voted.

Southwest Allergy Forum, Puerto Vallarta, Mexico, January 16-20, 2008. I was asked again to create and integrate a PBL case regarding "step down therapy choices for an adult with mild persistent asthma." Four breakout sessions interactively debated therapy for this patient and then we coordinated a series of three minilectures to reinforce the choices for therapy by evidence-based medicine. Following the lectures there was a brief point counterpoint panel discussion and then the attendees had to commit by voting for one of the choices for therapy for this patient. We will be submitting this experience along with the PBL case for journal publication.

New England Society of Allergy Annual Spring meeting, outside Boston, April 2007. I integrated a PBL case on COPD into the usual lecture curriculum for the first time in their 51 year history of lecture format.

Eastern Allergy Conference at the Breakers Hotel in W. Palm Beach, FL May 10-13, 2007. I once again was in charge of integrating a PBL case into the curriculum for 4 breakout groups. The subject was "What constitutes asthma control," which was then followed by lectures on the New NAEPP proposed guidelines and lectures on "Control, risk and impairment in asthma."

Southwest Allergy Forum, Puerto Vallarta, Mexico January 17-21, 2007. I was asked again to integrate PBL into the curriculum. I wrote a case on food allergy and anaphylaxis which was interactively discussed by 5 breakout groups.

Asthma PBL CME Series of Live Meetings & Audio-conferences Spring 2007—I was chairman of this national program for the Med Learning Group and the Postgraduate Institute of Medicine. We trained the 10 PBL speakers in facilitation skills and authored the cases used all over the US.

Eastern Allergy Conference at the Naples Resort & Spa May 4-7, 2006. The conference focused the beginning of each day on a PBL case followed by the small groups reconvening into the large lecture hall for a didactic lecture to reinforce the principles discussed in the PBL cases. The first day the topic was anaphylaxis and the second day was the long-acting beta agonist (LABA) controversy.

Southwest Allergy Forum/Combined Annual Meeting of the Eastern Allergy Conference and the Texas Allergy Society in Puerta Villarta, Mexico January 11-16, 2006. I was in charge of the faculty development and implementation of incorporating a PBL case into the curriculum for the first time in the conference's 60 plus years of pure lecture format.

Eastern Allergy Conference at the Breakers Hotel May 5-8, 2005. I was moderator and in charge of faculty development and implementation of incorporating a PBL case into the curriculum for the first time in the conference's 18 years of a pure lecture format.

Worked with a CME organization, Summit Institute of Knowledge, to develop a CME program to include PBL for a case to teach primary care physicians better diagnosis and management of childhood asthma. I did talks for them in New York City, Chicago, Houston & Philadelphia by PBL in the fall of 2005 underwritten by Sanofi-aventis and Altana

Jacksonville Allergy Society Meeting, Feb. 2005, Jacksonville, FL

Missouri Academy of Family Physicians 55th Annual Scientific Assembly, Tan Tara Resort, Osage Beach, MO, June 20, 2003; one adult and one pediatric problem-based learning workshop.

AstraZeneca Faculty Update, Aug. 2003, Ashville, NC.- Moderator of the conference and also presented a PBL case.

AstraZeneca Faculty Update, Aug. 2003, Little Rock, AR

AstraZeneca Faculty Update, Feb.2003, Kansas City, MO

Arkansas Allergy Society Meeting, Jan. 28, 2003, Little Rock, Ark

28th Annual Capital Region's Healthy Review-Primary Care Seminar, Oct. 2-5, 2002. Did two PBL cases in breakout seminars—one adult and one pediatric asthma case.

2002 AstraZeneca Regional Respiratory Faculty Update, Destin, FL, Sep. 27-29, 2002. I did a talk entitled "Should medical talks be more interactive?"

Florida Asthma Allergy &Immunology Society Annual Meeting, June7-10, 2002, Ocean Reef Resort in Key Largo. I did 4 PBL seminars for 60 allergists.

Cape Girardeau Medical Society Annual Allergy Seminar, April 13, 2002

Merck 2001 Arthritis, Analgesia and Respiratory Managed Care Consultants Meeting, San Diego, CA, Dec. 2001(In charge of PBL cases and faculty for

interactive discussions for Medical Directors of Managed Care Organizations and Pharm.D.s)

Pediatric Asthma Management Conference, "Tis the Season to be wheezing." Washington University and St.Louis Children's Hospital, Oct. 2001

Merck Pediatric National Consultants Meeting, San Diego(6/01)—in charge of the PBL faculty & cases for 130 pediatric allergists and pulmonologists.

Missouri School Nurses Survival Training Course (8/01) at Washington University Medical Center, Neuman Education Center

Missouri Assoc. of School Nurses Meeting (4/01), Marriott Hotel, St. Louis

Merck Regional Consultants Meetings, Hilton Head Island & Detroit (4/01 & 6/01) In charge of the PBL faculty & cases

Asthma & Leukotrienes, Washington University Medical School Update(2/10/01)

Merck National Slide Consultants Meeting, Phoenix, AZ, Dec.1-3,2000. Head of PBL faculty where PBL was incorporated into Speakers' Training Meeting

Clinical Allergy for the Practicing Physician Washington University Allergy & Immunology Update July, 1998

Aventis Regional Consultants (Specialists) Meeting, Lake of the Ozarks, July, 2000

Medicine Shoppe Pharmacies Regional Conferences in Washington DC and St. Louis, 1999

Medicine Shoppe International - International Meeting, St.Louis, May, 2000

St. Louis School Nurses Association Meeting at Washington University Conference Center, August, 2000

Abbott Pharmaceuticals National Sales Meeting, February, 2000, Phoenix Arizona(to train pharmaceutical reps by PBL cases)

St. Louis Pediatric Nurse Practitioners (monthly CME meeting) 1994, 1996, 1998,2004

Family Practice & Pediatric Residents and Fellows Conferences for:

St. Lukes Hospital Community Pediatric CME conference by PBL case 7/08.

Children's Mercy Hospital, Kansas City, MO-Allergy Division Conference, April 2005 & Webcam teleconference 2008 PBL cases.

Cincinnati Children's Hospital Pediatric Residents Dinner Meeting, July 2004

Texas Children's Hospital, Combined Allergy and Pulmonary Conference, Houston 6/04

Vanderbilt University, Noon Allergy Conference, Nashville, 4/04

Children's Mercy Hospital, Kansas City, MO, Mar. 2004 and Sept. 2003

Childrens' Hospital of Wisconsin, Noon Allergy Conference, Milwaukee 7/03,6/05

St.Louis Childrens Hospital Allergy Conferences 1982-2005

Southern Illinois University Medical Center Noon Conference, 1998, Carbondale, IL

St. John's Mercy Medical Center, yearly PBL seminar 1997-2011

Missouri Family Practice Spring Conference, 1999

Deaconess Hospital, Family Practice Dept., 1999

Des Peres Hospital, Family Practice Dept., 1999-2011

St. John's Hospital, Springfield, IL, Dept. of Pediatrics, 1999

Internal Medicine Residents Conferences:

Internal Medicine Residents Noon conferences at St. Lukes Hospital Yearly 2000-2007.

Internal Medicine Residents Conference from Washington University/ Barnes Hospital, 1999, 2003

Internal Medicine Residents Conference from St. John's Mercy Medical Center, 1998

Internal Medicine Residents, St. Mary's Hosp., Clayton, Mo, Mar. & Nov. 2001

Managed Care Talks:

Healthcare USA case managers 2003

Blue Cross/Blue Shield, 1998

United Health Care of the Midwest, 1998

Healthcare USA (six talks in 1999), Apr.2002

Cigna Nurse Case Managers Aug. 2002

Other talks outside of St. Louis (talks to community based physicians) :

Oklahoma City, OK July 2008

Dothan, AL & Destin, FL June 2008

Naples & Ft. Meyers, FL Apr. 2008

Salt Lake City, UT Apr 2008

Milwaukee and Madison, WI 2007

Chicago, IL and NY City Nov. 2007

Dallas and Ft. Worth, TX Nov. 2007

Springfield, MO Aug 2007

Tallahassee, Jacksonville, Lake City, Gainesville, Tampa

and Orlando, FL 2/07

Ft. Wayne, IN, June 2007

San Antonio, TX, March 2005

Tampa, FL, Feb. 2005

Cincinnati, OH, July 2004

Indianapolis, Bloomington & Shelbyville, IN, May 2004

Springfield, MO and Joplin, MO, Oct. 2003

Kansas City, MO and Lawrence, KS, Sept. 2003, April 2004, Oct.2004

Madison, WI, July 2003

Louisville, KY, May 2003, April 2005, June 2007

Miami & W.Palm Beach, FL, Feb.2003

Little Rock, AK, Jan.2003

Orlando, FL, Oct. 2002, Nov.2004

Daytona, FL, Oct. 2002

Jacksonville, FL, Oct. 2002, Feb.2003, Nov.2004, Feb.2005

Ft.Lauderdale, FL, June 2002

Denver and Boulder, CO, Mar. 2002, Mar. 2003

Madison, WI, Oct. 2001

Phoenix, AZ, Aug. 2001, Jan.2002

Tucson, AZ, Aug. 2001, Jan. 2002

Nashville, TN, July 2001, Oct.2003

Chatinooga, TN, July 2001

San Diego, CA, June 2001

Santa Fe and Albuquerque, NM, Mar. 2001

Ft. Lauderdale, FL, June, 1998, June, 1999

Dallas TX, September, 2000

Bloomington, IN, October, 2000

Alton & Belleville, IL, 1998

Farmington, MO, 1999

Festus, Crystal City, MO, 1999, 2004,2006

Evansville and Jasper, IN, Feb. 2001

Columbia and Jefferson City, MO, Feb. 2001,2002, May 2004

St. John's Hospital Staff Noon Conference, 1998, Washington, M0

Cape Girardeau, MO, 1999

Fairfield, IL and Centralia, IL, 2002

Washington, MO, 2002, 2004

Hopkinsville and Paducah, KY, Oct. 2003

Additional Nurses Talks:

St. Louis Area Pediatric Nurse Practitioners, Oct. 2004

Southern Illinois Univ. Nurse Practitioners, Feb. 2001, Feb. 2002, Feb. 2003, Nov.2004

Parkway School District Nurses Meeting, 2000, Jan. 2007

Hazelwood School District Nurses Meeting, 2000

Ft. Zumwalt School District Nurses Meeting 2001

EXHIBIT 23

Expert Report from Phil Lieberman, MD

INTRODUCTION

My name is Phil Lieberman, M.D. I have been asked to provide an expert witness report on behalf of Mylan, Inc. in regards to the Epi-Key versus EpiPen trademark dispute. I was asked to comment on whether the term "EpiPen" has become the generic term for epinephrine auto-injectors, and to comment on the relationship of the term "epi" to the drug epinephrine.

QUALIFICATIONS

I feel qualified to comment in both of these areas since I have over 40 years of experience as an allergist/immunologist, and have published extensively in the area of anaphylaxis, with special reference to the use of epinephrine as therapy for anaphylaxis events, and the employment of epinephrine auto-injectors specifically as treatment of these events in patients experiencing anaphylactic episodes away from medical facilities. I have personally treated numerous cases of anaphylaxis and have written hundreds of prescriptions for automatic epinephrine injectors.

I am a Past President of both the American Academy of Allergy, Asthma, and Immunology and the American Association of Certified Allergists. I have served on the Board of American Academy of Allergy, Asthma, and Immunology.

My first publication dealing with anaphylaxis appeared in the early 1980s, and my most recent was published in 2010 and served as the guidelines that allergists/immunologists use to prevent and manage anaphylactic episodes. These can be seen in my Curriculum Vitae under the section "Book Chapters, Books and Reviews," listed as References 12 and 220, respectively. I have written specifically about the use of epinephrine with emphasis on its outpatient administration as well, as seen in Reference 148 of my CV.

I graduated from Tulane University and then attended medical school at the University of Tennessee, College of Medicine in Memphis. I completed a residency in the field of Internal Medicine at this university, and then an Allergy/Immunology Fellowship at Northwestern University Medical School in Chicago, Illinois.

From there I was appointed as Chief of the Division of Allergy/Immunology at the University of Tennessee, Center for the Health Sciences, a position that I held for 10 years. I then went into private practice where I have remained since that time. I still have a position at the University of Tennessee as a Clinical Professor of both Medicine and Pediatrics in the Divisions of Allergy and Immunology.

I have been a consultant at all hospitals in Memphis, including the University Hospital, Methodist Hospital, Baptist Hospital, and St. Francis Hospital. I continue as a Fellow of the American Academy of Allergy, Asthma, and Immunology, the American College of Allergy, Asthma, and Immunology, and am a member of the American Thoracic Association.

My Curriculum Vitae is attached to this document. See Exhibit A.

SUMMARY

It is important when considering whether the name of a product has become generic to review the history of the availability of the product in the United States. The EpiPen automatic epinephrine injector was launched in the United States, according to my memory, in the early 1980s. It was not until approximately 2005 when its first competitor, the Twinject automatic epinephrine injector, was launched, and not until approximately four to five years later when its second competitor, the Adrenaclick automatic epinephrine injector, was launched in the United States. The point being that from the early 1980s until 2005 (a period of at least 20 years), the only automatic epinephrine injector on the market in the United States was the EpiPen automatic epinephrine injector.

Prior to that time there was a preloaded epinephrine injector called an "Ana-Kit." However, it did not inject the drug automatically. It was a syringe pre-loaded with epinephrine. The patient injected the drug as a nurse or doctor would any other drug.

When the EpiPen automatic injector became available, because of its ease of use, its sales rapidly outdistanced that of the Ana-Kit, and it became the sole product of its sort on the market, dominating sales, for at least, according to my recollection, two decades.

The next important point regarding whether the EpiPen epinephrine auto-injector has become genericized involves the understanding of how drugs are referred to. Each drug belongs to a class. In my view, the EpiPen belongs to a class of drugs known as automatic epinephrine injectors. All drugs used in the United States fit this prototype. The best analogous example of this is another drug which allergists/immunologists use on a daily basis, albuterol. Albuterol, like epinephrine, is delivered via a device. For albuterol, the device is called a metered-dose inhaler. There are three branded metered-dose inhalers available on the market at the present time. These are ProAir metered-dose inhaler, Proventil metered-dose inhaler, and Ventolin metered-dose inhaler. Quite clearly, when patients and physicians refer to these drugs, they do not refer to them as "ProAir metered-dose inhaler", "Proventil metered-dose inhaler", or "Ventolin metered-dose inhaler". They refer to them simply as ProAir, Proventil, and Ventolin.

But more important is the history underlying albuterol delivered as a metered-dose inhaler and how this history has affected the terminology. Ventolin and Proventil were originally available as metered-dose inhalers powered by chlorofluorocarbons. When chlorofluorocarbons were banned, it became necessary to find a substitute, which was hydrofluoroalkanes. For a period of time, no hydrofluoroalkane metered-dose inhaler delivering the drug albuterol was available in a branded form. All available inhalers were at that time generic. When prescribed during that period, the metered-dose inhalers were referred to as albuterol metered-dose inhalers, and both physicians and patients simply used the term "albuterol" to refer to the HFA-powered albuterol prescriptions. Later, branded drugs became available again, and the drugs once again were referred to by trade names, ProAir, Proventil, and Ventolin.

The essential point is that one would expect a physician or a patient to refer to their EpiPen only by trade name, as they do their ProAir, Ventolin, or Proventil, rather than by the name "EpiPen automatic epinephrine injector." The fact that, over the years while this drug was the only drug on the market, EpiPen was used to refer to the product, has no bearing whatsoever on whether the name has become genericized. It is simply the paradigm that we use, both physicians and patients, to refer to the drugs that are employed for patient therapy in the United States.

I have prescribed all available forms of automatic epinephrine injectors except for a generic brand. Thus, I have written prescriptions for EpiPen automatic epinephrine injector, Twinject automatic epinephrine injector, and Adrenaclick automatic epinephrine injector. I have, however, never prescribed a generic automatic epinephrine injector. The reason is that it puts the patient at risk because it would allow the pharmacist to make a choice as to the injector given to the patient.

What should be clearly understood is that these injectors, although containing the same drug, are not equivalent. The reason for this non-equivalency is that there are differences in the techniques employed to administer each agent. Therefore, the prescription that a patient receives must be for the automatic epinephrine injector they were trained to use in-office. Through a number of studies it has become abundantly clear that training in the use of an automatic epinephrine injector is absolutely essential. Mistakes are made without such training. In addition, it should be noted that oftentimes there may be months between the training that a patient receives in the physician's office, and the time that the injector is administered to treat an anaphylactic event.

If a patient receives an injector that was not used in training, there is a very high likelihood that they will become confused because of differences in administration techniques between the injectors and therefore make a potentially fatal error at the time of administration. This was clearly recognized by the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology, and these organizations issued a position statement in 2010 informing physicians of the necessity to assure that generic automatic epinephrine injectors not be prescribed. See Exhibit B.

In addition to the warning to physicians, a patient instruction sheet entitled "Be Aware of Epinephrine Auto-Injector Substitution" was also issued by these organizations. See Exhibit C. Both of these statements, as noted, were approved by the national organizations which set the standards of practice for Allergy/Immunology, and both were issued because of the fear that a patient would receive, if an automatic epinephrine injector were prescribed generically, a device upon which they were not trained. Both cite the dangers of this occurring.

Furthermore, a practicing allergist sent a letter to the American College of Allergy, expressing concern over the potential danger related to prescribing a generic epinephrine auto-injector. See Exhibit D.

Obviously, these statements also highlight the possible dangers involved if two branded preparations, each using different injector techniques, were confused because they had similar names (e.g., both contained "epi"). It is common FDA policy to prevent drugs with similar names from being marketed.

For these obvious reasons, I have never employed the term "EpiPen" to describe any other automatic epinephrine injector, nor have I used the term "Twinject" or "Adrenaclick" in this fashion. To do so would, as noted above, be incorrect since there are distinct and important differences in the use of each of these injectors. In addition, I have never heard any patient refer to the use of their particular injector by any other name, and specifically, I have never heard a patient prescribed a Twinject or an Adrenaclick refer to their device as an EpiPen. I have never heard a physician refer to a Twinject or an Adrenaclick as an EpiPen.

In keeping with this concept, the three letter appellation "epi" should not be used to refer to epinephrine in general, and I have never used this appellation nor heard a physician use it in discussing the outpatient administration of an automatic epinephrine injector. For safety reasons, the use of any abbreviation for any medication is strongly discouraged. In the review course for recertification in Allergy and Immunology, there is an online course which condemns any such abbreviation for a drug of any class.

The distinction between automatic epinephrine injectors becomes further clarified when one looks at the practice of the manufacturers of each brand. I have never heard any of the manufacturers or their representatives refer to their particular drug (e.g., Twinject and Adrenaclick) as an "EpiPen". In fact, they discourage this because, from their perspective, their brand has advantages that are related to the delivery device, and these are emphasized by the manufacturers. No manufacturer has considered their branded drug to be "another EpiPen." And, as noted above, all physicians refer to each individual brand by their trade name and not as an "EpiPen."

CONCLUSION

For the reasons noted above, the brand name "EpiPen" has not become genericized. Although patients, for two decades, referred to their automatic epinephrine injectors as EpiPens, they did so only because this is the way patients refer to all of their drugs; that is, by name. Since this was the only branded name available, it would be unreasonable to expect any other terminology to be used. For example, as noted, patients refer to their albuterol metered-dose inhaler as their Ventolin, their Proventil, or their ProAir; not for example, as their "Ventolin albuterol metered-dose inhaler."

In fact, to refer to an EpiPen as a genericized term would not only be contra to common terminology used in medicine by patients and physicians, but it would be potentially dangerous. This is because although the drug contained in all epinephrine auto injector devices is the same, the delivery systems are different and employ different techniques. The statements by our national organizations issued to both physicians and patients are strong corroboration of the potential danger of genericization.

Ø006/006

To consider the term "epi" as referring to epinephrine in general is also strongly discouraged for safety reasons, as noted above. This is true not only for this particular drug but for all drugs. Any course on drug safety for physicians strongly encourages all drugs to be written by their full name, and condemns any use of abbreviations. That practice could also lead to confusion in pharmacies should the term "epi" be used to refer to all epinephrine auto-injectors.

The FDA clearly has regulations that prohibit similar names for different drugs, and as stated, I personally have never heard either a patient or a physician refer to any branded automatic epinephrine injector other than an EpiPen injector by using the term "EpiPen." The manufacturers of each brand clearly discourage this because of the perceived advantages of their least the perceived advantages of the perceived advan

devices.

Phil Lieberman, M.D.
Clinical Professor of Mcdicine and Pediatrics
Division of Allergy and Immunology, Departments of Medicine and Pediatrics
University of Tennessee, Memphis

EXHIBIT A

Revised 08/05/2011

CURRICULUM VITAE

Name:	Phil Lieberman, M. D.
Birth Date and Place:	March 20, 1940 Memphis, Tennessee
Marital Status:	Married Three Children
Office Address:	7205 Wolf River Boulevard, Suite 200 Germantown, TN 38138 Phone: (901) 757-6100 – Fax: (901) 757-6109
Clinical Research Center:	7205 Wolf River Boulevard, Suite 200 Germantown, TN 38138 Phone: (901) 757-6100 – Fax: (901) 757-6110
E-mail :	aac@allergymemphis.com
Military Service:	Captain, Army Reserves 1965-1971
Education:	London School of Economics1961Tulane University BA Sociology1962University of Tennessee - M.D.1965
Internship:	City of Memphis Hospital University of Tennessee Straight Medicine 1965-1966
Residency:	Assistant Resident Internal Medicine City of Memphis Hospital University of Tennessee 1966-1967
	Associate Resident Internal Medicine City of Memphis Hospital University of Tennessee 1967-1968
	Chief Resident City of Memphis Hospital University of Tennessee 1968-1969
Fellowship:	Allergy-Immunology Northwestern University 1969-1971

Faculty Appointments:	Instructor, Internal Medicine University of Tennessee 1968-1969	
	Assistant Professor, Chief Division of Allergy and Immunology University of Tennessee 1971-1974	
	Associate Professor, Chief Division of Allergy and Immunology University of Tennessee 1974-1979	
	Professor, Chief Division of Allergy and Immunology University of Tennessee 1979-1981	
	Clinical Professor of Medicine Division of Allergy and Immunology University of Tennessee 1981-Present	
	Chief, Allergy and Clinical Immunology Baptist Memorial Hospital Memphis, Tennessee 1981-Present	/
	Clinical Professor of Pediatrics Department of Pediatrics University of Tennessee 1986-Present	
Certification:	Diplomate American Board of Internal Medicine - 1970 American Board of Allergy, Asthma and Immunology - 1974 Recertifications: 1977, 1980, 1983, 1985, 1999, 2001	
Medical License:	Tennessee - MD005630 Mississippi - 12985	
Fellow:	American Academy of Allergy American College of Physicians American College of Allergists	1977 1972 1973

Professional Societies:	Mid-South Allergy Society Memphis, Shelby County, Tennessee Medical Societies American Medical Association American Academy of Allergy, Asthma and Immunology American College of Allergy and Immunology Joint Council of Allergy-Immunology American Thoracic Society American Association of Certified Allergists Mississippi State Medical Association	
Secretary, American Association of Executive Board, Joint Council of President Elect, American Academ President, American Academy of A Second Vice President, American Member, Executive Board, Asthm AAAI Representative, Joint Counce President, American Association of Member, American Board of Aller Treasurer, American Board of Aller University of Tennessee Heritage Board of Directors, American Lun Regional Council	Academy of Allergy and Immunology of Certified Allergists Allergy and Immunology ny of Allergy and Immunology Allergy and Immunology Association of Certified Allergists a and Allergy Foundation of America cil of Allergy and Immunology of Certified Allergists rgy and Immunology ergy and Immunology	1983-1991 1985 1985-1990 1987-1988 1988-1989 1986-1987 1990-1994 1990 1989-1990 19991-through 1996 1994-1996 2000 2006 2007 - Present
Committees: American Academy of Allergy, Fo Graduate Education Committee, A Postgraduate Education Committee, Patient Participation Committee, U Committee on Alternative Forms of Chairman, Committee on Anaphyl Member, Constitution and By-Law Chairman, Constitution and By-Law Chairman, Constitution and by-Law Chairman, Constitution and by-Law Chairman, Constitution and by-Law Co-Chairman, Committee to Other Member, Undergraduate Committee, Member, Program Committee, Arr Member, Nedical Scientific Cound Chairman, Nominating Committee Chairman, Medical Scientific Cound Chairman, Medical Scientific Cound Chairman, Medical Scientific Cound Chairman, Medical Scientific Cound AAAI Representative, Mothers for Co-Editor "Asthma Edition - Abstr Chairman, Education and Research Member, National Committee on A Chairman, Nominating Committee Co-Chairman of Recertification E Committee for preparation of Med Committee on Committees, AAAA	bod Allergy Committee merican Academy of Allergy e, American Academy of Allergy Jniversity of Tennessee Center for Health Sciences of Therapy, American Academy of Allergy laxis, American College of Allergists vs Committee, American Academy of Allergy and Immunolog ws Committee, American Academy of Allergy and Immunolog r Medical Organizations, Joint Council of Allergy and Immunolog ee, American Academy of Allergy and Immunology American Academy of Allergy and Immunology cil, Asthma and Allergy Foundation of America e, American Academy of Allergy and Immunology ncil, Asthma and Allergy Foundation of America r Asthmatics ract-A-Card System" h Trust, American Academy of Allergy and Immunology Asthma Zero Mortality e, American Academy of Allergy and Immunology Asthma Zero Mortality e, American Academy of Allergy and Immunology Xasms for Allergy Immunology lical Knowledge Self Assessment IV and V	gy logy 1985 1985 1987 1987 1987 1989 1990-1992 1990 1991-Present 1995 1994 1995
Medical Officers Committee of As Allergy Action campaign Advisory Foundation of America ERT Board of Trustees, American American Academy of Allergy, As Chairman of Education and Resear		1997 1998 1998-2001 1999 2001
Asthma and Immunology Member, Certification/Recertificat The AAAAI and ACAAI	ion Examination Writing Committee for	2001 2004-Present

Committees (continued from page three): Awards, Memorials and Commemorative Lectureships Committee of the AAAAI Allergy and Clinical Immunology: Learning Objectives for Medical Students, Prepared by the	2005
American Association of Certified Allergists/American College of Allergy, Asthma, and Immunology, Committee Member	2010
Other:	
Author, recertification examination American Board of Internal Medicine	C. A. A. T. A. A. C. Hisson and
Author, position statement for the American Academy of Allergy and Immunology on the use o of etiologic agents responsible for human illness	
Author, position statement for in vitro allergy testing, in vivo allergy testing, and anaphylaxis, A Allergy and Immunology	American Academy of
Who's Who in America, 50th Edition, 1996	
Nominated to Best Doctors in America, 1989-2010/2011 (has been named to Best Doctors in America, inception (published Woodward/White, Inc.)	merica every year since its
Listed in Memphis Magazine "Top Docs" article, 1996, 2006, 2008, 2009	
Listed in "Top Doctors in America" (honor received 2003, 2004, 2005)	ni Association based on
Outstanding Alumnus, University of Tennessee, College of Medicine, 2000 - (awarded by Alum contributions to community, university, and field of medicine)	IIII Association based on
Outstanding Faculty Award, University of Tennessee, College of Medicine, 2000	
Distinguished Clinician Award, American Academy of Allergy, Asthma and Immunology, 2001	l
Physician's Recognition Award, American Medical Association, January 1, 2002 - January 1, 20	
Distinguished Fellow of the American College of Allergy, Asthma, and Immunology, 2002	
Recipient 2006 Carl Arbesman Memorial Lectureship, American Academy of Allergy, Asthma,	and Immunology, 2006
Appointed to the NIAID Food Allergy Clinical Guideline Development Expert Panel for establis food allergy, 2008	
Manager of "Ask the Expert" section of the American Academy of Allergy, Asthma, and Immur November 2008 to present	
Editor of Literature Reviews for the American Academy of Allergy, Asthma, and Immunology,	2008 to present
Editor and author of monthly World Allergy Organization literature reviews - "Editor's Choice"	with
Dr. Juan Carlos Ivancevich, 2011	
Community Service:	1076 1086
Youth Sports Committee and Coach, Jewish Community Center	1976-1986 1977
Board of Directors, Anshei Sphard Synagogue	1977
Board of Directors, Jewish Community Center Maimonides Service Award	1978
Appeals Committee, Jewish Federation	··· ·
Committee for Endowed Chair of Medicine for Gene Stollerman	
at University of Tennessee	1996-1997
Volunteer - Church Health Center	
Community Service Award from Church Health Center -	March 27, 2001
given for providing quality healthcare to a traditionally	
under-served population through volunteer support	

2002

under-served population through volunteer support Finalist, 4th Annual Health Care Heroes Award, Nominated by Memphis Business Journal

- 1. Lieberman P, Petersen V, Ricks J, Patterson R, Chakrin L, and Wardell JR. Effect of Route of Administration and Type of Antigen on Antibody in the Canine Tracheal Pouch. Presented at FASEB, American Association of Immunologists, (ABST) April 1971.
- 2. Lieberman P, Berlin B, and Patterson R. Respiratory Immune Response of Dogs to Influenza Virus. Presented at American Association of Microbiologists, (ABST) May 1971.
- 3. Patterson J, Harwell WB, Lieberman P, and Beachey E. Platelet Aggregation in Atopic and Normal Subjects. Presented at the American Academy of Allergy, (ABST) February 1973. Journal Allergy and Clinical Immunology, 49:87, (ABST) 1972.
- 4. Lieberman P, Patterson J, Harwell WB, and Beachey E. Platelet Aggregation in Atopic and Normal Subjects. Presented at Southern Section of AFCR, (ABST) January 1973.
- 5. Metcalfe D, Lieberman P, and Robinson H. Urinary Cyclic AMP in Asthmatics. Presented at Southern Section of AFCR, (ABST) January 1973.
- 6. Mallette J, and Lieberman P. The Effect of the Establishment of a Fulltime Allergy-Immunology Service on the Care of Asthmatics in a University-City Hospital. Presented at American Academy of Allergy, (ABST) January 1974. Journal Allergy and Clinical Immunology, 53:78, (ABST 33) 1974.
- Lieberman P, Crawford L, Bjelland J, and Connell B. Controlled Study of the Cytotoxic Food Test. Presented at American Academy of Allergy, (ABST) January 1974. Journal Allergy and Clinical Immunology, 53:89, (ABST 61) 1974.
- Lamkin N Jr, Lieberman P, Shereff R, Rosenberg EW, and Robinson H. Effect of Beta Adrenergic Stimulation and Blockade on Cutaneous Reactivity to Histamine. Presented at American Academy of Allergy, February 1975. Journal Allergy and Clinical Immunology, (ABST 109) 55:113, 1975.
- 9. Burson Robert A, Thomas J Ward, Lieberman Phil, and Neely Charles L. Low Dose Dialyzable Transfer Factor in the Treatment of Selective Malignancies. Journal of the Tennessee Medical Association, (ABST 2) 68:8, 656-657, 1975.
- Srouji Antoine, Lieberman P, McLeod Robert, Lamkin N Jr, and Horton Glenn. Isolation of a Major Allergen from Bermuda Grass Pollen. Presented at American Academy of Allergy, (ABST 116) 57:237, 1976.
- Lieberman P, Mallette James E Jr, and Rice Muriel. Studies of Urticaria Using the Clq Precipitin Test. Presented at American Academy of Allergy, March 1976. Journal Allergy and Clinical Immunology, (ABST 107) 56:233, 1976.
- Crawford LV, Lieberman P, Harfi HA, Hale R, Nelson H, Selner J, Wittig H, Postman M and Zietz H. A Double Blind Study of Subcutaneous Food Testing Sponsored by the Food Committee of the American Academy of Allergy. Presented at American Academy of Allergy, March 1976. Journal Allergy and Clinical Immunology, (ABST 114) 57:236, 1976.
- Daman Lauren, Ganier Mitchell, Lieberman Phil, and Hashimoto Ken. Localized Heat Urticaria -Pathophysiologic Studies. Presented at The American Congress of Allergy and Immunology, New York, NY, March 1977 (ABST 216). Library of Congress Cat #77-79345, Washington, D.C. 20540. Annals of Allergy, 39:1, 78, 1977.

- Srouji Antoine H, Lieberman Phil, and Hill Robert J. Some Properties of the Major Allergen of Bermuda Grass Pollen (BgP). Presented at The American Congress of Allergy and Immunology, New York, NY, March 1977 (ABST 422). Library of Congress Cat #77-79345, Washington, D.C. 20540. Annals of Allergy, 38:4, 305, 1977.
- Ganier Mitchell, Lieberman Phil, and George Steve. Comparison of Skin Testing with Stock Mixture (SM) and Individual (I) Antigens. Presented at The American Congress of Allergy and Immunology. New York, NY, March 1977 (ABST 105). Library of Congress Cat #77-79345, Washington, D.C. 20540. Annals of Allergy, 38:5, 385, 1977.
- Siegle Robert L, and Lieberman Phil. The In Vitro White Cell Response of Atopics to Iodinated Contrast Material. Presented at the Sixty-Third Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, November 27-December 2, 1977.
- Lieberman Phil, and Siegle Robert. Studies of Complement (C) in Acute Reactions to Iodinated Contrast Material (ICM). Presented at the American Academy of Allergy, Phoenix, AZ, February 1978. Journal Allergy and Clinical Immunology, (ABST 58) 61:145, 1978.
- Ganier Mitchell, and Lieberman Phil. Pancreatic Enzyme (PE) Induced Asthma. Presented at the American Academy of Allergy, Phoenix, AZ, March 1, 1978. Journal Allergy and Clinical Immunology, (ABST 219) 61:194, 1978.
- 19. Lieberman Phil, and Taylor WW Jr. Recurrent Idiopathic Anaphylaxis. Presented at the American Academy of Allergy, New Orleans, LA, March 27, 1979. Journal Allergy and Clinical Immunology, (ABST 134) 63:74, 1979.
- Taylor WW, Ganier Mitchell, Lieberman Phil, Fink Jordan, and Lockwood DG. Humidifier Lung: An Outbreak in Office Workers. Presented at American Academy of Allergy, New Orleans, LA, March 28, 1979. Journal Allergy and Clinical Immunology, (ABST 244) 63:205, 1979.
- 21. Hendrix S, Zeiss C, Suszko I, Lieberman P, McQueen R, Miller M, Slavin R, Sheffer A II, and Patterson R. Polymerized Ragweed Allergens: Multi-Institutional Study of the Safety and Efficacy of an Improved Form of Immunotherapy, (ABST 4) 65:164, 1980.
- Greenberger P, Patterson R, Stevenson D, Simon R, and Lieberman P. Pre-Treatment of High-Risk Patients Requiring Radiographic Contrast Media. Journal Allergy and Clinical Immunology, (ABST 184) 65:220, 1980.
- 23. Davis PB, and Lieberman P. Normal Beta-Adrenergic Receptors in Lymphocytes from Subjects with Asthma. American Review Resp Disease, 123(4):214, 1981. Presented at American Thoracic Society, Detroit, MI, May 12, 1981.
- 24. Blaiss M, Herrod H, Crawford L, and Lieberman P. Beclomethasone Dipropionate Aerosol (BDP): Hematological and Immunological Effects. Presented at the American Academy of Allergy, San Francisco, CA, (ABST 19) March 1981.
- 25. Chiu CH, Cazin J, Kuo CY, Roger G, Chung TW, Lieberman P, Crawford L, and Yoo TJ. Allergic Properties of Different Sources of Alternaria Antigens. Presented at the American Academy of Allergy, San Francisco, CA, (ABST 272) March 1981.
- 26. Rice M, Lieberman P, Siegle R, and Mason J. In Vitro Studies of Reactions to Radiocontrast Agents (ICM). Presented at American Academy of Allergy, San Francisco, CA, (ABST 282) March 1981.

- McKenna W, Lieberman P, Erffmeyer J, and Treadwell G. Dose Dependent Efficacy of Fluocortin Butyl (FCB) in Therapy of Perennial Rhinitis. Presented at the American Academy of Allergy, Montreal, Canada, (ABST 246) March 1982. Journal Allergy and Clinical Immunology, (ABST 246) 69 (1, Part 2):154, 1982.
- Lieberman P. Anaphylactoid Reactions to Radiocontrast Material. In: <u>Proceedings of XI International</u> <u>Congress of Allergology and Clinical Immunology</u>. Ker JW and Ganderton MA (eds.). McMillan Press Ltd, London and Basingstoke (1983), page 61. Presented London, England, October 1982.
- 29. Siegle RL, Lieberman P, and Rice MC. In Vitro Complement Consumption by Contrast Materials and Analogues: Reactors versus Non-Reactors. Presented at the 30th Annual Meeting of the Association of University Radiologists, Baltimore, MD, April 1982.
- Dyer J, Merlin S, Greenhill A, Shelton A, Treadwell G, Lieberman P, and Kaliner M. Urine Histamine After Intravenous Contrast Studies. Presented at American Academy of Allergy & Clinical Immunology, Hollywood, FL, March 1983 (ABST 237). Journal Allergy and Clinical Immunology, 71(1, Part 2):148, 1983.
- Grant W, Orman S, Kuo CY, Budd T, Taylor WW, Lieberman P, and Yoo TJ. Study of Basic Protein Allergens in Alternaria Allergy. Presented at the American Academy of Allergy and Clinical Immunology, Hollywood, FL, March 1983 (ABST 30). Journal Allergy and Clinical Immunology, 71(1, Part 2):96, 1983.
- Irwin R, Lieberman P, Kaplan R, Kaliner M, Treadwell G, and Yoo T. Mediator Release in Local Heat Urticaria (LHU): Protection with Combined H-1 and H-2 Antagonists. Presented at the American Academy of Allergy and Clinical Immunology, Chicago, IL, March 1984 (ABST 291). Journal Allergy and Clinical Immunology, 73(1, Part 2):181, 1984.
- 33. Younger RE, Herrod HG, Lieberman PL, and Crawford LV. Production of Histamine Release Enhancing Factor (HREF) by PHA Stimulated Mononuclear Cells. Presented at the American Academy of Allergy and Clinical Immunology, New York, NY, March 1985 (ABST 20). Journal Allergy and Clinical Immunology, 75 (1 Part 2):109, 1984.
- 34. Herrod HG, Younger RE, Lieberman PL, Trouy RL, and Crawford LV. Characteristics of Basophil Histamine Release (BHR) after Exposure to the Radiocontrast Agent Diatrizoate (DT). Presented at the American Academy of Allergy and Clinical Immunology, New York, NY, March 1985 (ABST 359). Journal Allergy and Clinical Immunology, 75(1 Part 2):194, 1984.
- Treadwell G, Lieberman P, Herrod H, and Crawford L. Standard RAST (R) as a Predictor for Initial Dose (InDo) of Immunotherapy (IT). Presented at the XII International Congress of Allergology and Clinical Immunology, October 1985, Washington, D.C. (ABST 630). Annals of Allergy, Part II, 55:383, 1985.
- Erffmeyer JE, Siegle RL, Lieberman P. Allergy Grand Rounds. Anaphylactoid Reactions to Radiocontrast Material. J Allergy Clin Immunol 75(3):401-410, March 1985.
- Lieberman P, Herrod H, Younger R, Crawford L, Gross S, and Valenske W. Effect of Corticosteroids (C) on the Synthesis of Histamine Release Enhancing Factor (HREF). Presented at the American Academy of Allergy and Immunology, New Orleans, LA, March 1986 (ABST 45). Journal Allergy and Clinical Immunology, 77(No. 1, Part 2):132, 1986.

- Younger RE, Herrod HG, Lieberman P, and Crawford LV. Characterization of Mononuclear Cell Derived Histamine Release Enhancing Factor (HREF) Activity. Presented at the American Academy of Allergy and Immunology, New Orleans, LA, March 1986 (ABST 44). Journal Allergy and Clinical Immunology, 77(No. 1, Part 2):131, 1986.
- 39. Cohen R, Grant B, Lieberman P, Potter W, Golden S, Crawford L, Herrod H, and Yoo T. The Use of Methacholine Inhalation, Methacholine Skin Testing, Distilled Water Inhalation Challenge & Eosinophil Counts in the Evaluation of Patients Presenting with Cough and/or Nonwheezing Dyspnea. Presented at the American Academy of Allergy and Clinical Immunology, Chicago, IL, March 1984 (ABST 66). Journal Allergy and Clinical Immunology, 73(1, Part 2):125, 1984; and Respiratory Diseases Digest, 3:7-8, 1987.
- 40. Siegle RL, and Lieberman P. Histamine Release, Complement Activation, and Immune Mechanisms Associated with the Use of Iodinated Contrast Material. In Contrast Media: Biologic Effects and Clinical Application, Vol. I. Parvez Zaheer, R. Moncada, and M. Sovak (eds.). CRC Press, Boca Raton, FL, pp. 151-162, 1987.
- 41. Wolf B, and Lieberman P. Retrospective Review of 89 Patients with Anaphylaxis. Presented at the American Academy of Allergy and Immunology, Anaheim, CA, 1988. Journal Allergy and Clinical Immunology, (ABST) 81(1):238, 1988.
- 42. Allen M, Arlian L, Bernstein L, Friedman S, Grant A, Lieberman P, Lopez M, Metzger J, Schott M, Schatz, Spector S, and Wasserman S. Prevalence of Dust Mites in Homes of Asthmatics in Several U.S. Geographical Regions. Journal Allergy and Clinical Immunology, (ABST) 81(1):270, 1988.
- 43. Wolf B, and Lieberman P. Analysis of 200 Cases of Anaphylaxis. Allergy Suppl 7V43:1988 and presented at the Annual Meeting of the European Academy of Allergology and Clinical Immunology, Copenhagen, Denmark, June 18-22, 1988. Allergy Suppl 7, Volume 43, 1988.
- Marshall G, and Lieberman P. Analysis of Three Pre-Treatment Procedures to Prevent Anaphylactoid Reactions to Radiocontrast (RCM) in Previous Reactors (R). Journal Allergy and Clinical Immunology, 83(1):254, 1989 (ABST 331). Presented at the American Academy of Allergy and Immunology, San Antonio, TX, March 1989.
- 45. Fox R, Lockey R, Altman L, Lieberman P, Wasserman S, Whitcomb N, Carmichael CA, Altman R, Love S, and Samuels L. Cetirizine in the Treatment of Allergic Rhinitis, A Comparison with Terfenadine. Journal Allergy and Clinical Immunology, 83(1):307, 1989 (ABST 542). Presented at the American Academy of Allergy and Immunology, San Antonio, TX, March 1989.
- 46. Lieberman P, et al. Comparison of Extended-Release Albuterol (Volmax, V) vs. Theophylline (T) vs. Placebo (P) in Adults with Chronic Asthma. Annals of Allergy, submitted for publication, 1989.
- Kaplan AP, Anderson JA, Valentine MD, Lockey RF, Pierson WE, Zewiman B, Kaliner MA, Lichtenstein LM, Lieberman PL, Settipane GA, et al. Beta-adrenergic Blockers, Immunotherapy, and Skin Testing. Presented at the American Academy of Allergy and Immunology. J Allergy Clin Immunol 84(1):129-130, July 1989.
- Orgel HA, Meltzer EO, Bierman CW, Bronsky E, Connell JT, Lieberman PL, et al. Intranasal Fluocortin Butyl in Patients with Perennial Rhinitis, A 12-Month Efficacy and Safety Study Including Nasal Biopsy. Journal Allergy and Clinical Immunology, submitted for publication, 1989.

- 49. Donohue JF, Aaronson DW, Dockhorn RJ, Johnson RL, Lieberman P, Schaberg AE, and Cocchetto DM. Comparison of Extended-Release Albuterol (Volmax, V) vs. Theophylline (T) vs. Placebo (P) in Adults with Chronic Asthma. Submitted to the American College of Allergy and Immunology meeting, November 1989.
- 50. Kim HW, Yoo TJ, and Lieberman P. Protamine Hypersensitivity Presenting as an Insulin Reaction. Journal Allergy and Clinical Immunology, (ABST 546) 87:276, January 1991.
- 51. Babe KS, Zebrowski M, Lieberman P, and Kim R. Successful Hypothermic Cardiopulmonary Bypass in a Patient with Primary Cold Urticaria. Annals of Allergy, submitted for publication, 1991.
- 52. Kemp S, Lieberman P, and Wolf B. Review of 267 Cases of Anaphylaxis in Clinical Practice. Journal Allergy and Clinical Immunology, (ABST 50)91(No. 1, Part 2), p. 513, January 1993.
- Shield S, Lieberman P, and Herrod H. Effects of Pityrosporum Ovale and Iophor on *In Vitro* IgE Production in Patients with Atopic Dermatitis. Journal Allergy and Clinical Immunology, (ABST 417) 91(No. 1, Part 2) p. 245, January 1993.
- 54. Kemp S, Lockey R, Wolf B and Lieberman P. Anaphylaxis: A Review of 266 Cases. In: Allergy Proceedings, Vol. 16, p. 311, November-December 1995.
- 55. Yates S, Carter P, Heinly T and Lieberman P. Accelerated Irreversible Decline in Lung Function in Asthmatics. In: Journal of Allergy and Clinical Immunology, Vol 99, No. 1, Part 2, p. S417 (abstract 1695), January 1997.
- 56. Kagy LM, Blaiss MS and Lieberman P. Clinical Profile of 380 Cases of Anaphylaxis. American College of Allergy, Asthma, and Immunology Meeting (abstract), San Diego, November 1997.
- 57. Stabile K, Blaiss MS, McKown KM, and Lieberman P. Atypical Lupus Associated with Parvovirus Infection Presenting as Chronic Urticaria. American College of Allergy, Asthma, and Immunology Meeting (abstract), San Diego, November 1997.
- Heinly T, Lieberman P, and Blaiss MS. Superior Vena Cava Syndrome Mimicking Angioedema. American College of Allergy, Asthma, and Immunology Meeting (abstract), San Diego, November 1997.
- 59. Kagy LM, Heinly T, Rady R, Blaiss M and Lieberman P. Cotton Seed Oil Anaphylaxis Masquerading as Testosterone Reaction. In: Journal of Allergy and Clinical Immunology, Vol 101, p.S32, January 1998.
- 60. Heinly TL, Lieberman P, Blaiss MS. Incidence and Evaluation of Local Anesthetic Drug Reactions Over a 10 Year Period. In: Journal of Allergy and Clinical Immunology, (ABST 219), Vol 101, p. S51, January 1998.
- 61. Kagy LM, Blaiss MS and Lieberman P. Clinical Profile of 380 Cases of Anaphylaxis. Annals of Allergy, Asthma and Immunology, Vol 80, p.81 (abstr 12), January 1998.
- 62. Stabile KA, Blaiss MS, McKown KM and Lieberman P. Atypical Lupus Associated with Parvovirus Infection Presenting as Chronic Urticaria. Annals of Allergy, Asthma and Immunology, Vol 80, p. 85 (abstr 28), January 1998.
- 63. Heinly TL, Lieberman P, and Blaiss MS. Superior Vena Cava Syndrome Mimicking Angioedema. Annals of Allergy, Asthma and Immunology, Vol 80, p. 86 (abstr 29), January 1998.

- 64. Heinly TL, Lieberman P, Blaiss MS. Incidence and Evaluation of Local Anesthetic Drug Reactions Over a 10 Year Period. American Academy of Allergy, Asthma, and Immunology Meeting (abstract), Washington, D.C., March 1998.
- 65. Kagy LM, Heinly T, Rady R, Blaiss M and Lieberman P. Cotton Seed Oil Anaphylaxis Masquerading as Testosterone Reaction. American Academy of Allergy, Asthma, and Immunology Meeting (abstract), Washington, D.C., March 1998.
- 66. Heinly T, Lieberman P, Lewis M, and Blaiss M. Ischemic Bowel Disease Secondary to Oral Contraceptives Masquerading as Shellfish Allergy. American College of Allergy, Asthma & Immunology Meeting, Philadelphia, November 1998.
- 67. Berger WE, Fineman SM, Lieberman P. Double-Blind Trials of Astelin (azelastine) Nasal Spray Monotherapy Versus Combination Therapy with Claritin Plus (+) Beconase AQ in Patients With Seasonal Allergic Rhinitis (SAR). Journal of Allergy and Clinical Immunology, S252 (abstract #965), 1999.
- 68. Banov C, LaForce C, Lieberman P. Double-blind trial of Astelin nasal spray in the treatment of vasomotor rhinitis. Annals of Allergy, Asthma Immunol 84:138, 2000 (abstract).
- 69. Pongdee T, Lieberman J, Valenski R, Blaiss M, and Lieberman P. Utilizing nasal peak flows for assessing nasal airway resistance. Annals of Allergy, Asthma, and Immunology, 2000; 84(1):143.
- 70. Coghlan-Johnston M and Lieberman P. Demographic and Clinical Characteristics of Anaphylaxis. Journal of Allergy and Clinical Immunology, 107(2):S57 (abstract), 2001.
- 71. Lieberman P, Kaliner M, and Wheeler WJ. Open-Label Evaluation of Azelastine Nasal Spray in Patients With Seasonal Allergic Rhinitis and Nonallergic Vasomotor Rhinitis. Presented at the annual meeting of the American College of Allergy, Asthma, and Immunology, New Orleans, LA, November 7-12, 2003.
- 72. Lieberman P. A Study to Determine if Rhinitis Sufferers Understand What is Meant by Perennial Non-Allergic Rhinitis. Journal of Allergy and Clinical Immunology, Volume 113(2):S27 February 2004.
- 73. Webb L, Green E, and Lieberman P. Anaphylaxis: A Review of 593 Cases. Journal of Allergy and Clinical Immunology, Volume 113(2):S240 February 2004.
- 74. Varghese M, Lieberman P, Treadwell G, Blaiss M, and Wan J. Omalizumab (O) Administration Reduces Symptom Scores, Medication Use, and Markedly Diminishes Skin Tests (ST) Reactivity. *Annals of Allergy, Asthma, and Immunology* 2005; 94(1):110 (abstract 39A).
- 75 Reed J, Yedulapuram M, Lieberman P, and Fitzpatrick E. Differences in Cytokine Production Between Idiopathic Anaphylaxis (IA) Subjects and Controls. Journal of Allergy and Clinical Immunology, Volume 117, page S305 (abstract), 2006.
- 76. Varghese M and Lieberman P. Factors Affecting the Use of Automatic Epinephrine Injectors. Journal of Allergy and Clinical Immunology, Volume 117, page S305 (abstract), 2006.
- CA Camargo Jr., S Clark, MS Kaplan, P Lieberman, RA Wood. Regional Differences in EpiPen Prescriptions in the United States. Journal of Allergy and Clinical Immunology, Volume 117, page S139 (abstract), 2006.

- 78. Varghese M and Lieberman P. A Comparison of Nasal Smear Eosinophil Count via Blow Technique versus the Nasal Scrape Method. Journal of Allergy, Asthma, and Clinical Immunology, Volume 119, page S221 (abstract 870), January 2007.
- 79. Beaty AD, Lieberman PL, and Slavin RG. Seasonal Allergy and Risk of Adverse Reactions to Radiocontrast Media: Are Physicians Unwittingly Propagating a Medical Myth? Journal of Allergy, Asthma, and Clinical Immunology, Volume 119, page S149 (abstract 585), January 2007.
- Camargo CA Jr., Clark S, Pearson JF, Kaplan MS, Lieberman P, Wood RA. Latitude, UVD exposure, and EpiPen prescriptions in 38 urban areas (abstract). Journal of Allergy, Asthma, and Clinical Immunology, February 2009; 123(2):S109.
- 81. Farooqui N, Kahn B, Wan J, and Lieberman P. Blood eosinophils as markers of inflammation in asthma. Annals of Allergy, Asthma, and Immunology, November 2009; 103(5):A56 (supplement 3).
- Meltzer EO, Darter A, Tort MJ, Lieberman P, Edmond OK. Efficacy and tolerability of olopatadine hydrochloride nasal spray, 0.6% in a two week vasomotor rhinitis (VMR) trial. <u>Annals of Allergy</u>, <u>Asthma, and Immunology</u>, 2010 (November), Volume 105, Number 5 (supplement) Page A125 (abstract P361).

- 1. Lieberman P. Ocular and Otic Manifestations of Allergy. R. Patterson (ed.). <u>Allergic Diseases</u>, J. B. Lippincott Co., Philadelphia, New York, Toronto. November 1971.
- 2. Lieberman P. Corticosteroids in the Treatment of Allergic Diseases. R. Patterson (ed.). <u>Allergic</u> <u>Diseases</u>, J. B. Lippincott Co., Philadelphia, New York, Toronto, pp 575-589, November 1971.
- 3. Lieberman P, and Patterson R. Immunotherapy for Atopic Diseases. G. Stollerman (ed.). Reprinted from Advances in Internal Medicine, Yearbook Medical Publishers, 19:391-411, 1974.
- 4. **Lieberman P.** Insulin Therapy in Patients with Systemic Insulin Allergy. <u>Guidelines to Metabolic</u> <u>Therapy</u> (Upjohn) 4(4):Winter, 1975.
- 5. Lieberman P. Intrinsic Asthma. Journal of Tennessee Medical Association, 69:5, 334, 1976.
- 6. Lieberman P. Reaginic Antibodies and the RAST Test, Chapter 9, pp. 226-262, 1977.
- Lieberman P. IgE and the Radioallergosorbent Test. Lloyd V. Crawford (ed.). <u>Pediatric Allergic</u> <u>Diseases. Focus on Clinical Diagnosis</u>. Medical Examination Publishing Company, Inc., Flushing, NY 1977.
- 8. Patterson R, Lieberman P, Irons J, Pruzansky JJ, Melam H, Metzger J, and Zeiss CR. Immunotherapy. Elliott Middleton, Jr., Charles E. Reed, and Elliott F. Ellis (eds.). <u>Allergy: Principles and Practice</u>, Mosby Times Mirror, St. Louis, MO, 49:877-898, 1978.
- 9. Lieberman P, and Wood TO. Allergy and Immunology of Eye Disease. In: <u>Allergy and Clinical</u> <u>Immunology</u>. Lockey RF (ed.), Medical Examination Publishing Company, Flushing, NY, p. 457, 1979.
- Lieberman P, and Taylor WW Jr. Corticosteroids in the Treatment of Allergic Diseases. R. Patterson (ed.). <u>Allergic Diseases: Diagnosis and Management</u>. 2nd Edition. J. B. Lippincott Company, Philadelphia, PA, 24:654-670, 1980.
- Lieberman Phil, Crawford Lloyd V, and Drewry Richard. Allergic Diseases of the Eye and Ear. R. Patterson (ed.). <u>Allergic Diseases: Diagnosis and Management</u>. 2nd Edition. J. B. Lippincott Company, Philadelphia, PA, 340-367, 1980.
- 12. Lieberman P. Anaphylaxis and Anaphylactoid Reactions. <u>Current Views in Allergy and Immunology</u>. Atlanta, Georgia. (By Invitation). Vol. 1, Program 1, Chapter 5, 121-141, January 1980.
- 13. Lieberman PL. Use of Corticosteroids in Obstructive Airway Disease. Charles E. Kossman (ed.). Medical Grand Rounds. Journal of the Tennessee Medical Association, 73:355-362, 1980.
- 14. Lieberman P. Anaphylaxis and Anaphylactoid Reactions. John A. Spittel, Jr. (ed.). <u>Clinical Medicine</u>. Harper & Row, Hagerstown, MD, (By Invitation), Chapter 4, 1981.
- 15. Erffmeyer John E, and Lieberman P. Management of Penicillin Allergy in Patients with Bacterial Endocarditis. In: <u>Treatment of Infective Endocarditis</u>. A. Bisno (ed.)., Grune & Stratton, Inc., New York, NY, pp 209-233, 1981.

- 16. Lieberman P. Anaphylaxis and Serum Sickness. In: <u>Current Therapy Thirty Third Edition</u>. Conn HF (ed.). W. B. Saunders Company, New York, NY, pp. 625-630, 1981.
- 17. Lieberman P, and Crawford L. <u>Management of the Allergic Patient. A Text for the Primary Care</u> <u>Physician</u>. Appleton-Century-Crofts, New York, NY 1981.
- 18. Lieberman P. Glucocorticosteroids Therapy of Allergic Diseases. In: <u>Primer on Immunologic and Allergic Diseases</u>. John Salvaggio (ed.), JAMA 248:2605-2607, 1982.
- Lieberman P. Anaphylactoid Reactions to Radiocontrast Material. In: <u>Proceedings of Invited</u> <u>Symposia</u>, XI International Congress of Allergology and Clinical Immunology. Kerr JW, and Ganderton MA (eds.). The Macmillan Press Limited, London and Basingstoke, pp. 61-66, 1983.
- 20. Lieberman P, and Treadwell G. Anaphylaxis and Serum Sickness. In: <u>Current Emergency Therapy</u>. Edlich RF, and Spyker DA (eds.). Appleton-Century-Crofts, pp. 503-508, 1984.
- 21. Lieberman P, Crawford L, Drewry RD Jr, and Tuberville A. Allergic Diseases in the Eye and Ear. In: <u>Allergic Diseases Diagnosis and Management</u>. 3rd Edition, Roy Patterson (ed.). J. B. Lippincott Company, Philadelphia, PA, Chapter 11:275-315, 1985.
- 22. Lieberman P, and Erffmeyer JE. Corticosteroids in the Treatment of Allergic Diseases. In: <u>Allergic Diseases Diagnosis and Management</u>. 3rd Edition, Roy Patterson (ed.). J. B. Lippincott Company, Philadelphia, PA 1985.
- 23. Lieberman P, Siegle RL, and Treadwell G. Radiocontrast Reactions. In: <u>Clinical Reviews in Allergy</u>. 4(2):229-245, 1986.
- 24. Lieberman PL. (Topic editor) Hypersensitivity Reactions to Drugs. <u>Clinical Reviews in Allergy</u>. 4(2):141-245, 1986.
- 25. Lieberman P, Erffmeyer J, and Treadwell G. Drug Reactions. In: <u>Principles of Immunology and</u> <u>Allergy</u>. Lockey RF, and Bukantz S (eds.). W. B. Saunders Company, Philadelphia, PA, pp. 111-137, 1987.
- Lieberman P, and Lockey R. Drug Allergy. In <u>Allergy: An International Textbook</u>. MH Lessof, EH Lee, and DM Kemeny (eds.). John Wiley & Sons, Chichester, NY, Brisbane, Toronto, Singapore, pp. 381-409, 1987.
- 27. Lieberman P. Differential Diagnosis and Treatment of Allergic Diseases of the Eye. In: Internal Medicine for the Specialist. 8(1):200-213, 1987.
- 28. Lieberman PL MD. Allergic Reactions to Insulin. <u>New Horizons in Allergy and Pulmonary Medicine</u>. V (2): by invitation, 1987.
- 29. Lieberman P. Rhinitis: Allergic and Nonallergic. <u>Hospital Practice</u>, 23(6):117-145, June 15, 1988.
- 30. Lieberman P. Clinical Conference: When Rhinitis is More than a Common Cold. <u>Respiratory World</u>, 1(11):3, (November) 1988.
- 31. Lieberman P. Anaphylaxis and Anaphylactoid Reactions. <u>The Allergy and Asthma Advance</u>, pp 4-6, Jan/Feb:4-6, 1989.

- 32. Lieberman P. The Use of Antihistamines in the Prevention and Treatment of Anaphylaxis and Anaphylactoid Reactions. Journal of Allergy and Clinical Immunology. 86(4 Pt 2)(S):684-686, 1990.
- 33. Lieberman P. Anaphylactoid Reactions to Radiocontrast Material. <u>Clinical Reviews in Allergy</u>. Vervloet, D (ed.), The Humana Press, Clifton, NJ, 9(3,4):319-338, Fall-Winter, 1991.
- 34. Lieberman P. Difficult Allergic Drug Reactions. <u>Immunology and Allergy Clinics of North America</u>. Kemp (ed.), W. B. Saunders Company 11 (1), pp. 213-231, February 1991.
- 35. Lieberman P. Asthma as an Inflammatory Disease. In: <u>Internal Medicine for the Specialist</u>. 12(6): 18-31, June 1991.
- 36. Lieberman P. Anaphylactoid Reactions to Radiocontrast Material RCM). <u>Annals of Allergy</u>, 67(2) 91-102, 1991.
- 37. Marshall G, and Lieberman P. Allergic Rhinitis. <u>Medicine for the Practicing Physician</u>. 3rd edition, J. Willis Hurst (ed.), Butterworth Heinemann, 1992.
- Lieberman P, and Crawford L. Allergic Diseases of the Eye and Ear. <u>Allergic Diseases Diagnosis and Management</u>, 4th edition. Roy Patterson, Leslie Grammer, Paul Greenberger, and C. R. Zeiss (eds.), p. 275. J. B. Lippincott Company, 1992.
- 39. Lieberman P. Comments on the Untoward Effects of Corticosteroids on the Musculoskeletal System. (editorial) Journal of Asthma, 29 (6), 363-368, 1992.
- 40. Reisman RE, and Lieberman P, editors. Immunology and Allergy Clinics of North America: Anaphylaxis and Anaphylactoid Reactions. W. B. Saunders Company, 12 (3), August 1992.
- Lieberman P. Anaphylactoid Reactions to Radiocontrast Material. In: <u>Immunology and Allergy</u> <u>Clinics of North America</u>: <u>Anaphylaxis and Anaphylactoid Reactions</u>. Reisman RE, and Lieberman P (eds.), W. B. Saunders Company, 12 (3) pp. 649-670, August 1992.
- 42. Lieberman P, and Lemanske R (eds.). Asthma Edition: Abstract-A-Card System. Physicians Postgraduate Press, Inc. 1(1-4), May 1991-May 1992.
- 43. Lieberman P. Using Drugs and Other Measures to Treat Rhinitis. <u>Contemporary Internal Medicine</u>, 47, November-December, 1992.
- 44. Lieberman P. A Restauranteur with a One Year Itch. Clinical Cases . In: <u>Allergic Diseases</u>, Vol. 2, No. 1, p. 5-8, Spring 1993.
- 45. Lieberman P. The Classic Antihistamines: Why Do They Work? <u>Allergies in Otolaryngology</u>, (Cliggott Communications, Greenwich, CT), 1(2):6-9, July 1993.
- 46. Lieberman P. Antihistamine-Induced Sedation: Patients May Not Recognize Impairment. <u>Allergies in</u> <u>Otolaryngology</u>, (Cliggott Communications, Greenwich, CT), 1(3):6-8, October 1993.
- 47. Lieberman P. Two Nonsedating Antihistamines: How Do They Compare? <u>Allergies in</u> Otolaryngology, (Cliggott Communications, Greenwich, CT), (4)7-9, December 1993.
- 48. Lieberman P. Update on Inflammation and Hyperresponsiveness in Asthma. Journal of Respiratory Disease, 15 (supplement 9):S8-S18, September 1994.

- 49. Lieberman P. Preventing Fatalities from Anaphylaxis: An Allergist-Immunologist's Perspective. (Editorial) <u>Allergy Proceedings</u>. Vol 16(3):109-111, (May-June) 1995.
- 50. Lieberman P. Distinguishing Anaphylaxis from Other Serious Disorders. Journal of Respiratory Disease, 16(4):411-420, April 1995.
- 51. Lieberman P. Anaphylaxis: Guidelines for Prevention and Management. Journal of Respiratory Disease 16(5):456-462, May 1995.
- 52. Lieberman P. Allergies in the Garden. <u>Greenthumb</u> 1:16, 1995.
- 53. Lieberman P. Antihistamines. In: <u>Clinical Immunology</u>, Robert R. Rich (ed), pp. 1968-1979, Mosby, 1995.
- 54. Winbery SL, and Lieberman P. Anaphylaxis. In: <u>Immunology and Allergy Clinics of North America</u>, Frank S. Virant, M.D. (ed.), W. B. Saunders Company, 15(3):447-476, August 1995.
- 55. Lieberman P. Office Management of Anaphylaxis and Anaphylactoid Reactions. Bierman, Pearlman, et al, 1996.
- 56. Lieberman P. Specific and Idiopathic Anaphylaxis: Pathophysiology and Treatment. <u>Allergy, Asthma</u> and <u>Immunology from Infancy to Adulthood</u>, 3rd Edition, edited by Bierman W, Pearlman D, Shapiro G and Busse W (W.B.Saunders Company, publishers), Section 4, Chapter 21:297-320, 1996.
- Winbery SL, and Lieberman P. Anaphylaxis and Histamine Antagonists. In: <u>Histamine and H₁</u> <u>Receptor Antagonists in Allergic Disease, Clinical Allergy and Immunology</u>. F. Estelle R. Simons (ed.). Marcel Dekker, Inc., Vol 7:297-327, 1996.
- 58. Lieberman P. Current Practice of Medicine, Editor. <u>Allergy and Immunology</u>, Section VII, Churchill Livingstone Publishers, 1996.
- 59. Lieberman P. Rhinitis. In: <u>Current Practice of Medicine</u>, pp. VII5.2–VII5.10, Churchill Livingstone Publishers (Roger Bone, series editor), 1996.
- 60. Patterson R, and Lieberman P. Idiopathic Anaphylaxis: A Purely Internal Reaction. In: <u>Hospital</u> <u>Practice</u>, Vol. 31, No. 7, pp. 47–66, McGraw Hill Publishers, July 15, 1996.
- 61. Lieberman P. Anaphylaxis and Anaphylactoid Reactions, Current Views, Inc., slide presentation, November 1996.
- 62. Lieberman P and Blaiss MS. Allergic Diseases of the Eye and Ear. In: <u>Allergic Diseases: Diagnosis and</u> <u>Management</u>, 5th edition, Patterson R, Grammer LC, and Greenberger PA, eds., Philadelphia, Lippincott-Raven, pp. 223-251, 1997.
- 63. Lieberman P and Anderson J. (Editors) Allergic Diseases: Diagnosis and Treatment, Humana Press, Inc., Totowa, NJ, 1997.
- 64. Lieberman P. Anaphylaxis. In: <u>Allergic Diseases: Diagnosis and Treatment</u>, pp. 47-64, Humana Press, Inc. publishers, 1997.
- 65. Lieberman P. Rhinitis. In: <u>Allergic Diseases: Diagnosis and Treatment</u>, pp. 131-149, Humana Press, Inc. publishers, 1997.

- 66. **Lieberman P.** Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Asthma and Allergic Disease. In: <u>Allergic Diseases: Diagnosis and Treatment</u>, pp. 315-322, Humana Press, Inc. publishers, 1997.
- 67. Lieberman P. Anticholinergic Agents. In: <u>Allergic Diseases: Diagnosis and Treatment</u>, pp. 323-330, Humana Press, Inc. publishers, 1997.
- 68. Kemp SF and Lieberman P. Inhibitors of Angiotensin II: Potential Hazards for Patients at Risk for Anaphylaxis? In: <u>Annals of Allergy, Asthma and Immunology</u>, Volume 78(6):527-529, June 1997.
- 69. Lieberman P. Anaphylaxis, Medscape Respiratory Care 1(7), 1997. Online journal, edited by C. Warren Bierman, M.D. (<u>http://medscape.com</u>, 1997.
- Carter PM, Heinly TL, Yates SW and Lieberman PL. Asthma: The Irreversible Airways Disease. Journal of Investigative Allergology Clinical Immunology, Vol. 7(6):566-571, November-December 1997.
- 71. Kemp SF, Lieberman P. Inhibitors of Angiotensin II: Potential Hazards for Patients at Risk for Anaphylaxis - Guest Editorial. <u>Annals of Allergy, Asthma and Immunology</u>, Vol. 78(6):527-529, June 1997.
- 72. Winbery SL and Lieberman P. Anaphylaxis and serum sickness. In: <u>Conn's Current Therapy</u> (edited by Robert E. Rakel, W. B. Saunders Company), 741-746, 1997.
- 73. Lieberman P. Anaphylaxis and Anaphylactoid Reactions. In <u>Allergy: Principles and Practice</u>, 5th Edition, edited by Middleton, Ellis, Yunginger, Reed, Adkinson and Busse (Mosby-Year Book, Inc., St. Louis, Missouri), Volume II, Section E, Chapter 77:pp 1079-1092, 1998.
- 74. Lieberman P. Section editor, Allergy & Immunology. <u>Current Practice of Medicine</u>, (published by Current Medicine, Inc, Philadelphia, PA) Volume 1, Number 1, September 1998.
- 75. Lieberman P. Rhinitis. In: <u>Current Practice of Medicine</u>, Allergy & Immunology, section editors Lillington and Lieberman, editor-in-chief Fitzgerald FT, (Current Medicine, Inc) Volume 1, Number 1, Chapter 14, pp 115-124, September 1998.
- 76. Marshall GD and Lieberman P. Anaphylactoid Reactions to Radiocontrast Agents. In: <u>Immunology and</u> <u>Allergy Clinics of North America</u>, Drug Hypersensitivity, guest editor, Stephen Tilles, Vol 18, No. 4:pp. 799-807, November 1998.
- 77. Lieberman P. Anaphylaxis. In: <u>Current Review of Allergic Diseases</u>, edited by Michael Kaliner (Current Medicine, Inc.), Chapter 13:pp. 133-143, 1998.
- 78. **Lieberman P.** Allergy & Immunology. In: <u>Atlas of Internal Medicine</u> (Current Medicine, Inc., Philadelphia), Eugene Braunwald, Editor-in-Chief, Chapter 6, pp. 6.2-7.49, 1998.
- 79. Lieberman P. Contributor: How To Outsmart Your Allergies, published by HealthPOINTS, Feeling Fine Company, 13160 Mindanao Way, Suite 270, Marina del Rey, CA 90292, in collaboration with Asthma and Allergy Foundation of America, (Art Ulene, M.D., lead author), 1998.
- 80. Lieberman P. Contributor, The Diagnosis and Management of Anaphylaxis (parameters of the Joint Task Force). In: Journal of Allergy and Clinical Immunology, June 1998.
- 81. Lieberman P. Management of Allergic Rhinitis with a Combination Antihistamine/Anti-Inflammatory Agent. Journal of Allergy and Clinical Immunology, Volume 103(3 Pt2):S400-404, March 1999.

- 82. Heinly T, Lieberman P, and Blaiss M. Mediastinal Neurilemmoma Masquerading as Asthma: A Case Report. Southeastern Allergy and Immunology Meeting, White Sulfur Springs, November 1998 (presentation).
- 83. Chowdhury B and Lieberman P. Drug Allergens, Haptens and Anaphylatoxins. In: <u>Allergens and Allergen Immunotherapy</u>. <u>Clinical Allergy & Immunology</u> No. 12, 2nd Edition, ed. Richard F. Lockey; Samuel C. Bukantz, series ed. Michael Kaliner (Marcel Dekker, Inc.), Chapter 16, pp 273-296, 1999.
- 84. Lieberman P. Understanding Asthma. University Press of Mississippi, 1999.
- 85. Lieberman P. Consultant: Adkinson NF Jr. Allergy and Immunology. In: Ladenson PW, ed. <u>The</u> <u>Consultation Guide</u>. Baltimore: Lippincott Williams and Wilkins, 1999:1-29.
- 86. Lieberman P. Anaphylaxis: How to Quickly Narrow the Differential Diagnosis, Journal of Respiratory Disease, 1999;20(3):221-231 (Part one of a two-part series).
- Lieberman P. Allergic Disease Research. In: <u>Current Drugs Ltd. Weekly Highlights</u>, Week 10, 1999:18-22.
- 88. Lieberman P. Rhinitis. In: Expert Guide to Allergy and Immunology (American College of Physicians, Philadelphia, P A.), ed. R. G. Slavin and R. E. Reisman, 1999:23-40.
- 89. Lieberman P. Anaphylaxis: Tips on Prevention and Management, Journal of Respiratory Disease, 1999;20(4):309-316 (Part two of a two-part series).
- 90. Lieberman P. American Academy of Asthma, Allergy and Immunology 55th Annual Meeting. In: <u>IDrugs</u>, 1999(2):405-409.
- 91. Lieberman P and Siegle RL. Reactions to Radiocontrast Material. Anaphylactoid Events in Radiology. Humana Press, Inc. publishers, Clinical Reviews in Allergy and Immunology 1999; 17(4):469-496.
- 92. Lieberman P. Section co-editor with Glen A. Lillington, M.D., Current Medicine Inc. Philadelphia, Pennsylvania publishers. <u>Current Practice of Medicine</u>, Volume 2, Number9, September 1999.
- 93. Lieberman P. Rhinitis. In: <u>Current Practice of Medicine</u>, Allergy & Immunology, section editors Lillington and Lieberman, editor-in-chief Antonio M. Gotto Jr., Volume 2, Number 9, Chapter 295, pp 1755-1767, September 1999.
- 94. Lieberman P. Is it a Cold or an Allergy. In: Wellness Guide, 4, 14-21, 1999.
- 95. Heinly TL and Lieberman P. Preparation and Mixing of Aeroallergen Vaccines. In: <u>Immunology and Allergy Clinics of North America Immunotherapy: A Practical Review and Guide</u>, W. B. Saunders Company publishers; edited by Dennis Ledford and Richard Lockey (guest editors), 20:(3):527-532, August 2000.
- 96. Heinly TL and Lieberman P. Anaphylaxis in Pregnancy. <u>Immunology and Allergy Clinics of North</u> <u>America</u>, Volume 20 (4), 831-838, 2000.
- 97. Winbery SL and Lieberman P. Anaphylaxis and Histamine Antagonists, accepted for publication in <u>Histamine and H1 Receptor Antagonists in Allergic Disease</u>; edited by Simons FER - Clinical Allergy and Immunology Series, published by Marcel Dekker, Inc., New York - 11:297-327, 2000.

- 98. Marshall GD and Lieberman PL. Determining Allergic Versus Non-Allergic Drug Reactions. In: <u>Diagnostic Testing of Allergic Diseases</u>; edited by Kemp SF and Lockey RF, published by Marcel Dekker, Inc., New York, Clin Allergy Immunol, Volume 15:217-232, 2000.
- 99. Pongdee T, Blaiss MS, and Lieberman P. Peak Flow Measurements of Nasal Airway Resistance (presented at the American College of Allergy, Asthma, and Immunology meeting, November 1999. Abstract). Annals of Allergy, Asthma, and Immunology.
- 100. Settipane R and Lieberman P. Update on Non-allergic Rhinitis. Resident and Staff Physician, 2000.
- 101. Lieberman P. Review of AAAAI New Drug Presentations. In: <u>Current Opinion in Anti-Inflammatory</u> and immunomodulatory Investigational Drugs, editors William Hagmann and Roger McMillan (issue editors David Howat and Mariano Elices), Volume 2, pp.153-159, 2000.
- 102. Lieberman P. A Pathophysiologic Link Between Allergic Rhinitis and Asthma. In: <u>Pediatric Annals</u>, edited by Ricardo Z. Vinuya, Volume 29, Number 7, pp. 405-410, 2000.
- 103. Lieberman P. Antihistamines. American Academy of Asthma, Allergy and Immunology 56th Annual Meeting, Anti-Inflammatory Drugs. In: <u>IDrugs</u> 3(6):615-620, 2000.
- 104. Lieberman P. Antihistamines. In: <u>Allergic Diseases: Diagnosis and Treatment</u>, 2nd edition, Phil Lieberman and John Anderson editors, Humana Press, Totowa, NJ, pp. 323-335, 2000.
- 105. Lieberman P and Anderson J. (Editors) <u>Allergic Diseases: Diagnosis and Treatment</u>, Humana Press, Inc., Totowa, NJ, 2nd edition, 2000.
- 106. Lieberman P. Comments on Sinusitis. In: Medical Crossfire, 2(8):21-22, 2000.
- 107. Lieberman P. The Quest to Define Asthma. In: Coping, pp. 2-3, May-June 2000.
- 108. Lieberman P. Airway Remodeling and Inflammation. <u>Allergy and Clinical Immunology</u> (publishers Hogrefe and Huber) 65:67 Supplement No. 1, 2000.
- 109. Graham M, McPherson H and Lieberman P. Skin Testing in the Evaluation of Hymenoptera and Drug Allergy. In: Immunology and Allergy Clinics of North America, 21:301-320, 2001.
- 110. Lieberman P. Relationship Between Upper Airway Disease and Asthma. In: <u>Resident and Staff</u> Physician, Volume 47, Number 3, page 1-4, March 2001.
- 111. Lieberman P, Calhoun W, Panettieri R, Peters S, and Rennard S. Asthma and Irreversible Lung Disease, Remodeling - Fact or Fiction? <u>Medical Crossfire</u>, 3(3):31-43, 2001.
- 112. Lieberman P. New Drugs. <u>Current Drugs Ltd</u>, pages 46-48, April 2001.
- 113. Lieberman P. Rhinitis. In: <u>Best Practice of Medicine</u>, Internet (<u>http://praxis.md</u>), New York, Praxis Press, May 2001.
- 114. Lieberman P. Editor Allergy and Immunology Section. In: <u>Best Practice of Medicine</u>, Internet (http://praxis.md), New York, Praxis Press, May 2001.
- 115. Settipane RA, Lieberman P. Update on Nonallergic Rhinitis. <u>Annals of Allergy, Asthma and</u> Immunology, Volume 86(5):494-507; quiz 507-508, May 2001.

- 116. Lieberman P. Antihistamines. In: <u>Clinical Immunology Principles and Practice</u>, 2nd edition, edited by Robert R. Rich, publishers Mosby, Harcourt-International USA, Canada, Australia, pages 109.1-109.11, June 2001.
- 117. Lieberman P. Oligodeoxynucleotides. In: IDrugs 4(6):636-638, June 2001.
- 118. Lieberman P. Novel Drugs. In: <u>IDrugs</u> 4(6):639-642, June 2001.
- 119. Lieberman P: Treatment Update: Non-Allergic Rhinitis. <u>Allergy and Asthma Proceedings</u>, 22:199-204, 2001.
- 120. Lieberman P. Non-Allergic Rhinitis. In: <u>Conn's Current Therapy</u> (edited by Robert E. Rakel and Edward Bope), Published by W. B. Saunders Company (Harcourt Health Sciences), Independence Square West, Philadelphia, Pennsylvania, pp. 235-238, 2002.
- 121. Lieberman P. The Year in Allergy. In: Praxis Post, New York, Praxis Press, 2001.
- 122. Lieberman P and Stuart Stoloff. Clinician's Manual on Rhinitis: Both Allergic and Non-Allergic. Science Press Ltd., 34-42 Cleveland Street, London, W1T 4LB, U.K, 2001.
- 123. Lieberman P, Yates S, and Welk K. Pulmonary Remodeling in Asthma. In: <u>The Journal of</u> <u>Investigational Allergology and Clinical Immunology</u>, 11(4):220-234, 2001.
- 124. Bochner B, Bratton D, Corren J, Ferguson B, Lemanske R, Lieberman P, Rosenthal M, Shapiro G, Storms W (in alphabetical order). Asthma and Allergic Rhinitis: Connecting Common Pathways and Treatment. Internal Medicine, 23:1-24, 2001.
- 125. Lieberman P. Unique Clinical Presentations of Anaphylaxis. In: <u>Immunology and Allergy Clinics of</u> North America (edited by Stephen Kemp, M.D.), 21(4):813-827, 2001.
- 126. Lieberman P. Correlating Rhinitis with its Treatment. In: <u>Current Reviews of Rhinitis</u> (Current Medicine, Inc. publishers), edition one, 145-154, 2001.
- 127. Kaliner M and Lieberman P. Examination of the Nasal Cavity. In: <u>Current Reviews of Rhinitis</u> (Current Medicine, Inc. publishers), edition one, 7-12, 2001.
- 128. Lieberman P, and Blaiss MS. Co-editor, Atlas of Allergic Diseases. Current Medicine, Inc., 400 Market Street, Suite 700, Philadelphia, Pennsylvania, 2002.
- 129. Lieberman P. Immunoglobulin Structure and Function. In: <u>Atlas of Allergic Diseases</u> (Current Medicine, Inc. publishers), 2:13-16, 2002.
- 130. Rakel RE, Lieberman P, and Hedges H. New Tools for Diagnosing Rhinitis. In: Family Practice Recertification (Supplement), 24(2):1-12, 2002.
- 131. Heinly T and Lieberman P. Asthma. In: <u>Best Practice of Medicine</u>, Internet (<u>http://praxis.md</u>), New York, Praxis Press, 2002.
- 132. Heinly T and Lieberman P. Differential Diagnosis of Asthma. In: <u>Asthma</u>, Raymond G. Slavin and Robert E. Reisman, editors (American College of Physicians, Philadelphia), 3:39-50, 2002.

- 133. Lieberman P and Blaiss MS. Allergic Diseases of the Eye and Ear. In: Patterson's <u>Allergic Diseases</u>, 6th Edition, Leslie C. Grammar and Paul A. Greenberger, editors (Lippincott Williams & Wilkins, Philadelphia, PA), Chapter 11:195-223, 2002.
- 134. Lieberman P. Asthma and Allergic Rhinitis Connection. In: <u>The Link</u>, Issue 1, May 2002 (magazine).
- 135. Lieberman P, Calhoun W, Panettieri R, Peters S, and Rennard S. Airway Remodeling in Asthma. In: Medical Crossfire, Volume 4, May 15, 2002.
- 136. Winbery SL and Lieberman P. Histamine and Antihistamines in Anaphylaxis. In: <u>Anaphylaxis</u>, edited by Simons FER published by Marcel Dekker, Inc., New York 9:287-317, 2002.
- 137. Lieberman P. Allergy & Immunology. In: <u>Atlas of Internal Medicine</u>, Second Edition (Current Medicine, Inc., Philadelphia), Eugene Braunwald, Editor-in-Chief, Chapter 6:253-277, 2002.
- 138. Lieberman P. Anaphylactic Reactions During Surgical and Medical Procedures. In: <u>The Journal of</u> <u>Allergy and Clinical Immunology</u> (Natural Rubber Latex Sensitivity), Volume 110:S64-S69, 2002.
- 139. Lieberman P. Preclinical Evidence of Azelastine Hydrochloride Activity. In: <u>Current Therapeutic</u> <u>Research</u>, 63(9):556-571, 2002.
- 140. Lieberman P. Evaluation and Management of the Patient with a History of a Previous Episode of Anaphylaxis. Allergy and Clinical Immunology (2002).
- 141. Lieberman P. Chronic Non-allergic Rhinitis. In: <u>Allergy and Clinical Immunology International</u>, Volume 14, pages 266-273, 2002.
- 142. Lieberman P. Anaphylaxis and Anaphylactoid Reactions. In: <u>Allergy: Principles and Practice</u>, 6th Edition, edited by Middleton, Adkinson, Yunginger, Busse, Bachner, Holgate, and Simons (Mosby-Year Book, Inc., St. Louis, Missouri), Volume II, pp 1497-1522, 2003.
- 143. Lieberman P and Settipane RA. Azelastine Nasal Spray: A Review of Pharmacology and Clinical Efficacy in Allergic and Nonallergic Rhinitis. In: <u>Allergy and Asthma Proceedings</u>, 24:95-105, 2003.
- 144. Lieberman P. Is There an Epidemic of Asthma in the African-American Population of the U.S.? In: <u>Physician's Q&A</u>, Midsouth Edition, pp. 50-51, 2003 (January/February).
- 145. Lieberman P. Chronic Nonallergic Rhinitis. Submitted for publication to UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2003.
- 146. Lieberman P. Non-Allergic Rhinitis. In: <u>Conn's Current Therapy</u> (edited by Robert E. Rakel and Edward Bope), Published by Saunders, The Curtis Center (Elsevier Science), Independence Square West, Philadelphia, Pennsylvania, pp. 204-207, 2003.
- 147. Lew DB and Lieberman P. Lung Remodeling in Asthma. In: <u>Allergy and Clinical Immunology</u> International, Volume 15, pp. 4-10, 2003.
- 148. Lieberman P. Use of Epinephrine in the Treatment of Anaphylaxis. In: <u>Current Opinion in Allergy and</u> Clinical Immunology, 3:313-318, 2003.

- 149. Hernandez-Trujillo VP, Lieberman PL, and Chowdhury BA. Drug Allergens, Haptens, and Anaphylotoxins. In: <u>Allergens and Allergen Immunotherapy</u>, 3rd edition, edited by Richard Lockey, Stan Bukantz, and Jean Bousquet. Part of Clinical Allergy and Immunotherapy Series, Executive Director, Michael Kaliner. Publisher Marcel Dekker, pp. 387-419, 2004.
- 150. Lieberman P. Clinician's Manual on Anaphylaxis (published by Current Medicine), 2003.
- 151. Lieberman P. Contributor Understanding Anaphylaxis: Defining, Identifying and Treating Severe Allergic Reactions. In: <u>Infectious Diseases in Children</u>, CME sponsored activity (supplement), April 2004.
- 152. Lieberman P. Biphasic Anaphylaxis. In: <u>Allergy and Clinical Immunology International</u>, Journal of the World Allergy Organization, Volume 16(6), pp 241-248, November/December 2004.
- 153. Lieberman P, Kemp S, Oppenheimer J, Lang D, Bernstein I, and Nicklas RA. The Diagnosis and Management of Anaphylaxis: An Updated Practice Parameter, sponsored by The Joint Task Force on Practice Parameters representing the American Academy of Allergy, Asthma, and Immunology, the American College of Allergy, Asthma, and Immunology, and the Joint Council of Allergy, Asthma, and Immunology. Journal of Allergy, Asthma, and Immunology 2005; 115(3):S483-S523.
- 154. Sampson HA, Munoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA, Decker WW, Furlong TJ, Galli SJ, Golden DB, Gruchalla RS, Harlor AD, Hepner DL, Howarth M, Kaplan AP, Levy JH, Lewis LM, Lieberman PL, Metcalfe DD, Murphy R, Pollart SM, Pumphrey RS, Rosenwasser LJ, Simons FE, Wood JP, and Camargo CA Jr. Symposium on the Definition and Management of Anaphylaxis: Summary Report. Journal of Allergy and Clinical Immunology, 115(3):584-592, March 2005.
- 155. Lieberman P, Belleau J. Anaphylaxis and Anaphylactoid Reactions. In: <u>Practical Allergy</u>, edited by Etan Milgrom, Richard P. Usatine, Ricardo Tan, and Sheldon Spector. Publisher Mosby, 2004; pp 97-109.
- 154. Lieberman P. Biphasic Anaphylactic Reactions. <u>Annals of Allergy, Asthma, and Immunology</u> 2005; 95:217-228.
- 155. Lieberman P, Kemp S, Oppenheimer J, Lang D, Bernstein IL, and Nicklas RA. Beta-blockers and anaphylaxis: are the risks overstated? Journal of Allergy and Clinical Immunology 2005; 116:931-935.
- 156. Lieberman P. Anaphylaxis. In: <u>Medical Clinics of North America</u>, (guest editor Anthony Montanaro). Publisher Elsevier, Saunders, January 2006; Volume 90, Number 1, pages 77-95.
- 157. Dey JH, Horak F, Briscoe M, Canonica G, Fineman S, Krug N, Leynadier F, Lieberman P, Quirce S, Takenak H, and Van Cauwenberge P. The Role of Allergen Challenge Chambers in the Evaluation of Anti-Allergic Medication: An International Consensus Paper. <u>Clinical and Experimental Allergy</u> <u>Reviews</u> 2006; 6:31-59.
- 158. Waikart L and Lieberman P. Non-Allergic Rhinitis. In: <u>Conn's Current Therapy</u>, edited by Rakel and Bope, publisher Saunders (Elsevier), John Kennedy Boulevard, Philadelphia, PA, 2006; pages 258-263.

- 159. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudy J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman P, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, and Decker WW. Second Symposium on the Definition and Management of Anaphylaxis: Summary Report Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. Journal of Allergy and Clinical Immunology, Volume 117(2), page 391-397, February 2006; and Ann Emerg 47(4):373-380, April 2006.
- Lieberman P, Kaliner M, Lockey R, and Simons FER. Anaphylaxis and the American Academy of Allergy, Asthma, and Immunology. <u>Journal of Allergy and Clinical Immunology</u>, Volume 117(2), page 478-482, February 2006.
- 161. Lieberman P. Translating Science to Community Action. In: <u>Annals of Allergy, Asthma, and</u> Immunology, 96(3):381-382, March 2006.
- 162. Leonard Bieolory, Michael Blaiss, Stanley Fineman, Dennis Ledford, Phil Lieberman, Estelle Simons, David Skoner, and William Storms. "Concerns about intranasal corticosteroids for over-the-counter use: Position Statement of the Joint Task Force of the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology." <u>Annals of Allergy</u>, <u>Asthma, and Immunology</u>, 2006; 96(4):514-525.
- 163. Lieberman PL, Camargo C, Simons FER, Jick H, Sheikh A, Bohlke K, and Miller R. Epidemiology of Anaphylaxis: Findings of the ACAAI Epidemiology of Anaphylaxis Working Group. In: <u>Annals of Allergy, Asthma, and Immunology</u>, November 2006, pp 596-602.
- 164. Lieberman PL. Chronic Nonallergic Rhinitis. In: <u>UpToDate</u>, Rose, BD (Ed), UpToDate, Waltham, MA 2006.
- 165. Waikart L, Kaliner M and Lieberman P. Examination of the Nasal Cavity. In: <u>Current Reviews of</u> <u>Rhinitis</u>, Kaliner, M (ed.) (Current Medicine, Inc., PA publishers), second edition, pp 9-14, 2006.
- 166. Waikart L and Lieberman P. Appropriate Treatment Choices in the Management of the Symptoms of Rhinitis. In: <u>Current Reviews of Rhinitis</u>, Kaliner, M (ed.) (Current Medicine, Inc., PA publishers), second edition, pp 149-160, 2006.
- 167. Lieberman P. Allergen Immunology. In: <u>Atlas of Internal Medicine</u>, Eugene Braunwald (ed) (Current Science Ltd., publisher), third edition, pp 255-279, 2007.
- 168. Varghese M and Lieberman P. The Effects of Repeat Omalizumab Administration on Skin Test Positivity and the Assessment of the Safety of Administration in Patients with Positive Skin Tests for Mouse Antigen. <u>Allergy and Asthma Proceedings</u>, 28(3):320-323, May-June 2007.
- 169. Lieberman P. Biphasic Anaphylaxis. In: UpToDate, Rose BD (ed), UpToDate, Waltham, MA, 2006.
- 170. Lieberman P. Chronic Nonallergic Rhinitis. In: <u>UpToDate</u>, Rose BD (ed), UpToDate, Waltham, MA, 2007.

- 171. Lieberman P. Editor. Anaphylaxis. In: <u>Immunology and Allergy Clinics of North America</u>, Volume 27, No. 2, May 2007. Published by Saunders, an imprint of Elsevier, Inc.
- 172. Tole J, Lieberman P. Biphasic Anaphylaxis: Review of Incidence, Clinical Predictors, and Observation Recommendations. In: <u>Immunology and Allergy Clinics of North America</u>, Volume 27, No. 2, May 2007, pp 309-326. Published by Saunders, an imprint of Elsevier, Inc.
- 173. Mitchell G, Hernandez-Trujillo V, and Lieberman P. Allergy. In: <u>Textbook of Family Medicine</u>, edited by Robert Rakel, 7th edition. Published by Saunders, Elsevier 2007, pp 463-477.
- 174. Lieberman P, Decker W, Camargo CA, O'Connor R, Oppenheimer J, and Simons FER. SAFE. A Multi-Disciplinary Approach to Anaphylaxis Education in the Emergency Department. <u>Annals of</u> <u>Allergy, Asthma, and Immunology</u> 2007; 98(6):519-523.
- 175. Lieberman P. The Unusual Suspects: A Surprise Regarding Reactions to Omalizumab. <u>Allergy and</u> <u>Asthma Proceedings</u>, 28(3):259-261, May-June 2007.
- 176. Beaty AD, Lieberman PL, and Slavin RG. Seafood Allergy and Risk of Adverse Reactions to Radiocontrast Media: Are Physicians Unwittingly Propagating a Medical Myth? (<u>The American Journal</u> of Medicine, August 2007).
- 177. Lehman J and Lieberman P. Office Based Management of Allergic Rhinitis in Adults. <u>The American</u> Journal of Medicine, August 2007, 120:659-663.
- 178. Lieberman P and Anderson J. <u>Allergic Diseases: Diagnosis and Treatment</u>, Third Edition. Humana Press, Totowa, New Jersey, 2007.
- 179. Hernandez-Trujillo V and Lieberman P. Antihistamines. In: <u>Allergic Diseases: Diagnosis and</u> <u>Treatment</u>, 3rd edition. Phil Lieberman and John Anderson, editors. Humana Press, Totowa, New Jersey, 2007; pages 319-335.
- 180. Hernandez-Trujillo V, Lieberman J, and Lieberman P. Antihistamines. In: <u>Clinical Immunology</u> <u>Principles and Practice</u>, 3rd edition, edited by Robert R. Rich, publishers Mosby, Harcourt-International USA, Canada, Australia (in press; due late 2007 or early 2008).
- 181. Lieberman P. Nonallergic Rhinitis. In: <u>UpToDate</u>, Rose, BD (Ed), UpToDate, Waltham, MA. Accepted for publication 2008.
- 182. Lieberman P. Measuring Asthma Control: Sputum Eosinophils, Nitric Oxide, and Other Inflammatory Markers. <u>Allergy and Asthma Proceedings</u>, Volume 28, Number 5, page 510-513, 2007.
- 183. Lieberman P. (date posted pending 2007) Allergic Remodeling [online]. World Allergy Organization, Allergic Diseases Resource Center. Available from: <u>http://www.worldallergy.org/adrc/</u>.
- 184. Lieberman P. Automatic epinephrine injectors: a change in perspective from the pulmonologists' standpoint? In: <u>Pulmonary Perspectives, Chest Physician</u>, page 11, December 2007, volume 2, number 12.
- 185. Mitchell G, Hernandez-Trujillo V, and Lieberman P. Allergy. In: <u>Textbook of Family Medicine</u>, 2007. Published by Saunders. Editor Rakel, 7th Edition, pages 463-476.

- 186. Lieberman P. Co-editor (with H. James Wedner), Anaphylaxis and Drug Allergy Section of <u>Current</u> <u>Allergy and Asthma Reports</u>, Volume 8 (1), March 2008, Volume 1, pages 35-63. Published by Current Science.
- 187. Lieberman P. Clinical Trials Report, Hereditary Angioedema. Anaphylaxis and Drug Allergy Section of <u>Current Allergy and Asthma Reports</u>, Volume 8 (1), March 2008, Volume 1, pages 35-37.
- 188. Lieberman P. Co-editor, with Dr. James Wedner. Anaphylaxis and Drug Allergy Section. <u>Current</u> Allergy and Asthma Reports 2008; Volume 8 (1), pages 35-63.
- 189. Lieberman P. Clinical Trial Reports: Treatment of Hereditary Angioedema. <u>Current Allergy and</u> <u>Asthma Reports</u> 2008; Volume 8(1), page 35-36.
- 190. Lieberman P, Hernandez-Trujillo V, Lieberman J, and Frew A. Antihistamines. In: <u>Clinical</u> <u>Immunology Principles and Practice</u>, Third Edition; editors, Robert R. Rich, et al.; publisher, Mosby (Elsevier); pages 1317-1330, 2008.
- 191. Lieberman P. Epidemiology of anaphylaxis. <u>Current Opinion in Allergy Clinical Immunology</u> 2008; 8(4):316-320.
- 192. Khan BQ and Lieberman P. Anaphylaxis in the elderly. In: <u>Aging Health</u>, Volume 4, Number 4, August 2008, pages 377-387.
- 193. Lieberman P. Section editor on Anaphylaxis. Current Allergy and Asthma Reports 2008.
- 194. Lieberman P. Anaphylaxis. In Middleton's Allergy: Principles and Practice, 7th Edition, edited by Atkinson F, Bochner B, Busse W, Holgate S, Lemanske R, and Simons FER (Publisher Mosby, an affiliate of Elsevier, Inc.), 2009; 1027-1051.
- 195. Lieberman P: Is This a Death Knell for Anti-Interleukin-5 Therapy in Asthma? In: <u>Current Allergy and</u> <u>Asthma Reports</u> 2009; 9(1):41-42.
- 196. Lieberman P. Allergy Immunology. <u>Atlas of Internal Medicine</u>, 3rd edition, edited by Eugene Braunwald, published by Current Medicine LLC, 2009; pages 255-274.
- 197. Lieberman P. A case for switching to HFA-BDT: a review of patients with poorly controlled symptoms. In: <u>Reviews and Trends in Respiratory Medicine</u> 2009; Volume 1, Number 4; pages 4-9.
- 198. Lieberman P. The peripheral eosinophil count. World Allergy Organization Journal, online publication, Volume 6, Issue 6, June 3, 2009 (<u>http://www.worldallergy.org/clinical_allergy_tips/tips_lieberman.pdf</u>).
- 199. Lieberman P. Intranasal antihistamines for allergic rhinitis: mechanisms of action. <u>Allergy and Asthma</u> <u>Proceedings</u>, accepted for publication June 7, 2009 (in press).
- 200. Kaliner M, Baraniuk J, Benninger M, Bernstein J, Lieberman P, Meltzer O, Neclario R, Settipane R. Consensus definition of nonallergic rhinopathy. <u>World Allergy Organization Journal</u>, online publication, Volume 6, Issue 6, 2009.

- 201. Jacobs R, Lieberman P, Kent E, Silvey M, Locantore N, and Philpot, EE. Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment. <u>Allergy Asthma Proceedings</u> 2009; 30:120-127.
- Simons FER, Lieberman P, Read EJ, and Edwards ES. Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. <u>Annals of Allergy, Asthma, and Immunology</u> 2009; 102:282-287.
- 203. Lieberman P. Clinical aspects and diagnosis of anaphylaxis. In: <u>Allergy Frontiers: Diagnostics and Health Economics</u>, 2009; Volume 4, Pages 319-335. Published by Springer, edited by Pawankar R, Rosenwasser L, and Holgate S.
- 204. Lieberman P. Intranasal antihistamines for allergic rhinitis: mechanism of action. <u>Allergy and Asthma</u> <u>Proceedings</u> 2009; 30(4):345-348.
- 205. Lieberman P. The role of antihistamines in the treatment of vasomotor rhinitis. World Allergy Organization Journal 2009 (August); 2(8):156-161.
- 206. Lieberman P. Histamine, antihistamines, and the central nervous system. <u>Allergy and Asthma</u> <u>Proceedings</u>, September-October, 2009; 30(5):482-486.
- 207. Lieberman P, Kemp S, Oppenheimer J, Lang D, Bernstein I, and Nicklas RA. The Diagnosis and Management of Anaphylaxis: An Updated Practice Parameter, sponsored by The Joint Task Force on Practice Parameters representing the American Academy of Allergy, Asthma, and Immunology, the American College of Allergy, Asthma, and Immunology, and the Joint Council of Allergy, Asthma, and Immunology. Submitted for publication, Journal of Allergy, Asthma, and Immunology 2009.
- 208. Cho S, Blaiss M, and Lieberman P. Allergic Diseases of the Eye and Ear. In: Patterson's <u>Allergic Diseases</u>, 7th Edition, Leslie C. Grammar and Paul A. Greenberger, editors (Lippincott Williams & Wilkins, Philadelphia, PA), 2009.
- 209. Lieberman P. Management of anaphylaxis. <u>Allergy Frontiers: Therapy and Prevention</u>, 2010; Volume 5 (edited by Pawankar, Holgate, and Rosenwasser; published by Springer), pages 311-325.
- Simons FER, Lieberman P, Reid E, and Edwards E. Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. <u>Annals of Allergy, Asthma and Immunology</u> 2009; 102:282-287.
- 211. Daher N and Lieberman P. Immunosuppression medication as an approach to treat chronic idiopathic urticaria in children. <u>Current Allergy and Asthma Reports</u> 2010 (January); Volume 10, Number 7; published online prior to print, DOI:10.1007/S11882-009-0084-4 (two pages).
- 212. Daher N and Lieberman P. Immunosuppression medication as an approach to treat chronic idiopathic urticaria in children: a clinical trial report. <u>Current Allergy and Asthma Reports</u> 2010; Volume 10, Number 1; pages 1-2.
- 213. Lieberman P, Mahr T, Ratner P, Pattanaik D. Advances in the treatment of adults and young children with allergic rhinitis. Medscape CME, <u>Allergy and Clinical Immunology</u>, published online 2/8/2010.
- 214. Pattanaik D and Lieberman P. Vasomotor Rhinitis. <u>Current Allergy and Asthma Reports</u> 2010; 10(2):84-91.

- 215. Lieberman P. The role of intranasal antihistamines in the treatment of allergic rhinitis: the basics of histamine biology. <u>Annals of Allergy, Asthma, and Immunology</u> 2011 (February); 106(2):S2-S5 (Supplement).
- 216. Lieberman P, Nicklas R, Oppenheimer J, Kemp S, Lang D, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 Update. In: Journal of Allergy and Clinical Immunology 2010 (September); 126(3):477-480 e42.
- 217. Lieberman P. Pulmonary remodeling in asthma. F1000 Medicine Reports, 2010, 2:74.
- 218. Asteitie R, Jones N, Toskala A, Crews A, Powe D, Neclario D, Shusterman P, Lieberman P, Viraniauk J, Mullol J, Baroody F, Wagenmann M, White M, Scaddin G, Settipane R, Fokkens W, Pawnkr R, Togias A. Nonallergic rhinitis identifying gaps in therapy (abstract). Accepted for presentation, <u>American</u> <u>Academy of Allergy, Asthma, and Immunology</u> 2010.
- 219. Lieberman P. Definition and criteria for the diagnosis of anaphylaxis. In: <u>Anaphylaxis and</u> <u>Hypersensitivity Reactions</u>, Humana Press, publisher (editor, Mariana Casales), 2010; pages 1-12.
- 220. Lieberman P (an NIAID-sponsored expert panel author; one among 19). Guidelines for the diagnosis and management of food allergy in the United States. Report of the NIAID-sponsored expert panel. Journal of Allergy and Clinical Immunology December 2010; 126(6) (supplement).
- 221. Lieberman P. Chronic nonallergic rhinitis. <u>UpToDate</u>, edited by Denise S. Basow, published by UpToDate, Waltham, MA, 2011.
- 222. Lockey RF, Kemp S, Simons FER, Lieberman P, and Sheik HA. Anaphylaxis. In: <u>World Allergy</u> Organization White Book on Allergy, edited by R Pawanker, S Holgate, G Canonica, and R Lockey, published online at http://www.worldallergy.org/publications/, March 13, 2011, Pages 43-47.
- 223. Lieberman P. International Guidelines Anaphylaxis, published by the International Guidelines Center, 5740 Executive Drive, Baltimore, MD, 2011.
- 224. Cox L, Lieberman P, Wallace D, Simons E, Finegold I, Platts-Mills T, Schwartz L. American Academy of Allergy, Asthma, and Immunology/American College of Allergy, Asthma, and Immunology, omalizumab-associated anaphylaxis: Joint Task Force follow-up report. Journal of Allergy and Clinical Immunology, published online May 2, 2011.
- 225. Cox L, Lieberman P, Wallace D, Simons FER, et al. American Academy of Allergy, Asthma, and Immunology/American College of Allergy, Asthma, and Immunology Omalizumab-Associated Anaphylaxis Joint Task Force Follow-up Report. J Allergy Clin Immunol 2011; 128(1):210-212.
- 226. Hernandez V, Mitchell G, Lieberman P. Allergy. In: <u>Textbook of Family Medicine</u>, 8th edition (edited by Robert Rakel and David Rakel; published by Elsevier) 2011; 343-359.

- Lieberman P, Ricks J, Chakrin L, Wardell JR Jr, and Patterson R. Immunoglobulins in Respiratory Secretions Obtained From the Canine Tracheal Pouch. Proc. Soc. Exptl. Biol. Med. 135(3):713-716, 1970.
- 2. Lieberman P, Patterson R, Metz R, and Ucena G. Allergic Reactions to Insulin. JAMA 215(7):1106-1112, 1971.
- 3. Lieberman P, Patterson R, Petersen V, Chakrin L, Wardell JR, and Ricks J. Effect of Antigen Variation on Production of Antibody in Canine Tracheal Pouch. Journal of Immunology, 107(5):1349-1356, 1971.
- 4. Lieberman P, Patterson R, and Kunske R. Complications of Long-Term Steroid Therapy for Asthma. Journal of Allergy and Clinical Immunology, 49(6):329-336, 1972.
- 5. Lieberman P, Berlin B, Metzger J, and Patterson R. Production of Antibody in the Canine Tracheal Pouch after Local and Systemic Influenza Immunization. Journal of Immunology, 109(4):864-869, 1972.
- 6. Harwell W, Patterson J, Lieberman P, and Beachey E. Platelet Aggregation in Atopic and Normal Subjects. Journal of Allergy and Clinical Immunology, 51:274, 1973.
- Shereff R, Harwell W, Lieberman P, Rosenberg W, and Robinson H. Effect of Beta Adrenergic Stimulation and Blockade on Immediate Hypersensitivity Skin Test Reactions. Journal of Allergy and Clinical Immunology, 52(6):328-333, 1973.
- Lieberman P, Crawford L, Bjelland J, Connell B, and Rice M. Controlled Study of the Cytotoxic Food Test. JAMA, 231(7):728-730, 1975.
- 9. Kitabchi AE, Lamkin N Jr, Lieberman P, Ayyagari V, and Baskin F. Allergic Response to Glucagon Injection ass a Result of Insulin Contamination. Journal of Clinical Endocrinology and Metabolism, 41:863, 1975.
- 10. Stimpson PG, Paty JG, Hudson T, and Lieberman P. Delayed Hypersensitivity Skin Testing for Assessing Anergy in the Mid-South. Southern Medical Journal, 69(4):424-426, 1976.
- 11. Siegle RL, and Lieberman P. Measurement of Histamine, Complement, and Immune Complexes During Patient Reactions to Iodinated Contrast Material. Investigative Radiology, 11(2):98-101, 1976.
- 12. Hashimoto K, Lieberman P, and Lamkin N Jr. Angiokeratoma Corporis Diffusum. Archives of Dermatology. 112:1416, 1976.
- Lamkin N Jr, Lieberman P, Shereff R, Rosenberg EW, and Robinson H. Effect of Beta Adrenergic Stimulation and Blockade on Cutaneous Reactivity to Histamine. Journal of Allergy and Clinical Immunology, 57(5):449-453, 1976.
- 14. Thomas JW, Jenkins G, Cox C, and Lieberman P. Defective Cell Mediated Immunity in Carcinoma of the Prostate. Investigative Urology, 14:72, 1976.
- Lamkin Nelson, Lieberman Phil, Hashimoto Ken, Morohashi Masaaki, and Sullivan Pete. Clinical Conference: Allergic Reactions to Insulin. Journal of Allergy and Clinical Immunology, 58(1 Pt 2):213-223, 1976.

- 16. Lieberman Phil, Siegle Robert L, Kaplan Robert J, and Hashimoto Ken. Chronic Urticaria and Intermittent Anaphylaxis: Reactions to Iophendylate. JAMA, 236(13):1495-1497, 1976.
- 17. Lieberman PL, Rice MC, and Mallette JE Jr. Studies of Urticaria and Acute Serum Sickness with the Clq Precipitin Test. Archives of Internal Medicine, 137(4):440-442, 1977.
- 18. Ganier LM, and Lieberman PL. Infantile Agammaglobulinemia and Immediate Hypersensitivity to Penicillin. JAMA, 237:1852-1853, 1977.
- 19. Ganier LM, Lieberman PL, and George SL. Comparison of Results of Skin Testing with Stock Antigen Mixtures versus Individual Antigens. Submitted for publication, 1977.
- 20. Daman Lauren, Lieberman Phil, Ganier Mitchell, and Hashimoto Ken. Localized Heat Urticaria. Journal of Allergy and Clinical Immunology, 61(4):273-278, 1978.
- 21. Siegle Robert L, and Lieberman Phil. The *In Vitro* White Cell Response of Atopics to Iodinated Contrast Material. Submitted for publication, 1978.
- 22. Siegle Robert L, and Lieberman Phil. A Review of Untoward Reactions to Iodinated Contrast Material. Journal of Urology, 119(5):581-587, 1978.
- 23. Lieberman Phil, Siegle Robert L, and Taylor WW Jr. Anaphylactoid Reactions to Iodinated Contrast Material. Journal of Allergy and Clinical Immunology, 62(3):174-180, 1978.
- Kelly Joseph, Patterson Roy, Lieberman Phillip, Mathison David A, and Stevenson Donald D. Radiographic Contrast Media Studies in High-Risk Patients. Journal of Allergy and Clinical Immunology, 62(3):181-184, 1978.
- 25. Lieberman Phil, and Siegle Robert L. Complement Activation Following Intravenous Contrast Material Administration. Journal of Allergy and Clinical Immunology, 64(1):13-17, 1979.
- 26. Ganier Mitchell, and Lieberman Phil. IgE Mediated Hypersensitivity to Pancreatic Extract (PE) in Parents of Cystic Fibrosis (CF) Children. Clinical Allergy, 9:125-132, 1979.
- 27. Lieberman P, and Taylor WW Jr. Recurrent Idiopathic Anaphylaxis. Archives of Internal Medicine, 139(9):1032-1034, 1979.
- Greenberger Paul, Patterson Roy, Kelly Joseph, Stevenson Donald, Simon Ronald and Lieberman Phil. Administration of Radiographic Contrast Media in High Risk Patients. Investigative Radiology, 15(6 Suppl):S40-S43, 1980.
- 29. Ganier Mitchell, Lieberman Phil, Fink Jordan, and Lockwood Dudley G. Humidifier Lung: An Outbreak in Office Workers. Chest, 77(2):183-187, 1980.
- Meyer Marvin C, Straughn AB, and Lieberman P. A Multiple-Dose Study of Sustained-Release Theophylline and Aminophylline. Chest, 78(2):300-303, 1980.
- Siegle Robert L, Lieberman Phil, Jennings Billy R, and Rice Muriel C. Iodinated Contrast Material: Studies Relating to Complement Activation, Atopy, Cellular Association, and Antigenicity. Investigative Radiology, 15(6 Suppl):S13-S17, 1980.

- 32. Hendrix SG, Patterson R, Zeiss CR, Pruzansky JJ, Suszko IM, McQueen RC, Slavin RG, Miller MP, Lieberman PL and Sheffer AL. A Multi-Institutional Trial of Polymerized Whole Ragweed for Immunotherapy of Ragweed Allergy. Journal Allergy and Clinical Immunology, 66(6):486-494, 1980.
- Greenberger P, Patterson R, Simon R, Lieberman P, and Wallace W. Pretreatment of High-Risk Patients Requiring Radiographic Contrast Media Studies. Journal Allergy and Clinical Immunology, 67(3):185-187, 1981.
- 34. Herrod HG, Miller MM, Crawford LV, Lieberman PL, and Holbert JM. Abnormal Immunologic Measurements in Asthmatic Children and Adults. Annals Allergy, 47(4):267-272, 1981.
- 35. Lewis J, Lieberman P, Treadwell G, and Erffmeyer J. Exercise-Induced Unticaria, Angioedema and Anaphylactoid Episodes. Journal Allergy and Clinical Immunology, 68(6):432-437, 1981.
- 36. Blaiss MS, Herrod HG, Crawford LV, and Lieberman PL. Beclomethasone Dipropionate Aerosol: Hematologic and Immunologic Effects. Annals Allergy, 48(4):210-214, 1982.
- 37. Davis PG, and Lieberman P. Normal Alpha₂-Adrenergic Responses in Platelets From Patients with Asthma. Journal Allergy and Clinical Immunology, 69(1, Part 1):35-38, 1982.
- 38. Davis P, and Lieberman P. Normal Beta-Adrenergic Responses in Lymphocytes from Patients with Asthma. Submitted Journal Allergy and Clinical Immunology, 1982.
- Meyer MC, Straughn AB, Lieberman P, and Jacob J. Serious Bioavailability Problems with a Generic Prolonged-Release Quinidine Gluconate Product. Journal Clinical Pharmacology 22:131-134, 1982.
- 40. Erffmeyer JE, McKenna WR, Lieberman PL, Yoo TJ, Taylor W Jr. Efficacy of Phenylephrine-Phenylpropanolamine in the Treatment of Rhinitis. South Med J 75(5):562-564, May 1982.
- 41. Lieberman P. Glucocorticosteroid Therapy <u>In Primer on Allergic and Immunologic Diseases</u>: J Amer Med Assoc, 248:2605, 1982.
- 42. Rice M, Lieberman P, Siegle R, and Mason J. *In Vitro* Histamine Release Induced by Radiocontrast Media and Various Chemical Analogs in Reactor and Control Subjects. Journal Allergy and Clinical Immunology, 72(2):180-186, 1983.
- 43. Self TH, Brooks JB, Lieberman P, and Ryan MR. The Value of Demonstration and Role of the Pharmacist in Teaching the Correct Use of Pressurized Bronchodilators. Canadian Medical Assoc J, 128(2):129-131,1983.
- 44. Arbesman C, Bernstein IL, Bierman CW, Bocles JS, Katz R, Lieberman PL, Mattucci K, Meltzer EO, Middleton E Jr., Noyes J, Pearlman DS, Pence HL, Slavin RG, and Spector SL. Multi-Center Double-Blind Placebo-Controlled Trial of Fluocortin Butyl in Perennial Rhinitis. Journal Allergy and Clinical Immunology, 71(6):597-603, 1983.
- 45. Siegle RL, Lieberman P, and Rice MC. *In Vitro* Complement Consumption by Contrast Materials and Analogues: Reactors versus Nonreactors. Investigative Radiology, 18(4):387-389, 1983.
- 46. Kaliner M, Dyer J, Merlin S, Shelton A, Greenhill A, Treadwell G, McKenna W, and Lieberman P. Increased Urine Histamine and Contrast Media Reactions. Investigative Radiology, 19(2):116-118, 1984.

- 47. Straughn AB, Henderson RP, Lieberman PL, and Self TH. Effect of Rifampin on Theophylline Disposition. Therapeutic Drug Monitoring, 6(2):153-156, 1984.
- 48. Erffmeyer JE, Lieberman P, and Siegle R. Anaphylactoid Reactions to Radiocontrast Material. Journal Allergy and Clinical Immunology, 75:401-410, 1985.
- 49. Hartley TF, Lieberman PL, Meltzer EO, Noyes JN, Pearlman DS, and Tinkelman DG. Efficacy and Tolerance of Fluocortin Butyl (FCB) Administered Twice Daily in Adult Patients with Perennial Rhinitis. Journal Allergy and Clinical Immunology, 75(4):501-507, 1985.
- Irwin RB, Lieberman P, Friedman MM, Kaliner M, Kaplan R, Bale G, Treadwell G, and Yoo TJ. Mediator Release in Local Heat Urticaria: Protection with Combined H1 and H2 Antagonists. Journal Allergy and Clinical Immunology, 76(1):35-39, 1985.
- 51. Cohen R, Grant W, Lieberman P, Potter W, Golden E, Crawford L, Herrod H, and Yoo TJ. The Use of Methacholine Inhalation, Methacholine Skin Testing, Distilled Water Inhalation Challenge and Eosinophil Counts in the Evaluation of Patients Presenting with Cough and/or Nonwheezing Dyspnea. Annals Allergy, 56(4):308-312, 1986.
- Younger RE, Herrod HG, Lieberman PL, and Crawford LV. Reduced Production of Histamine Release Enhancing Factor (HREF) by Cord Blood Mononuclear Cells. Pediatric Research. Submitted 1985.
- Younger RE, Herrod HG, Lieberman PL, Trouy RL, and Crawford LV. Characteristics of Diatrizoate-Induced Basophil Histamine Release. Journal Allergy and Clinical Immunology, 77(No. 1, Part 1):94-100, 1986.
- Younger RE, Herrod HG, Lieberman PL, Valenske, WR, Trouy RL, and Crawford LV. Characterization of Mononuclear Cell-Derived Histamine Release Enhancing Factor. Journal Allergy and Clinical Immunology, 80(4):547-557, 1987.
- 55. Betlach CJ, Straughn AB, Meyer MC, Lieberman PL, Micle T, and Gonzalez MA. The Absorption of Theophylline from Theo-Dur(R) Sprinkle Dosed One-Half Hour Before a Meal. Submitted Journal Allergy and Clinical Immunology, 1987.
- 56. Siegle RL, and Lieberman P. Histamine Release, Complement Activation and Immune Mechanisms Associated with the Use of Iodinated Contrast Material. In: Contrast Media: Biologic Effects and Clinical Application. Vol I. (Zaheer Parvez, Rogelio Moncada, Milos Sovak, eds.) CRC Press, Inc. (Boca Raton, FL), pp 151-162, 1987.
- Orgel HA, Meltzer EO, Bierman CW, Bronsky E, Connell JT, Lieberman PL, Nathan R, Pearlman DS, Pence HL, Slavin RG, et al. Intranasal Fluocortin Butyl in Patients with Perennial Rhinitis: A 12-Month Efficacy and Safety Study Including Nasal Biopsy. Journal Allergy and Clinical Immunology, 88(2):257-264, August 1991.
- Sheffer AL, Lieberman PL, Aaronson DW, Anderson JA, Kaplan AP, Pierson WE, Ellis EF, Lichtenstein LM, Lockey RF, Salvaggio JE, et al. Measurement of Circulating IgG and IgE Food-Immune Complexes. Journal of Allergy and Clinical Immunology, 81(4):758-760, 1988.

RESEARCH PAPERS

- 59. Marshall G, and Lieberman P. Comparison of Three Pretreatment Protocols to Prevent Anaphylactoid Reactions to Radiocontrast Media. Annals of Allergy, 67(1):70-74, July 1991.
- 60. Betlach CJ, Straughn AB, Meyer MC, Bialer M, Vashi VI, Lieberman P, and Gonzales MA. The Effect of Raising Gastric pH with Ranitidine on the Absorption and Elimination of Theophylline from a Sustained-Release Theophylline Tablet. Pharmaceutical Research, accepted for publication, 1991.
- 61. Lockey R, Wasserman ST, Altman LC, Whitcomb NJ, and Lieberman P. A Placebo-controlled Comparison of Cetirizine Terfenadine in Seasonal Allergic rhinitis, 1991.
- 62. Arlian LG, Bernstein D, Bernstein IL, Friedman S, Grant A, Lieberman P, Lopez M, Metzger J, Platts-Mills T, Schatz M, Spector S, Wasserman SI, and Zeiger RS. Prevalence of Dust Mites in the Homes of People Living in Eight Different Geographic Areas of the United States. Journal Allergy and Clinical Immunology, 90(3 Pt 1):292-300, September 1992.
- Lockey R, Findley S, Mitchell D, Woehler T, Lieberman P, and Nicodemus C. Effects of Cetirizine versus Terfenadine in Seasonal Allergic Rhinitis. Annals of Allergy, 70(4):311-315, April 1993.
- Dykewicz MS, Kim HW, Orfan N, Yoo TJ, and Lieberman P. Immunologic Analysis of Anaphylaxis to Protamine Component in Neutral Protamine Hagedorn Human Insulin. Journal Allergy and Clinical Immunology, 93(1 Pt 1)117:125, January 1994.
- 65. Kemp SF, Lockey RF, Wolf BL, and Lieberman P. Anaphylaxis, A Review of 266 Cases. Archives of Internal Medicine, Vol. 155(16):1749-1754, September 1995.
- 66. Berger WE, Fineman SM, Lieberman P, Miles RM, and the Rhinitis Study Group. Double-Blind Trials of Azelastine Nasal Spray Monotherapy Versus Combination Therapy with Loratadine Tablets and Beclomethasone Nasal Spray in Patients with Seasonal Allergic Rhinitis. Annals of Allergy, Asthma, & Immunology, 82(6):535-541, June 1999.
- 67. Banov C, Lieberman P. Vasomotor Rhinitis Study Groups: Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Annals of Allergy, Asthma, & Immunology, 86(1):28-35, January 2001.
- 68. Lieberman P, Rakel R, Hedges H, Kuritzky L, Ledgerwood G, Suillace S, and Stoloff S. Quantifying the Incidence of Mixed Rhinitis with a New Patient Screening Tool. Today's Therapeutic Trends 20:221-232, 2002.
- 69. Lieberman P, Kaliner M, and Wheeler WJ. Open-Label Evaluation of Azelastine Nasal Spray in Patients With Seasonal Allergic Rhinitis and Nonallergic Vasomotor Rhinitis. Current Medical Research and Opinions, 21(4):611-618, 2005.
- 70. Webb L and Lieberman P. Anaphylaxis: A Review of 601 Cases. Annals of Allergy, Asthma, and Immunology, July 2006; 97(1):39-43.
- 71. Lieberman P, Decker W, Camargo C, O'Connor R, Oppenheimer J, and Simons S. SAFE: A Multidisciplinary Approach to Anaphylaxis Education in the Emergency Department. Annals of Allergy, Asthma and Immunology (accepted for publication February 7, 2007).
- Camargo CA Jr., Clark S, Kaplan MS, Lieberman P, Wood RA. Regional Differences in EpiPen Prescriptions in the United States: The Potential Role of Vitamin D. Journal of Allergy and Clinical Immunology, 2007; 120:131-136.

RESEARCH PAPERS

- 73. Beaty AD, Lieberman P, and Slavin, RG. Seafood Allergy and Radiocontrast Media: Are Physicians Propagating a Myth? American Journal of Medicine 2008; 121(2):158. e1-158. e4 (published online prior to print).
- 74. Jacobs R, Lieberman P, Kent E, Silvey M, Locantore N, and Philpot E. Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid therapy. Allergy and Asthma Proceedings (accepted for publication 2008).
- Simons FER, Lieberman PL, Reid E, and Edwards ES. Hazards of unintentional injection of epinephrine from auto-injectors: a systematic review. Annals of Allergy, Asthma, and Immunology 2009; 102:282-287.
- 76. Commins SP, James H, Tran N, Kelly E, Mullins R, Lieberman P, Platts-Mills T. Testing for IgE antibody to the carbohydrate galactose-a-1, 3-galactose in patients with recurrent idiopathic anaphylaxis: How many cases are we missing? J Allergy Clin Immunol 2010; 125(2):AB119 (Supplement).
- 77. Lieberman P, Meltzer E, LaForce C, Darter A, and Tort M. Two week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. In: Allergy and Asthma Proceedings 2011 (March-April); 32(2):151-158.
- 78. Lieberman P, Rahmaoui A, and Wong DA. The safety and interpretability of skin tests with omalizumab. Annals of Allergy, Asthma, and Immunology 2010; 105(6):493-495.
- 79. Esteitiel R, Jones NS, Toskala E, Cruz AA, Powe DG, Naclerio R, Shusterman DJ, Lieberman P, Baraniuk JN, Mullol J, Baroody FM, Wagenmann M, White M, Scadding G, Settipane R, Fokkens W, Pawankar R, Togias A. Nonallergic rhinitis-identifying gaps in research (abstract). J Allergy Clin Immunol, February 2011. Abstract Number 986, page AB324.
- 80. Lieberman P, Schwartz L, Valent P, Metcalfe D, Akin C, Castells M, et al. Definitions, criteria, and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal, Manuscript 201101025, accepted for publication, April 2011.

EXHIBIT B

Be Aware of the Generic Epinephrine Autoinjector

Dear Members:

It has come to our attention that there is a generic epinephrine autoinjector (without a specific name) that is being distributed by Greenstone (a generic division of Pfizer). According to Greenstone's website, this injector is identical to a product named *Adrenaclick*, distributed by Shionogi Pharma. Apparently Shionogi has authorized Greenstone to distribute the same device as an unbranded or "generic" item.

We call your attention to this because it may result in substitution by the pharmacy of the generic for a brand name prescription, or vice versa. The issue which merits comment is that the instructions for the administration of *EpiPen*, a product distributed by Mylan Pharmaceuticals, is different than the instructions for the administration of either the *Adrenaclick* or the "generic" automatic epinephrine injector. There is presently no generic autoinjector which employs the same administration technique as the *EpiPen*.

Thus, you may have trained your patient for the administration of one type of injector, and the pharmacy may provide another type on which the patient has not been trained. During the stress of an anaphylactic reaction, this may be confusing to a patient and could result in the delay or perhaps an error in the administration of the drug.

You can view each type of injector and the instructions for its administration at each of the respective websites:www.adrenaclick.com; www.epipen.com; dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16934

Sincerely,

Mark Ballow, MD, FAAAAI, FACAAI President, AAAAI

Sami L. Bahna, MD, DrPH, FACAAI, FAAAAI President, ACAAI

American Academy of Allergy, Asthma & Immunology 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 Phone: (414) 272-6071 E-mail: info@aaaai.org.

You have received this measure because you are a member of the AAAAI of the second states and previous consist with the AAAAI. If you do not wish to be introduced at our simulities, please forward this measure to info@aaaai.org.

EXHIBIT C

Be Aware of Epinephrine Autoinjector Substitution

This article has been reviewed by Thanai Pongdee, MD, FAAAAI

An epinephrine autoinjector is used to treat a severe allergic reaction or to prevent anaphylactic shock caused by stinging insects, foods, latex, medications or other allergens.


If you have a severe allergy and carry epinephrine, it is important to know that each brand functions a little differently. The stress of an anaphylactic reaction is not the time to realize you have a different autoinjector than what was demonstrated to you by your allergist.


There are three readily available brands of epinephrine autoinjectors: EpiPen®, Adrenaclick® and Twinject®. Adrenaclick is sometimes substituted for EpiPen, depending upon the prescription from your doctor, the pharmacy you use to fill your prescriptions and your insurance coverage. Although the medication is the same, the method for injecting it is a little different in each brand. The next time you pick up your prescription, be sure to compare the brand you received with the brand you have been trained to use. If the medication appears to be different than what you expected, find out why a substitution was made. Also, be sure to get a demonstration on how to use the product.

Your pharmacist and your doctor's office want to make sure you know how to use the autoinjector in an emergency, so ask as many questions as you need to feel comfortable. If you have additional concerns, contact your allergist for more information.

DID YOU KNOW?

- It is estimated that the number of cases of anaphylaxis in the United States from foods increased from 21,000 per year in 1999 to 51,000 per year in 2008.
- Food allergies cause approximately 150 to 200 fatalities per year.
- Fatal food anaphylaxis is most often caused by peanuts (50-62%) and tree nuts (15-30%).





EpiPen®






Your source for more information or to find an allergist/immunologist.

► To the Point ←

Be sure to discuss your prescription with your allergist and pharmacist so you know exactly which brand of epinephrine autoinjector you are receiving and how to use it.

EXHIBIT D



Advertisement ACAAI's journal for the allergy/ immunology specialist



 Evidence-based
 Latest current clinical science
 CME activities

Allergies	Asthma	Tools	Living &	Managing	Resources	News	ACAAI.org			
ACAAE>F	ATIENTS & PUBLI	IC >RESOUR	CES NLETT	ERS TO THE EDI	TOR			Sha	re	PRINT
Allergy ar Glossary	nd Immunology	G	eneric E	pinephrin	e Injector M	lay Caus	e Confusion	ı		AND ASTHNA STORIES
Ask the A	llergist	we	e routinely	prescribe this	medication for n	nany of our	ent of anaphylax patients. For ye A as it was the so	ars we only had	1	Read stories of people just like you. Learn how they found relief
Patient's I Care Refo	Rights on Healt rm	h av.	to remember the name EpiPen (http://www.epipen.com/) as it was the sole product available for our patients to safely and easily use. Recently we added new injectors, the latest being the Adrenaclick (http://www.adrenaclick.com/).						(47)	 from their allergy and asthma symptoms by visiting an allergist.
	the Editor	ep	In May 2010 a "generic" epinephrine auto-injector was released for distribution. This epinepirfine auto-injector (http://dailymed.nim.nih.gov/dailymed/drugInfo.cfm?id=15934					fo.cfm?id=15934)	LEARN M	
Patient No	ewsletter		has no trade name currently (it is distributed by Greenstone, a generic division of FIND AN ALLERGIST							
FAQ		of co	of the Adrenactick. This is somewhat confusing as all of the auto-injectors are considered by the FDA as BX rated indicating that the FDA has determined that there is both alteroies and					specialists at treating both allergies and		
Photo Gal	lery	eq	insufficient data showing that epinephrine auto-injector products are therapeutically equivalent and safe to substitute. Normally to be generically equivalent a drug would explain how					asthma. They can explain how your		
Patient Su Organizat			we an AB ra	-	the back a success	ic auto Joli	actor and the Cre	enstone generic		allergies can affect na and steps you need to ap both conditions under
Research					annot be substil			ensione generic	code and f	
Meetings	& Events						issouri, there is a		LEARN M	ORE >
Download Resources		co mi ins of	about what products the patients may receive. Patients report they would like to continue to receive the same auto-injector they had previously and are concerned they might not know how to use a new injector if a substitute is given to them without instruction. Pharmacists have yet to see the new auto-injector and most were unaware of its existence. One pharmacist was very concerned that EpiPen prescriptions might							
Top Allergy Content		the inj	get substituted in less scrupulous pharmacies. Other pharmacists freely admit that they do not always take the time to instruct the patients in the use of the auto- injectors. When asked the pharmacists agree that this a formula for confusion and potentially a reason for delay or error in administration of the epinephrine.							
FOOD ALLERGIES SKIN ALLERGIES EYE ALLERGIES DUST ALLERGY LATEX ALLERGY		pro pre the	Here are a few tips to decrease the confusion. For the prescriber: Write for the exact product that you and the patient agree upon and sign dispense as written on the prescription. Make sure that the patient has been instructed in your office in the use of the specific injector. Empower your patient to check out their epinephrine auto- injector BEFORE they leave the pharmacy.							
SINUSITIS			For the patient: Make sure you know how to use your auto-injector before you leave							
RHINITIS Top Asthma Content		get leg cor	your doctor's office. Check your auto-injector IN the pharmacy and make sure you are getting the product your doctor prescribed and trained you on. If you determine that a legitimate substitution has been made, make sure you are trained in its use and comfortable with the new injector before leaving the pharmacy. Epinephrine is life saving and you should be able to competently use this for yourself or a loved one.							
ASTHMA SYMPTOMS			You can view each type of injector and review the instructions for their administration at the websites listed above.							
ASTHMA TREATMENT CHILDHOOD ASTHMA ASTHMA TRIGGERS ASTHMA SCREENING		Alli	Janna Tuck, MD, FACAAI Allergy Partners of Cape Giraideau Cape Girardeau, Missouri							
Allergies	Asth	ma		Stay Conn	ected	Top Cont	lent	Other Resour	ces	
Types Symptoms Treatment Children Seasonal Anaphylaxis	Types Sympi Treatr Other Childr	toms ment Conditions	5	Patient News Facebook Twitter YouTube RSS		Hives Eye Allergic Dust Allerg Allergy Tes Pet Allergic Drug Allerg Allergic Rh	lY .ting es jies	Find an Allergist Household Allergi Seasonal Allergie Ask the Allergist Patient Stories Patient Support Organizations ACAAI Research Letters to Web Ec	jies s	About the ACAAI Members Fellows in Training Alled Health Professionals Alliance ACAAI Foundation Media Sponsors

Find an Allergist FAQ Glossary Member Contact Us

American College of Allergy, Asthma & immunology # 2010

EXHIBIT 24

Expert Report From Martha V. White, M.D.

My name is Martha V. White, M.D., and I've been asked to address the question of whether the term "Epipen" has become the generic term for "epinephrine autoinjector."

Qualifications

I feel that my training and experience make me well qualified to address this question, as I have been a practicing allergist since 1984, and have been board certified in allergy and immunology since 1985. I graduated from Virginia Commonwealth University School of Medicine in 1978, completed three years of Pediatric training at the same institution, then completed two years of Allergy/Immunology training at the University of Southern California and Georgetown University (one year each). Following my Allergy/Immunology Fellowship, I worked in the Allergic Diseases section of the Laboratory of Clinical Investigation, a laboratory in the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH), where I spent nine years performing research in the field of allergic inflammation and coordinated the pediatric part of the NIH Allergy Fellowship program. During one of those years I was employed by the Food and Drug Administration (FDA), but continued my research at the NIH. After leaving the NIH in 1993, I helped to form the Institute for Asthma and Allergy, where I am a practicing allergist and have served as director of research since we began clinical trials in early 1994. To date, I have been an investigator in over 200 clinical trials in a variety of allergic disorders. I believe strongly in patient education, and as such, am a founding board member of the Allergy and Asthma Network/ Mothers of Asthmatics, a lay organization devoted to patient education and advocacy for allergy and asthma patients and their families. My curriculum vitae is attached to this report as Exhibit A.

Summary:

There are three marketed brands of epinephrine auto-injectors that I am aware of: EpiPen, produced by Mylan, Inc.; Twinject, produced by Shionogi Pharma and Adrenaclick, also produced by Shionogi. Recently, Greenstone has received FDA authorization to market a generic version of the Adrenaclick, also produced by Shionogi Pharma, and identical to the branded version. It is marketed under the name of Epinephrine auto-injector; thus the generic device is not a distinct device. All four products are available in either 0.15 mg or 0.3 mg doses of epinephrine. The Twinject contains two doses in one device, while the others contain a single dose. While all three distinct products contain epinephrine, the mechanics of actual use are quite different, making these products distinct and not interchangeable. Because these devices are meant to be used by non-medical personnel under emergency, often life-threatening circumstances, hands-on patient instruction on the prescribed device is critical to a successful outcome. Thus, when I prescribe an EpiPen, I am referring to the trademarked product produced by Mylan, Inc., and I expect the pharmacist to dispense an EpiPen. To do otherwise would potentially endanger my patient's life. Thus, it is my opinion that the term EpiPen is a trademarked name of a particular epinephrine auto-injector, not to be confused or substituted with the Twinject, the Adrenaclick, or the generic version of the Adrenaclick.

Discussion:

My patient population includes both adults and children with asthma and a variety of allergic disorders, including food and hymenoptera allergies (i.e., yellow jackets, honey bees, etc.). Allergic reactions to food and hymenoptera include airway obstruction and hypotension leading to shock, and such reactions can be life-threatening. The standard of care for food and hymenoptera allergy includes a prescription for an epinephrine auto-injector which should be available to the patient at all times in the event of anaphylaxis.

I believe strongly in patient education and have personally provided my patients with hands-on education on the use of epinephrine auto-injectors. These products are designed to be life-saving treatments used in emergency situations by non-medical allergy patients or their care-givers. In studies of fatal anaphylaxis from food ingestion, the most common finding is delayed use or failure to use epinephrine after the onset of anaphylaxis. Being both knowledgeable about and comfortable with the mechanics of using the epinephrine auto-injector is critical for a successful outcome.

There are three branded epinephrine auto-injectors that I am aware of: the EpiPen, the Twinject (containing two doses in one device), and the Adrenaclick (a single dose version of the Twinject, now also available in an identical generic version). All three products contain epinephrine and all three are shaped similarly (EpiPen is long and oval, while the other three are long and round). However, as one who has actually handled both the EpiPen and the Twinject products, it is obvious to me that here is where the similarity stops. Just as various makes of automobiles differ in their mechanical properties, the EpiPen differs from the Shionogi Pharma products in its mechanics of usage as described below.

The Twinject is a small cylindrical device containing two doses of epinephrine. To use it requires two hands. One must take the device out of its case, remove caps both at the top and the bottom of the device, then press the correct end at a 90 degree angle into the thigh to trigger a spring loaded injection. The process usually requires that the device be manipulated from one hand to another, and once the injection has been delivered, a contaminated needle remains exposed at the end of the device. In case a second dose is required several minutes later, it is necessary to keep the needle from coming into contact with surfaces in the environment. If the second dose is required, one must unscrew the cap at the base of the exposed needle and carefully lift the cap up and over the needle, taking precautions to avoid accidental needle stick injury. During this procedure a spring sometimes comes flying out of the device. A syringe is then extracted from the device, a safety clip must be removed, and the needle is then injected into the muscle, and the barrel of the syringe manually depressed by the patient or care giver. I have heard that some school nurses refuse to accept the Twinject from their students

p.5

because of the risk of accidental needle stick injuries, and also because of a concern that, since the syringe can be accessed by unscrewing the inside cap, students might bring in devices in which the contents have been replaced with illegal drugs.

The Adrenaclick is identical to the Twinject except that it contains only a single dose. Thus, the three-step instructions for use are identical to those of the first dose of the Twinject. After injection, an exposed, contaminated needle remains on the device.

The EpiPen is a long oval device, egonomically designed to be held in the fist, and can be operated easily with one hand. Thus, a caregiver of a struggling child can hold the child with the non-dominant arm and hand, while operating and administering the EpiPen with the dominant hand. The hard case holding the device can be opened with the flick of the thumb. After removal from the case the device can be grasped in the fist, and the blue safety cap flicked off with an upsweep of the thumb. The device is already in proper position to press the black tip of the device at a 90 degree angle into the thigh muscle to trigger a spring loaded injection. As the device is removed from the leg, a safety sheath springs out and covers the contaminated needle. The syringe is encased within a hard plastic shell, and cannot be accessed.

When prescribing an epinephrine auto-injector, my overwhelming preference is for the EpiPen because of its ease of use. When shown both the Twinject and the EpiPen techniques, I can recall only one patient who stated a preference for the Twinject, even if the EpiPen was more expensive under the patient's insurance plan. This is true even for those who anticipate requiring only a single dose, mainly because of the one-handed design of the EpiPen. Thus, when I prescribe an EpiPen, I am referring to the branded product produced by Mylan, Inc. , and that is the product that my patient will have been trained on. The various epinephrine auto-injectors are not interchangeable, and substitutions are potentially dangerous and could lead to fatal outcomes.

I have read Dr. Amin Mery's report, and I must respectfully, but strongly disagree with him over his statement that "It is my opinion that patients, physicians, and the public in general are using the term "epipen" to refer to any epinephrine auto-injector containing epinephrine. Therefore the trademark EPIPEN has become genericized." I note that he referred several times to having a Twinject, Adrenaclick, or the generic Adrenaclick in the office. I did not find any mention that he had actually used or handled an EpiPen before, and perhaps this may explain why he fails to appreciate the significant differences between the EpiPen and the three Shionogi Pharma devices.

In fact, the differences between an EpiPen and the other three epinephrine autoinjectors on the market are both mechanically and therapeutically significant. Allergic patients require training on the specific devices prescribed, and failure to receive the device on which the patient has had specific training could lead to mechanical failure in life-threatening situations. That patients understand the difference between the devices is evidenced by this passage from the "Hot Topics media Center of the Food Allergy and Anaphylaxis Network website (http://www.foodallergy.org/page/epinephrine-autoinjectors--patients-may-need-re-training): "If you or someone you know has been prescribed an epinephrine auto-injector, please be aware that specific brand-name epinephrine auto-injectors, such as Adrenaclick[™], EpiPen[®] or Twinject[™], as well as the generic version, each have their own unique instructions for proper administration." The full webpage on which this statement appears is attached to this report as Exhibit B. The topic has also been addressed by the Allergy and Asthma Network/Mothers of Asthmatics on its web site (<u>http://www.aanma.org/2010/06/epipens-and-so-calledgeneric-versions-the-facts/</u>) as follows: "Recent news reports have presented patients with conflicting and confusing information about EpiPen Auto-Injector and a so-called generic version. These articles contain information that is inaccurate, inflammatory and, in some instances, dangerous." The full webpage on which these statements appear is attached to this report as Exhibit C.

Thus, clearly, the two lay organizations most interested in allergic diseases that might require the use of epinephrine auto-injectors have published statements indicating that there are fundamental differences between the EpiPen and the other epinephrine auto-injectors. I agree with those organizations that the term EpiPen is a trademarked term referring to the EpiPen device made by Mylan Laboratories, and is not a genericized term for epinephrine auto-injectors.

Respectfully,

Main ula.

Martha V. White, MD, CPI

EXHIBIT A

Curriculum Vitae (updated 2-16-2011)

)
Name:	Martha Vetter White, M.D., C.P.I.	
Home Address:	4223 Everett Street Kensington, Maryland 20895 (301)962-6006	
Business Address:	Institute for Asthma and A 11002 Veirs Mill Rd # 414 Wheaton, MD 20902	Allergy, P.C. 5454 Wisconsin Ave. #700 Chevy Chase, MD 20815
	Phone: 301-962-5800 Fax: 301-962-9585 Email: martywhite@hotmail.com	
Date & Place of Birth: October 23	, 1951, Richmond, Virginia	
Citizenship: United States		
Marital Status: Married, two child	ren	

Education:

1971 - Vanderbilt University
1973 - B.A., magna cum laude, University of Richmond
1978 - M.D., Medical College of Virginia, Virginia Commonwealth University

Board Certification:

American Board of Pediatrics, 1983 American Board of Allergy and Immunology, 1985 Certified Physician Investigator (APPI, # FDA-I-0906-064), 2006

Liscensure:

Virginia	033800		
District of Columbia	20325	Maryland	D0056193

Brief Chronology of Employment:

1978-1981	Internship and Residency, Pediatrics, Medical College of Virginia, Virginia Commonwealth University, Richmond Virginia
1981-1982	Locum Tenens, Emergency Room, and Public Health Physician, Richmond, Virginia
1982-1983	Fellowship, Allergy and Immunology, University of Southern California, Los Angeles, California
1983-1984	Fellowship, Allergy and Immunology, Georgetown University Hospital,
1984-1985	Washington, DC Guest Worker, Allergic Diseases Section, National Institute of Allergy and
1985-1986	Infectious Diseases, National Institutes of Health, Bethesda, Maryland Staff Fellow, Center for Drugs and Biologics, Allergenics Division,

	Food and Drug Administration, Bethesda, Maryland
1986-1988	NRSA Fellow, Allergic Diseases Section, National Institute of Allergy and
	Infectious Diseases, National Institutes of Health, Bethesda, Maryland
1988 -1993	Senior Staff Fellow, Allergic Diseases Section, National Institute of Allergy
	and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
1988 - 1993	Coordinator of Pediatric Allergy, National Institute of Allergy and Infectious Diseases,
	National Institutes of Health, Bethesda, Maryland
1993 - Date	Director of Research, Institute for Asthma and Allergy, P.C.
	11002 Veirs Mill Rd # 414 (primary, research & clinical)
	Wheaton MD 20902
	And
	5454 Wisconsin Ave #700 (secondary, clinical only)
	Chevy Chase MD 20815
	•

Societies

Society of Principal Investigators, President (2002-2003) American Academy of Pediatrics, Fellow American Academy of Allergy Asthma and Immunology, Fellow American College of Allergy Asthma and Immunology, Fellow American Thoracic Society, Member

Honors & Other Special Scientific Recognition:

Beta Beta Psi Chi Gamma Sigma Epsilon Geigy Fellowship, 1984 Asthma & Allergy Foundation of America Fellowship, 1985 (\$5,000) Norwich Eaton Research Award, 1987 (\$4,000) Merrell Dow Scholar in Allergy Award, 1989 (\$50,000) Best Doctors In America America's Top Pediatricians Helping Others Breath Easier Award, 1995 (Allergy & asthma Network/Mothers of Asthmatics)

Special Interests:

Late phase allergic reactions The role of the mast cell in inflammation Mast cell physiology Airway hyperreactivity Asthma Sinusitis Rhinitis

Activities:

Allergy & Asthma Network/Mothers of Asthmatics Board of Directors, 1987-Present Medical Editor, MA Report, 1986-Present Allergy, Asthma & Immunology Guide

Associate Editor, 1989-1990 American Academy of Allergy Asthma & Immunology Public Education Committee, Member, 1995-present, Co-Chair 1996-7, 2001-2002, Chairman 2002-2004 Post Graduate Education Committee, Member, 1995-1997 Asthma, Rhinitis and Other Respiratory Diseases Interest Section Workshops representative 1995-1998 Rhinitis, Sinusitis, Occular & Dermatologic Interest Section Secretary 2004-present, Workshops representative 2004-present Liason to Charitable Organizations Committee, 1996-present, Chairman, 2002-2004 Allergy & Asthma Network/Mothers of Asthmatics representative Women's Involvement in the AAAAI Committee, Member, 1998-present Society of Principal Investigators, Member, 2000-present, Treasurer 2001-2002, President 2002-2003 MKSAP – Allergy & Immunology, Second Edition - Contributor

Research Oversight Activities:

Internal Review Boards:	National Institute of Allergy & Infectious Diseases Member, Clinical Research Committee (IRB), 1990-1992 Medlantic Research Institute Member, Institutional Review Board, 1996-2001 Member, Research Committee, 1996-2001
Data Safety Monitoring Board: Safety Monitoring Committee:	SpineWave 2007- current Biota 2010- Current (Chair)
Institute for Asthma & Allergy:	Research Director: 1993 -current

Clinical Research:

Industry Interactions:

Asthma:	3-M: 1163-BRON, 1192-BRON, 1195-BRON
	Abbott: M94-199, M96-464
	Astra: 004-3100, 004-0144
	Astra-Zeneca: SD-039-0726, SD-004-0764, SD-004-0620, D5896C00005,
	D5896C00001, D5896C00022
	Aventis: XRP1526B-102, XRP1526B-322, XRP1526B-324, XRP1526B-325,
	XRP1526B-342, MO16455P-3001, MO16455P-3003, MO16455A
	Boehringer Ingelheim: 205-416
	Forrest ADS-401, ANC-MD-03-000, ANC-MD-01-000
	Genentech: Q0723G, Q2948G, Q3662G
	Glaxo: SFCA3002, SFCA3003, SALA3003, SAS30003, FLTA3020, FLTA4014,
	SALA3007, SLGA3009, SLGA5018, NAI30008, SAS40020, SLGA5011,
	FMS30058, FMS30059, SAS40024, SAS40025, SAS40026, SFCA3006
	GlaxoSmithKline: SAS30022, SAS40036, SFA103153, ADA103578, ADA109055,
	HZA113091
	Immunex: 13.0014
	MedImmune: Medi 563/MI-CP197, CP-198
	Merck: MK0467, SNG477/120-01, SNG477/120-05

Miles: HRV Epidemeology Study CRF9303, CRF9405 Neurobiological Technologies, Inc.: Novartis: RhuMAB-P010, CQAB149-B2338, CQAB149-B2357 Pfeizer: PDEAAS-1500-002 RG5016Y-204, RG5016T-203, RG5016T-202, RG5016T-303 Rhone-Poulenc-Rorer: Sanofi: DFI2588 Scherring: C98-005, PO1431, P04295, P04073, P04334, P04431, P04703 Sepracor: 051-031, 051-202, 110-060, 051-356, Smith Klein Beecham: 205312/011, 205312/141, 205312/087 Teva: ABS-AS-306 United Biosource Corporation: UBC-A2-6485 Wyeth: PDA-641, 0881A8-205-WW Zeneca: 9188IL/0150, 9188IL/0139, 9188IL/0060, 9188IL/0079, 9188IL/0156, 9188IL/0155

COPD

Altana: By217/M2-124 Boehringer Ingleheim:, 205-252 Dey: 191-076 Glaxo: SLGA4021, HCZ112207 GlaxoSmithKline: SB207-499-156 Novartis: CNVA 237A-2303 Pfizer: PDEACO-9287-001, A2641022 Sepracor: 051-914, 091-051, 091-061

Allergic Rhinitis:

Alcon: C-00-10, C05-69, SMA-08-06, C-08-32 Altana: BY9010/M1-403 Apotex: Tria-Naso-05RB02-CE Astra-zeneca: D5360C0073 Aventis: M0164551/3112, M016455P/2113, M016455C/3212, M016455A-4120, M016455A-4143, M016455A-4144, M016455A-4146, M016455M-3002 Curalogic: RPE 04 Dey Laboratories DL-047 Dvnavax: DV1-SAR-06 Glaxo: FNM30034 GlaxoSmithKline: FFR106080, FFU111439 Hoechst Marion Roussel, Inc.: M061455/3097, PJPR0009, .M061455/4092, 99-4104 Medeva/Adams: SPX-D9701 414, 419, 425, 430, 435, 436 MedPointe: Pfizer: L-0325 Scherring: C98-001, P00361, P00677, P01998, P01999, P01875, P01435, P00375, P02772, P01861, P04095, P05067, P05528, P05233 Sepracor: 110-024, 051-356, 110-073 Strategic Pharmaceuticals: SMAN-0708 Teva: BDP-AR-303

Vasomotor Rhinitis: Glaxo: FFR 30007 Winston Laboratories: WL-1002-03-01 SRXA: SMAN-0708

Sinusitis:	Accentia: ACC-05-01 Bayer: Bay12.8039-100107, Bay D96-024 Medeva/Adams: MEMU-FL1-95-001, MEMU DE20950002, SPX-D9 Scherring: C96-252, C97-251				
Urticaria:	Hoechst Marion Roussel, Inc.:PJPR0039, M061455/3097, PJPR0009, .M061455/4092, 99-4104 Sepracor: 110-050				
Immune Deficiency:	Bayer: Bay.100174 Nabi: 7101				
Hereditary Angioedema:	Dyax: DX-88/4, DX-88/5, DX-88/14, DX-88/19, DX-88/20 Lev Pharmaceuticals: LEVP2005-1, LEVP2006-1, LEVP2006-4, LEVP2006-5 Pharming: C1 12-5-01 ViroPharma: 0624-400 Shire: CB-058				
Upper Respiratory Infection	ons: Boehringer Ingleheim: 244-2465				
Infectious Diseases:	Food Products Assoc: CDC-030				
Consulting:	Astra Astra-Zeneca Aventis Ciba Geigy Dey Pharmaceuticals Dyax Genentech GlaxoSmithKline Hoechst Marion Roussel, Inc. Lev Pharmaceuticals MedImmune MedPointe Miles NovoNordisk Sandoz Pharmarceuticals SanofiAventis Sepracor Zeneca				
FDA – Related Consultin	ng: Dyax Genentech				

Lev Pharma

Novartis

Investment Consulting:	Medacorp					
Speakers Bureau:	Aventis, Inc Astra-Zeneca Boehringer Fisons GlaxoSmithKele Hoechst Marion MedPointe Merck Sepracor ViraPharma Zeneca					
Educational Films:	Glaxo Fisons	Rhone Poulenc Rorer Hoechst Marion Roussel, Inc.	Sepracor Information Television Network			
Television Interviews:	All local news stations, MSNBC, Dateline, CNN, since 1993					
Expert Witness:	Corporate, patent, and medical practice issues since 1995					
	Medical Malpractice:					
	Christopher J. Mattingly 1995: plaintiff Maurice R. Dundie LLP					
	Amira Archer-Davies v. Raymond Nwadiuko, MD et al. ; 2002 : defendant Armstrong, Donohue, Ceppos & Vaughan					
	Berkshire/Atkinson, File No.: 07861.00001; 2004 : plaintiff Wilson, Elser, Moskowitz & Dicker LLP					
	Quarles v. Bojan Realty DC File No. 2009CA007111B; 2010: defendant Hartel, Kane, DeSantis, MacDonald & Howie, LLP					
	Corporate Pate	nt Law:				
		; 2005 : defendant n & Parr, Toronto, Canada				
	Product Liability:					
		vs McDonald's Corp, 2007 – Kiernan Trebach & Crociata LLP				
<u>Public Education</u> :	<u>c Education</u> : MA Report (Allergy & Asthma Network/Mothers of Asthmatics) Ask Dr. White Column, 1987 – present Consumer Health Interactive Web page: Ask the Expert					